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1- INTRODUCTION 
 
1.1 Alzheimer’s disease 
 
 First described by Alois Alzheimer (1864-1915) in 1907, the disease that bears his name 
largely remained an enigma until the twilight of the 20th century. During the Psychiatric Convention 
Tübingen Alzheimer presented the case of a 51 years old woman, Auguste Deter, with an unknown 
form of dementia; the psychiatrist E. Kraepelin four years later, in his treatise, named this form of 
dementia, Alzheimer's disease (AD). 
Alzheimer’s disease is the leading and common cause of dementia in the elderly and it is the most 
common cause of adult-onset dementia in Western world. It is a progressive neurological condition 
characterized at the beginning by short-term memory impairment and it evolves to profound 
cognitive and physical disability.1 AD is a multifactorial disorder caused by genetic, environmental 
and endogenous factors that include excessive protein aggregation, oxidative stress, free radical 
formation, mitochondrial abnormalities and neuro-inflammatory processes that involve the activation 
of astrocytes and microglia.2 More in detail, environmental factors, such as trauma or exposure to 
toxic substances (aluminum, aromatic hydrocarbons), may play an important role.  
Aging is a major risk factor for neurodegenerative disorders such as AD. Analyses suggest that the 
number of Americans with Alzheimer's disease in 1997 was 2.32 million (range: 1.09-4.58 million) 
and that this number will nearly quadruple in the next 50 years, at which time 1 in 45 Americans will 
be living with the disease. The growth in the prevalence of Alzheimer's disease results from the 
aging of the US population. In 1997, the percentages of Americans more than 65, 75, and 85 years 
of age were 13%, 6%, and 1.4%, respectively. By the year 2047, the corresponding percentages of 
such individuals will increase to approximately 20%, 11%, and 4%. The percentages of persons 
living with Alzheimer's disease among 75, 80, 85, and 90-year-olds are 4.3%, 8.5%, 16.0%, and 
28.5%, respectively.3 The incidence of AD is increasing at an alarming rate along with aging of 
populations of industrialized countries. United Nation population projections estimate that the 
number of people older than 80 years will approach 370 million by the year 2050. Therefore, if these 
statistics hold true, in 50 years, more than 100 million people worldwide will suffer from dementia. 
The vast number of people requiring constant care and other services will severely strain medical, 
monetary, and human resources. High level of education and jobs that require a high level of 
cognitive activity appear a protective effects on the onset of dementia, due to increased efficiency 
of neuronal circuits and to the ability of the brain to activate alternative neural circuits.  
Diagnosis of AD is based on clinical features, although it should be confirmed by brain 
histopathological examination. There are three clinical stages of AD with cognitive and functional 
decline stretching over 5–8 years: mild, moderate and severe (fig. 1). 
The initial stage usually lasts 2–3 years and is characterized by short-term memory impairment often 
accompanied by symptoms of anxiety and depression. In a small proportion of them, slurred speech, 
executive functions, perception, or movement disfunctions are more prominent than memory 
problems. Episodic memory, semantic memory and implicit memory are affected to a lesser degree 
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than new facts or recent memories. In this stage, patients are able of adequately communicating 
basic ideas. As the disease progresses, people with AD can often continue to perform many tasks 
independently, but may need assistance or supervision with the most cognitively demanding 
activities.  
In the moderate stage, these symptoms appear to abate as neuropsychiatric manifestations, such 
as visual hallucinations, false beliefs and reversal of sleep patterns. Speech difficulties become 
evident and frequently they use incorrect word substitutions. Reading and writing skills are also 
progressively lost. Complex motor sequences are less coordinated. Memory problems worsen, and 
the person could not recognize relatives. Long-term memory becomes impaired. Common 
neuropsychiatric manifestation are irritability and labile effect, depression and aggression.  
 
 
 
Figure 1: morphological changes of healthy brain during the progression of AD.4 
 
The severe and final stage is characterized by motor signs, such as motor rigidity and prominent 
cognitive decline. Patients are completely dependent upon caregivers. Language is reduced to 
simple phrases or even single words and, at the end, there is a complete loss of speech. Usually 
extreme apathy and exhaustion are much more common. Patients will ultimately not be able to 
perform even the most simple tasks without assistance. Finally comes death, usually caused by 
some external factor such as pressure ulcers or pneumonia, not by the disease itself. The mean life 
expectancy following diagnosis is approximately seven years. Less than 3% of individuals lives more 
than fourteen years after diagnosis. Cognitive and functional decline tend to be linear throughout 
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the three stages of the disease, whereas caregiver burden peaks with the onset of neuropsychiatric 
symptoms and declines somewhat during the final stage, when the patient is more sedentary. This 
is the result of neuronal degeneration in the cortex, particularly in the temporal lobes, hippocampus 
and basal ganglia, which leads to reduction of the weight of the brain, dilation of ventricular cavities 
and cortex and the thinning of the convolutions. Linear correlation between the stages of AD and 
volume of brain structures, suggest that successful therapeutic intervention might stop the progress 
of pathological changes at any stage of disease. 
The disease can be caused by a “sporadic” or a "familiar" form with early onset;5 the latter is 
transmitted through a dominant autosomal mechanism. 99% of cases of AD is sporadic and occurs 
in people who do not have a clear familiarity. Only 1% of cases of AD is caused by an altered gene 
that determines the transmission from generation to generation.  
Generally, hereditary forms have a high penetrance, in fact many people of a family (3 or more) are 
affected by the disease. Furthermore, most of the hereditary forms appear in relatively early age 
(before 65-70 years) and the age of onset of the first symptoms is relatively stable within the same 
family.  
To date, mutations identified relate to chromosomes 21, 4, 1. The mutations located on chromosome 
21 are responsible for the synthesis of β-amyloid, those in the chromosomes 14 and 1 are 
responsible for the synthesis of abnormal presenilins (the neuronal membrane proteins that control 
the phosphorylation of τ protein). In addition, a mutation not related to familiar form was discovered: 
it affects the chromosome 19, which encodes proteins responsible for the transport of fat in the 
blood. Its aberration causes the production of ApoE 4, an apolipoprotein (Apo) that is not efficient 
for the transport of cholesterol; this prevents cholesterol to reach the damaged neuronal membranes 
and to repair them. Moreover, a recently emerged and still quite unknown system that could be 
involved in the disease was found to be the endocannabinoid system. Some studies showed that 
cannabinoids play a protective role against the toxicity of amyloid peptide. 
 
1.2 Ethiopathology 
 
 Data show that the accumulation of abnormal proteins during aging of the brain is connected 
to oxidative and inflammatory damage and to a deficit of neurotransmitter systems, among which 
the most affected appears to be the cholinergic system. Moreover, a reduction of various other 
neurotransmitters such as dopamine, glutamate and serotonin was revealed. For this reason, 
several theories were formulated with the aim of defining the molecular mechanisms of the disease: 
 
 Cholinergic hypothesis 
 β -Amyloid peptide hypothesis 
 Tau protein thesis 
 ApoE 
 Others causes 
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1.2.1 The cholinergic hypothesis 
 
 In the past decade, treatment for AD has largely involved the replacement of 
neurotransmitters that are known to be lacking in AD, mostly based on the “cholinergic hypothesis” 
of AD. A deficit in central cholinergic transmission caused by degeneration of the basal forebrain 
nuclei is an important pathological and neurochemical feature of AD.  
 
 
Figure 2: acetylcholine methabolism 
 
The deficit shows reduced activity of choline acetyl transferase (ChAT) enzyme, decrease of axonal 
transport, synthesis of acetylcholine (ACh) and choline reuptake (fig. 2). There is also a reduction in 
the number of cholinergic receptors in the hippocampus and cortex.6 Presynaptic nicotinic receptors 
control the release of neurotransmitters (acetylcholine, glutamate, serotonin and norepinephrine) 
that are important for memory and behavior. Experimental studies showed that Aβ binds presynaptic 
nicotinic α-7 receptors, essential for cognitive processes, reducing in this way the release of ACh 
and that, levels of muscarinic receptors is reduced in patients with Alzheimer's disease.7 The 
therapeutic approach aims to reduce the neuronal decline and symptoms through the reintegration 
of lacking neurotransmitters. This is demonstrated with the use in therapy of inhibitors of 
acetylcholinesterase (AChE), the enzyme that hydrolyzes ACh forming acetic acid and choline. To 
date, this is the most important therapeutic strategy for the Alzheimer's disease treatment. 
Unfortunately, it is only a symptomatic treatment considering that these inhibitors do not prevent or 
reverse the progression of the disease.  
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AChE is an enzyme with a very fast action and it is able to hydrolyze approximately 5.000-10.000 
molecules of ACh per second. AChE is localized in synaptic or junctional space. In brain, AChE 
hydrolyzes neurotransmitters such as P substance and encephalins and it was found in association 
with glial cells and with the blood brain barrier. It is also present in the blood and in peripheral organs. 
The AChE is the best-known representative of a group of enzymes designated with the name of 
cholinesterase and which have the function to catalyze the hydrolysis of choline esters of various 
carboxylic acids. In 1991, Sussmann et al. determined the three-dimensional structure at the AChE 
through X-ray analysis of a crystal of the homodimeric form of the enzyme obtained by electric organ 
of a race (Torpedo californica). Previously, it was showed that the AChE oligomeric forms present 
in the electric organs of fish (electrophorus and torpedo) were structurally homologous to those 
coming from the muscles and nerves of vertebrates. The monomer studied by Sussmann is a 
polypeptide of 537 amino acids with ellipsoidal shape, belonging to the class of / protein; the 
secondary structure of the molecule has 12 segments in -sheet and 14 -helices. The most typical 
feature of the structure is the presence of a deep groove (gorge) that extends for about 20 Å within 
the molecule (fig. 3). At the base of this cavity, initially narrow but gradually larger, there is the so-
called catalytic triad of the AChE.  
 
 
Figure 3: aromatic gorge of AChE 
 
It consists of the three residues (Ser200, His440, Glu327) responsible for the hydrolytic action of the 
enzyme. Another important residue located in the bottom of the gorge is the Trp84; to its indole ring 
was assumed the bond of cationic head of ACh with a cation-π bond. The mechanism of hydrolysis 
of ACh involves the nucleophilic attack of a Ser 200 hydroxyl of the enzyme to the carbonyl carbon 
of the ACh, which forms the acetylated enzyme and the choline. Subsequently, the ester bond of 
the complex is hydrolyzed, allowing the regeneration of the AChE and the formation of acetate ion. 
In order to improve cholinergic neurotransmission, many strategies have been investigated including 
the increasing of acetylcholine synthesis, the augmentation of presynaptic acetylcholine release and 
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the stimulation of cholinergic postsynaptic muscarinic and nicotinic receptors. Current data do not 
support the use of precursors of acetylcholinesterase, presynaptic releasing agents, or muscarinic 
agonists because of a lack of efficacy and unacceptable side effects.8 It is important to underline 
that the AChE can accelerate the deposition of Aβ. In fact, a peripheral anionic site (PAS) was 
identified. It is approximately situated at 14 Å from the active site, with which the Aβ can interact, 
contributing, in this way, to the formation of senile plaques.9,10. In fact, the interaction of Aβ with the 
peripheral anionic site (PAS) of AChE, accelerates the aggregation of this toxic peptide, since it 
catalyzes the conformational conversion of the fibrils in β-sheet. 
Butyrylcholinesterase is also known as pseudocholinesterase, non-specific cholinesterase or simply 
cholinesterase. It preferentially acts on butyrylcholine, but also hydrolyzes ACh. BuChE exhibits the 
substrate activation in excess substrate and has higher activity in liver, intestine, heart, kidney and 
lung.11 In AD BuChE is found as well as AChE in CNS. In fact, many AChEIs also inhibit BuChE, 
because both AChE and BuChE enzymes are found in the CNS. Moreover, AChE and BuChE share 
65% amino acid sequence homology even though being encoded by different genes on human 
chromosomes. The BuChE inhibition can lead to adverse peripheral side effects. Functionally, both 
enzymes hydrolyze acetylcholine efficiently but at different rate, that is, at the same temperature 
and pH, AChE has higher hydrolytic acetylcholine activity than BuChE. The physiological role of 
BuChE is still unclear. Moreover, BuChE did not affect amyloid formation because three aromatic 
residues of the AChE PAS are missing in the PAS of BuChE. The PAS of BuChE had weaker affinity 
than AChE, which mediates substrate activation. Nevertheless, BuChE may play a compensatory 
role in the hydrolysis of acetylcholine in brain with degenerative changes; in fact, AChE activity 
decreases in certain brain regions as AD progresses, while BuChE activity is not affected or even 
increases, making BuChE available in neuritic plaques. Considering this assertion, mixed inhibition 
of AChE/BuChE enzymes could lead to an improved AD therapeutic benefit but the inhibition of 
BuChE, more than the AChE, can give adverse peripheral side effects. The differences in the 
enzyme kinetic properties and locations of brain of AChE and BuChE suggested that, in the normal 
brain, AChE is the main enzyme responsible for acetylcholine hydrolysis, while BuChE plays a 
secondary functional role.12  
More in detail, the difference between the two enzymes can be explained by the different structures 
around the main entrance area. In AChE, there are eight aromatic residues associated with the main 
door: three of them are located on the entrance of the active site (Tyr 72, Trp 286, and Tyr 341); five 
of them are located almost the same depth inside the gorge (Tyr 124, Phe 295, Phe 297, Tyr 337, 
and Phe 338), (fig. 4, A). 
In BuChE, however, six of these residues are changed to smaller ones, including Tyr 72 to Asn 68, 
Tyr 124 to Gln 119, Trp 286 to Ala 277, Phe 295 to Leu 286, Phe 297 to Val 288, and Tyr 337 to Ala 
328, with both sets of residues (fig. 4, B, C). These smaller residues will significantly enlarge the 
entrance radius, which makes it possible for larger substrates to enter the active site. 13 
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Figure 4: (A, top) The eight residues with aromatic or indole side chains in the gorge of AChE. (B, 
middle) The eight residues in the gorge of BuChE. (C, bottom) Superimposing of the gating residues 
in AChE and BuChE. 
 
1.2.2 β-Amyloid peptide hypothesis 
 
 A neurological macroscopic point of view shows that the main brain lesions that characterize 
the disease are accumulations of: extracellular beta-amyloid protein (Aβ) that constitutes the so-
called "senile plaques", intracellular neurofibrillary tangles and neuronal degeneration. The amyloid 
cascade theory proposes Aβ as the central trigger of the pathological changes observed in the brains 
of AD patients, such as synapse loss, activation of inflammatory processes, the induction of 
neurofibrillary changes leading to the formation of paired helical filaments (PHF) and, ultimately, 
neuronal death (fig. 5). It formed the basis for numerous research activities, which significantly 
contributed to our understanding of AD. 14 "Amyloid" means "starch-like", and it is due to the property 
to react with iodine and indicates the protein material rich of glycosaminoglycans, which is extra-
cellular deposited. Several proteins with amyloid characteristics are associated with many diseases. 
Among these, is included the β-amyloid protein, that is involved in the AD pathology. The main 
hypothesis about the causes of AD is called “amyloid cascade hypothesis” that defines the Aβ as 
the initiator. This hypothesis states that the increase in production, aggregation and accumulation 
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of Aβ in the brain cause a cascade of neurotoxic events that can lead to widespread neuronal 
degeneration and the clinical symptoms of dementia. The β amyloid protein is the main constituent 
of senile plaques and extracellular aggregates formed by a conformational change of the protein. It 
is produced starting from the “amyloid precursor protein” (APP), a membrane protein encoded by a 
gene located in the central portion of the long arm of chromosome 21.  
 
 
Figure 5: β-amyloid cascade 
 
It consists of three domains: the extracellular hydrophilic N-terminal, the hydrophobic 
transmembrane and the intracellular C-terminal. It is expressed in different cells, particularly in brain, 
heart, spleen and kidneys. Until today at least 10 isoforms have been identified; the three most 
common are called C (mainly located in neurons), B (located in T cells) and A; them are respectively 
composed of 695, 751 and 770 aminoacids. Although the physiological role of APP and its isoforms 
has to be clarified, it seems involved in various physiological processes. I. e., it demonstrates 
neuroprotective properties; moreover, its addition to cell cultures decreases intracellular calcium 
levels. APP is synthesized in ribosomes then, it is transported into the endoplasmic reticulum and 
in the Golgi apparatus where it undergoes several changes such as phosphorylation, glycosylation 
and sulphurization. Most of it is degraded during the transport to the cell membrane. This protein 
can undergo the action of three different enzymes, present at the cellular level: α-, β- and γ-
secretase. At physiological conditions, the α-secretase enzyme acts at residue 687, between 
residues Lys and Leu, and, in this way, allows to the not amyloidogenic process. This process forms 
a large soluble N-terminal fragment, called α-APPs, and a C-terminal fragment of 83 residues, which 
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undergoes the action of γ-secretase, forming two other fragments, P-340 and P-342, which are soluble 
and thus harmless and are released in the extracellular. 
On the other hand, the amyloidogenic pathway begins with the action of β-secretase (BACE-1, beta 
site amyloid precursor protein-cleaving enzyme 1) which releases a soluble N-terminal fragment, 
called β-APPs, shorter if compared to α-APPs. The remaining C-terminal fragment, with 99 residues, 
is a substrate for the γ-secretase that forms Aβ40, a peptide fragment consisting of 40 amino acids, 
soluble and harmless, and Aβ42, which it is insoluble, toxic and has a tendency to aggregate (fig. 6).  
 
 
Figure 6: β-amyloid plaques and neurofibrillary tangles in AD15 
 
The action of γ-secretase occurs within the cell membrane and further to its action a short tail (AICD) 
consisting of about 50 amino acids, is also formed; it is released into the cytoplasm and it has as its 
cellular target the nucleus, where it activates gene transcription.  
Aβ42 accumulates in patients with AD or Down syndrome; recent studies demonstrate that 
individuals with trisomy 21 faster progress the disease and show signs of mitochondrial alterations, 
causing premature aging, which appear to be due to an accumulation of APP, codified precisely on 
chromosome 21. The β-amyloid peptide aggregates spontaneously in many forms. One of these 
consists of oligomers (from 2 to 6 peptides) which merge into intermediate forms.16,17 It can grow 
into fibrils, which are arranged in β-sheets in order to form β-amyloid plaques. It is not yet clear if 
the formation of insoluble peptides is the event that triggers the process of neuronal death or if it is 
a consequence of the damage.18 Although Aβ42 seems to be the responsible of AD, also soluble 
forms could be correlated with the different neuropathological aspect of the disease. 
 
1.2.3 Tau protein 
 
 The formation of aggregates of tau protein is very important in AD. In normal conditions, in 
healthy subjects, Tau is a soluble protein and it acts as a stabilizer of the cytoskeleton of neurons, 
promoting the assembly, the microtubule stability and the transport of vesicles. In fact, the 
cytoskeleton is formed by microtubules, in particular of polymers of tubulin. These microtubules are 
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linked to associated proteins that regulate their stability. The most important of these proteins at 
axonal level is tau protein, a very hydrophilic protein that contains several phosphorylation sites. A 
high degree of phosphorylation by the kinase causes a detachment of the protein from microtubules 
and induces neuronal damage. More in details, in patients affected by AD and other 
neurodegenerative disorders, called "tauopathies", tau protein undergoes a series of changes 
leading to the formation of neurofibrillary tangles (NTFs), filamentous inclusions that are the main 
microscopic changes along with senile plaques (fig. 7). Six isoforms are expressed in human brain, 
originating from the alternative splicing of a single gene, located on chromosome 17.  
 
 
Figure 7: neurofibrillary tangles 
 
Its physiological location is in the cytoskeleton of axons, but in conditions of neurodegenerative 
disease is also found in cell bodies and dendrites. The main component of tangles is a 
hyperphosphorylated and aggregated form of tau. Four repeated sequences constitute the binding 
site of tau to microtubules. Standard tau phosphorylation occurs at serine and threonine; when 
followed by proline, these aminoacids are phosphorylated by GSK-3β (Glycogen Synthase Kinase 
3β), cdk5 (cyclind-dependent kinase) or by MAPK (mitogen-activated protein kinase). The 
hyperphosphorylated form is insoluble, lacks affinity for microtubules and it is associated in pairs of 
helical filaments; finally, it forms intracellular aggregates in order to obtain neurofibrillary tangles. In 
this way, axonal transport and cell vital processes are damaged. 
The amount of tangles is a pathological marker of the severity of the disease; in fact, increased 
levels of phosphorylated protein in the cerebrospinal fluid are correlated with the reduction in scores 
on cognitive tests.19 Tau hyperphosphorylation could be induced by Aβ or it could come from by a 
mutation of the PS-1 gene that encodes for presenilin-1 protein; the latter is responsible for the 
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phosphorylation of tau by kinase GSK-3β.20 However, tau protein if dephosphorylated is able to 
recover the ability to bind microtubules. Recently, a gene encoding a protein involved in cholesterol 
transport, the apolipoprotein E (ApoE) has been identified as a molecular factor implicated in the 
pathogenesis of AD. In particular, ApoE4 genotype is a risk factor that can lead to early onset of the 
disease. The general idea is that ApoE4 activity increases the concentration of the peptide Aβ 
decreasing in this way its clearance. At the same time, ApoE increases the activity of glycogen 
synthase kinase 3β (GSK3β), the kinase that cause tau hyperphosphorylation. 
 
1.2.4 Neuroinflammatory hypothesis 
 
 The neuroinflammatory hypothesis states that inflammation plays a critical role in promoting 
the degenerative process of AD. Although inflammation represents the first line of defense against 
dangerous agents, a disproportionate response can increase the damage to neuronal cells and, 
thereby, allow to the progression of the disease.21 Extracellular Aβ deposits and tau protein 
intracellular tangles induce microglial cells and astrocytes to the inflammatory response through the 
production of factors, such as cytokines (IL-1, IL-2, TNF), chemokines and ROS. Initially the 
microglial cells phagocytize and degrade Aβ and also astrocytes are involved in its elimination 
through receptor-mediated internalization and facilitating its transport out of the central nervous 
system in the bloodstream. Aβ plaques and activation of glial cells too, stimulate the intervention of 
the classical complement pathway.22 Activated cells release proteins of the acute phase, alpha1-
antichymotrypsin, alpha2-macroglobulin, C-reactive protein, which aggravate the disease.23 The 
contradictory role of microglia (elimination of Aβ and release of pro-inflammatory molecules) 
complicate the treatment; it was reported that the use of nonsteroidal anti-inflammatory agents could 
reduce risk of the onset of the disease and will slow down the progression.24 Their mechanism of 
action would include the reduction of Aβ42, the inhibition of cyclooxygenase-2 or the receptor of 
prostaglandin E2, the stimulation of phagocytosis by microglia, and the activation of PPARγ 
(peroxisome proliferator-activated receptor gamma), which regulates the deposit of fatty acids and 
the glucose metabolism. 25 
 
1.2.5 The oxidative stress 
 
 Oxidative stress is a cause of neuronal death in AD (fig. 8). This is related to a mitochondrial 
dysfunction, caused by exposure to Aβ, which inhibits key mitochondrial enzymes and in particular 
seems to be affected cytochrome c-oxidase, the last enzyme complex involved in the electron 
transport, in addition to enzymes key of the Krebs cycle (α-ketoglutarate and pyruvate 
dehydrogenase) and mitochondrial DNA, which is damaged.26 In patients, high concentrations of 
reactive oxygen species (ROS) are observed. Abnormal mitochondria lead to an increase in the 
concentration of hydrogen peroxide in the cytoplasm, the interaction of this with iron induces the 
production of free radicals.  
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This interaction is possible thanks to the higher concentration of free iron resulting from a decrease 
in the concentrations of ferritin observed in patients. Free radicals oxidize lipids and damage the 
membranes of the brain. The products of lipid peroxidation, e.g. the aldehydes formed by oxidation 
of polyunsaturated fatty acids, have a half-life longer than radicals. Thus, aldehydes can spread to 
other sites and react. 
 
 
Figure 8: the oxidative stress 
 
Free radicals oxidize proteins causing the loss of activity that leads to destabilization of the various 
systems and balances into neurons. High levels of oxidation products of DNA and RNA, that may 
have serious consequences on the function of ribosomes and protein synthesis, were also observed 
in neurons of patients. In addition to the disorder of iron homeostasis, there is also a change in the 
concentration of zinc and copper. Aβ peptide binds copper ions with high affinity, and after several 
redox exchanges, Cu2+ is able to reduce the oxygen and to generate H2O2. 
 
1.2.6 Interconnected pathways in Alzheimer’s disease 
 
 The Aβ monomers that are released outside neurons can be removed by microglia, which 
release insulin-degrading enzyme (IDE) that destroys them (fig. 9). This aberrant peptide increases 
the influx of Ca2+ by forming Ca2+ permeable channels in the plasma membrane. Aβ42 has high 
potential to aggregate to form Aβ oligomers, which rate of aggregation is also increased by the 
interaction of Aβ with the peripheral anionic site of AChE. Aβ oligomers can interact with metal ions 
Fe2+ or Cu+ activating the generation of reactive oxygen species (ROS). 
These species damage the plasma membrane facilitating the influx of different ions resulting in 
membrane depolarization. Membrane depolarization and sub products of lipid peroxidation affect 
the function of different receptor and channels such as N-methyl D—aspartate receptors (NMDAR), 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPAR) voltage-dependent 
calcium channels (VDCCs). Aβ oligomers can affect also the activity of these receptors and channels 
directly. Presenilins (PS) function as Ca2+ leak channels at the endoplasmic reticulum (ER), mutated 
PS are highly related to familial AD. PS were found at ER membranes. Mutations in PS modify their 
ability to regulate Ca2+ in the ER enhancing Ca2+ release through ryanodine receptors (RyR) and 
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inositol triphosphate receptors (InsP3R) channels. There is also evidence that PS can interact 
directly with InsP3Rs, RyRs, and the SERCA pump to alter ER Ca2+ release and uptake.  
 
 
Figure 9: interconnected pathways 
 
AICD migrates to the nucleus, interacts with transcription regulators, and modifies gene transcription 
to disrupt Ca2+ homeostasis. 
Elevated Ca2+ can also affect the attachment/detachment equilibrium of protein Tau (τ) to tubulin to 
form the cytoskeleton. GSK3β and other kinases are involved in this equilibrium; Ca2+ can modify 
their activity inducing τ hyperphosphorylation to generate, after its aggregation, the neurofibrillary 
tangles. Aβ also affect mitochondria inducing oxidative stress and Ca2+ dysregulation resulting in an 
increase in the production of radicals and decreased production of ATP. High concentrations of Ca2+ 
can be stored by mitochondria through mitochondrial Ca2+ uniporter (MCU), resulting in Ca2+ 
overload of mitochondria leading to opening of mitochondrial permeability-transition pore (mtPTP) 
and apoptosis.” 27 
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1.3 Therapeutic approaches  
 
 Most of the drugs on the market acts on the cholinergic system that appears to be the most 
affected. First of all, considering that there is a decrease in ACh levels, the first approach was to 
restore physiological levels or, otherwise, to mimic the action at receptor level of this 
neurotransmitter. Cholinergic receptors in central nervous system are located in presynaptic and 
postsynaptic levels and they can be either of nicotinic or muscarinic type. These differ not only for 
the various types of ligands that are able to interact with them, but also for many other basic aspects, 
as a function, molecular architecture, localization and biological mechanisms associated with their 
activation. Nicotinic receptors are ionotropic and pentamers, constituted, in most cases, of different 
subunits classified as α and β. Presynaptic nicotinic receptors control the release of ACh and also 
of glutamate, serotonin and norepinephrine, that are important neurotransmitters for memory and 
behavior. Thus, the presence of agonists able to interact with these receptors would be 
pharmacologically useful. 
Studies concerning the various receptor subtypes present in the central nervous system, show that 
best results were obtained with active substances against subtypes α4β2 and α7, designed by 
modifying the pyridine ring and pyrrolidine nicotine, specific agonist of nicotinic receptors. Despite 
their potential function, these are not used in therapy for several reasons, including lack of selective 
ligands for the various receptor subtypes, with consequent difficulty of differentiate therapeutic 
effects. Another potential approach is to modulate the action of metabotropic muscarinic receptors. 
Therefore they are membrane proteins associated with their effectors via a functional unit including 
a G protein. They are also characterized by a single polypeptidic chain that crosses the membrane 
seven times, forming in this way seven transmembrane domains. Five receptor subtypes, named 
M1, M2, M3, M4, are pharmacologically characterized. Subtype M5, has not yet been characterized 
from a pharmacological point of view, due to a lack of selective ligands and knowledge on its specific 
location. Among different compounds that can modify cholinergic neurotransmission, the only class 
of drugs that obtained from regulatory authorities the indication for the symptomatic treatment of AD 
are the cholinesterase inhibitors (ChEIs).28 These drugs act by slowing the biochemical breakdown 
of acetylcholine and thereby, prolonging cholinergic neurotransmission. Of interest is that humans 
have two types of cholinesterases, AChE and BuChE. The physiological role of BuChE is unknown, 
but levels of this enzyme have been shown to increase as AD progresses and it contributes at the 
hydrolysis of acetylcholine while levels of AChE decrease. In AD patients, both enzymes are located 
in neuritic plaques, and their inhibition with ChEIs may modify the deposition of Aβ, a key component 
of the pathophysiology of AD. Tacrine was the first approved drug (1993) able to inhibit AChE. 
Thereafter, donepezil, galantamine and rivastigmine were approved (fig. 10). The latter three drugs 
are currently the most widely used for the treatment of mild to moderate stages of Alzheimer's 
although some studies suggested a small benefit also in patients suffering from more advanced 
stages of the disease. However, their clinical use is limited by many side effects such as confusion, 
hallucinations, mood swings and nausea, resulting from excessive activation of the cholinergic 
system. Donepezil is a reversible AChE inhibitor. It also binds PAS and decreases the beta amyloid 
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aggregation induced by AChE. Donepezil is metabolised in the liver by the cytochrome P450 
isoenzymes CYP2D6 and CYP3A4 and byuridine-diphosphate glucuronosyl transferase, with 
extensive first-pass metabolism. It has a long half-life of elimination (70 h) and is assumed once 
daily. Rivastigmine is a slowly reversible (pseudoirreversible) inhibitor of both AChE and BuChE, 
has low plasma-protein binding (40%), and is hydrolyzed by esterases. It is not metabolized by 
cytochrome P450 and its short elimination half-life necessitates two doses daily. It can be orally or 
transdermally administered and it has good capacity to cross the blood-brain barrier; then, it 
performs its pharmacological action on both the central and the peripheral acetylcholinesterase.  
Galantamine is a selective reversible AChE inhibitor and a positive allosteric modulator of nicotinic 
receptors on pyramidal neurons increasing the release of ACh. It is poorly bound to plasma protein 
(18%) and is metabolized in the liver via cytochrome P450 isoenzymes (mainly CYP2D6 and 
CYP3A4). With its terminal elimination of about 5h, two doses are required daily. To date the clinical 
relevance of this pharmacological heterogeneity is unknown.  
Memantine was recently approved; it is a non-competitive NMDAR (postsynaptic receptors) 
antagonist and reduces glutamatergic excitotoxicity; it was developed considering the role of Ca2+ 
in the pathogenesis of Alzheimer's. Glutamate is an excitatory neurotransmitter in the brain and it is 
implicated in neurodegenerative disorders. However, excessive glutamatergic stimulation can cause 
neuronal damage, which leads to a pathological condition of neurotoxicity. Such excitotoxicity 
ultimately leads to neuronal calcium overload and has been implicated in neurodegenerative 
disorders. Glutamate stimulates various postsynaptic receptors, including the NMDA receptor, which 
has been particularly implicated in memory processes, dementia, and the pathogenesis of AD. 
However, it is not a ChEI and therefore, is different from other drugs currently used for AD treatment. 
The mechanism of action of memantine is a voltage-dependent, low-moderate affinity, uncompetitive 
NMDA receptor antagonism with fastblocking/ unblocking kinetics. The low-moderate affinity is 
important because other NMDA receptor antagonists, such as ketamine and amantadine, are high-
affinity compounds with neuropsychiatric side effects. The fast on/off kinetics are also important 
because this means that memantine sits on the receptor just long enough to prevent pathologic 
activation of the glutamate receptors and then quickly goes away when physiologic activation of the 
glutamate receptors is needed. 
Memantine blocks the effects of abnormal glutamate activity that may lead to neuronal death and 
cognitive dysfunction. The fast on/off kinetics and low-moderate affinity are the key of memantine 
action because it blocks the effects of excessive glutamate while preserves physiologic activation of 
NMDA receptors required for learning and memory. Like other NMDA receptor antagonists, 
memantine at high concentrations can inhibit mechanisms of synaptic plasticity that are supposed 
to underlie learning and memory. However, at lower, clinically relevant concentrations memantine 
can promote synaptic plasticity and preserve or enhance memory in animal models of AD. Moreover, 
memantine can protect against the excitotoxic destruction of cholinergic neurons. 
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Figure 10 
 
Inflammation and glial activation observed in patients of AD led to the idea that NSAIDs (nonsteroidal 
antiinflammatory drugs) might be important for the Alzheimer's treatment and especially due to its 
prevention. Other targets such as the GSK3β, BACE-1, -secretase were investigated for the 
development of neuroprotective and neurotrophic agents. In fact, other pharmacotherapeutic 
treatment of AD should be directed to the prevention of Aβ production, aggregation, toxicity or 
degradation, or a combination. Two main classes of disease-modification approaches can be 
defined, namely, the neurotrophic and neuroprotective strategies. Neurotrophic strategy includes 
hormone replacement therapy and drugs acting on insulin signal transduction. Neuroprotective (anti-
amyloid strategies) include secretase inhibition, statins to lower cholesterol, neprilysin to promote 
Aβ degradation, metal chelators that block Aβ aggregation. and NSAIDs that reduce Aβ production. 
Some studies in cultured cells and Aβ precursor protein transgenic mice suggest that some NSAIDs 
associated with protection from AD (such as ibuprofen) can actually modulate -secretase 
processing of Aβ precursor protein to decrease Aβ protein 42 production without lowering overall 
Aβ protein levels or interfering with Notch cleavage.29  
This unexpected finding could lead to derivatives of certain NSAIDs being used as a special type of 
‘‘-secretase. Agents promoting clearance of Aβ from brain may also represent a promise as 
therapeutic intervention for AD. For instance, the removal of Aβ by active and passive immunization 
strategies results in clearance of Aβ from brain and improves performance in behavioral tests. 
Various antioxidants, free radical scavengers, calcium-channel blockers, metal chelators, or 
modulators of certain signal transduction pathways might protect neurons from the downstream 
effects of accumulation of Aβ protein. Some studies suggest that high intake of vitamins C, E, B6, 
and B12, and folate, unsaturated fatty acids, and fish are related to a low risk of AD, but the results 
of different reports are inconsistent. Modest to moderate alcohol intake, particularly wine, may be 
related to a low risk of AD. Alpha-tocopherol (Vitamin E) is a lipid-soluble vitamin that interacts with 
cell membranes, traps free radicals, and interrupts the chain reaction that damages cells. Vitamin E 
is an antioxidant and it is thought to mitigate the inflammatory effects of plaque formation in the 
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brain. Selegiline, a monoamine oxidase inhibitor, similarly to alpha-tocopherol may have beneficial 
effects in patients with AD. Selegiline also increases levels of catecholamines, and adrenergic 
stimulation may improve cognitive deficits associated with AD. A number of studies have examined 
evidence for the use of selegiline, a selective monoamine oxidase inhibitor, in the treatment of AD.30  
As demonstrated by several hypotheses that were formulated with the attempt to define the 
molecular mechanisms of the disease, the multifactorial nature of AD leads to not focus the attention 
on a single therapeutic target. From a pharmacological point of view, the actual problem is that there 
are no drugs able to stop progression and worsening of the disease but, nowadays, all available 
treatments can only relieve symptoms.  
 
1.4 New directions: MTLD strategy 
 
 Although the etiology of AD is not very clear, multiple factors, such as β-amyloid and τ 
protein aggregation, excessive metal ions (e.g. Cu2+, Zn2+, Fe3+), oxidative stress and reduced 
acetylcholine level, have been considered to play important roles in the pathogenesis of AD. This 
provides various targets for screening AD-modifying drugs. Indeed, numerous synthetic or natural 
molecules have been screened to decrease Aβ production to prevent Aβ or τ aggregation, to chelate 
transition metals, to scavenge reactive oxygen species (ROS) or to inhibit acetylcholinesterase or 
monoamine oxidase (MAO). However, the success of the one-drug-one-target strategy (fig. 11, i.e. 
1) is limited considering that it is not sufficient to effectively treat a multifactorial disease, which has 
stimulated the search for more efficient combined weapons to combat AD. 31 Moreover, at present, 
as assumed before, all treatments approved by the FDA are only palliative and they do not heal the 
disease.  
 
 
Figure 11: pharmaceutical strategies 
 
To hit the multiple targets implicated in the complex diseases, three strategies are conceivable. One 
is called “MMT” (multiple-medication therapy) and it consists in a “cocktail” or “combination of drugs”; 
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the MMT (fig. 11, i.e. 2) can be formed by two or three different drugs combining different therapeutic 
mechanisms.32 
However, this approach could be disadvantageous for patients with compliance problems; 
moreover, also pharmacokinetic interferences might appear. Another strategy is the “MCM” 
(multiple-compound medication), which incorporates two or more active ingredients in one single-
pill drug combination (fig. 11, i.e. 3) which involves the incorporation of different drugs into the same 
formulation in order to simplify dosing regimens and improve patient compliance. This strategy has 
been successfully used in traditional medicine (in China and many other countries) for thousands of 
years and in current drug cocktails as well to suppress the spreading of HIV. The other attempts is 
to employ one compound to hit multiple targets: the multi-target-directed ligands (MTDL) strategy 
(fig. 10, i.e. 4). More in detail, the MTDL strategy consists in the combination of various 
pharmacophores of different already known drugs in order to obtain a new hybrid molecule able to 
interact with all selected targets. Although the latter strategy seems more convenient than the 
former, it is more difficult to be fulfilled. Nevertheless, the accumulating experience gained in the 
battle against AD displays the feasibility of the latter strategy. A therapy with a single drug with 
multiple biological properties would have several advantages over MMT or MCM that have different 
bioavailability, pharmacokinetics, and metabolism. In fact, if a single molecular species can show a 
complex ADMET profile, an MMT/MCM approach might be unpredictable. Considering 
pharmacokinetic and ADMET optimization, the clinical development of a drug able to hit multiple 
targets should not be different from the development of any other single lead molecule, offering a 
simpler approach than MMT/MCM; moreover, the risk of possible drug-drug interactions would be 
eluded. 
Despite the in vitro success of synthetic multifunctional agents, the potential risks in safety, 
absorbability and pharmacokinetics is a big hurdle in their further development. Hence, it is exciting 
to note that some natural products also hold multiple functions. I. e. the beneficial effect of curcumin 
to prevent AD has been shown by transgenic mouse experiment and epidemiologic investigation 
that AD prevalence is only 1% in people over age 65 of rural India, where turmeric is commonly 
used in food. The AD-preventing mechanism of curcumin was naturally related to its well known 
antioxidant and anti-inflammatory activities. Besides curcumin, flavonoids, such as gossypetin, (-)-
epicatechin- 3-gallate and myricetin, are pleiotropic natural products too. They have long been 
known as excellent ROS scavengers endowed with high metal-chelating ability. The different 
structures of curcumin and flavonoids suggest that the structural requirements to fulfill the 
multifunction are diverse. Thus, it can be expected to find more candidates from natural product 
libraries that can be regarded as a multifunctional pharmacophore, which means that the multiple 
targets in AD can be hit not only by one compound but also by one pharmacophore. 
 
1.5 New targets: the endocannabinoid system 
 
 The endocannabinoid system (ECS) is a complex endogenous system of communication 
among cells. It is composed of cannabinoid receptors, their endogenous ligands and proteins 
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involved in the metabolism and transport of endocannabinoids themselves. This system is essential 
for the normal functioning of the body and it has been identified in mammals, fish, shellfish, 
amphibians, birds and leeches. It plays a key role in neuronal development as well as in 
neurodegenerative processes. Endocannabinoids are a class of bioactive lipids, which includes 
amines, esters, and ethers of long chain fatty acids with the mutual ability to bind to cannabinoid 
receptors. Phytocannabinoids indicate a class of chemical compounds present in Cannabis sativa 
from which is named the entire system. Natural phytocannabinoids are a class of aromatic 
hydrocarbons containing oxygen and until today over 60 of them have been identified; their 
distribution varies in different cannabis strains and usually only three or four cannabinoids are found 
in a plant at a concentration of 0.1%. ECS constitutes a neuromodulator system that can regulate 
neuronal excitability by inhibiting communication through tight junctions or through interactions with 
GABA, serotonergic, glutamatergic and dopaminergic transmissions. According to the localization 
of cannabinoid receptors it has been hypothesized that the system is involved in a large number of 
physiological processes33 especially in the central nervous system (CNS), where it acts as a 
neuromodulator mediating the effects of psychoactive constituent of Cannabis Δ9-
tetrahydrocannabinol (THC), but also in the immune, cardiovascular and gastrointestinal systems.34 
Nowadays, THC and its analogs are used to treat nausea and vomiting caused by chemotherapy 
and radiotherapy and also in patients with AIDS.  
Regarding endogenous compounds, the first to be identified in 1992, is anandamide (AEA), followed 
by 2-arachidonoylglycerol (2-AG). More recently at least three other endogenous cannabinoids have 
been identified: the 2-arachidonyl glyceryl ether (noladin, 2-AGE), a structural analogue of 2-AG, 
the Virodhamine and N-Arachidonoyl dopamine (NADA). AEA and 2-AG (fig. 12) mimic some of the 
pharmacological effects of THC. Cannabinoid receptors CB1 and CB2, the endogenous ligands 
endocannabinoid (EC) anandamide and 2-arachidonoylglycerol and their degradative enzymes fatty 
acid amide hydrolase (FAAH) and monoacylglyceride lipase (MAGL) are key elements of the ECS 
implicated in several physiological functions including cognitive, motor activities and immune 
response. 
Endocannabinoids are produced inside cells through multiple synthetic routes and differ from other 
neurotransmitters: they are not stored inside the vesicles, but are produced on-demand from 
membrane phospholipid precursors. The process of biosynthesis is activated by a stimulus that 
causes the depolarization of the cell membrane. The lipid precursor that is processed for the 
synthesis of anandamide (AEA) is the N-arachidonoyl-phosphatidylethanolamine (NArPE), on 
which, first the N-acetyltransferase and then a phospholipase D type act in a sequential manner; the 
process ends with the release of AEA and phosphatidic acid (PA). The biosynthetic pathways that 
lead to the formation of 2-arachidonoylglycerol (2-AG), can follow different mechanisms, but the 
most probable hypothesis consists in the formation of di-acyl-glycerol that then is hydrolyzed to 2-
AG through the action of a phospholipase C-type. Synthesized endocannabinoids are immediately 
released from the cell in order to bind receptors on neighboring cells or on the same cell that 
produced them, thus acting as both paracrine and autocrine mediators. In particular, it has been 
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suggested that endocannabinoids behave as retrograde messengers: after being synthesized in the 
postsynaptic cell, they would activate the receptors of the axons of the presynaptic cell. 
 
 
Figure 12: AEA and 2- AG. 
 
The inactivation of these compounds involves different enzymatically regulated mechanisms: their 
reuptake can be done thanks a passive diffusion across the membrane or through a specific carrier 
or they may undergo hydrolysis mediated by a specific enzyme. The AEA is inactivated by a 
reuptake mediated by the AMT (AEA membrane transporter) and it is subsequently enzymatically 
degraded by the action of FAAH, which releases arachidonic acid and ethanolamine. In addition to 
hydrolysis mediated by FAAH, the AEA is also metabolized by other enzymes such as COX-2 and 
the complex of cytochrome P450.35 The 2-AG too is inactivated by reuptake mediated by the AMT 
or by a passive diffusion across the membrane and by subsequently enzymatic degradation caused 
by MAGL, like the other monoacylglycerols, which releases arachidonic acid and glycerol. As for the 
AEA, other enzymes such as COX2 can also intervene. 
 
1.5.1 CBs receptors 
 
 Endocannabinoids and cannabinoid receptor type 1 and 2 (CB1, CB2) play a significant role 
in physiological and pathological processes, including cognitive and immune functions.36 There is a 
growing appreciation of the therapeutic potential of cannabinoids in many pathological conditions 
involving the chronic inflammation. The two receptors have different physiological properties. The 
psychoactive effect is associated with cannabinoid CB1 receptor, while CB2 receptor has primarily 
anti-inflammatory, and immunomodulatory actions. CB1 receptor was discovered by Devane and 
coworkers in 1988. It is widely distributed in regions of the brain, particularly the frontal cortex, 
hippocampus and amygdala, sensory and motor areas and hypothalamus. Instead, CB2 receptor 
was isolated from human myeloid cells in 1992; between the two receptors, there is a structural 
homology of 44%. The endocannabinoid receptors belong to the superfamily of G protein-coupled 
receptors (GPCRs); they have an amino terminal extracellular extremity, seven transmembrane α-
helices and a carboxy terminal intracellular extremity. The most important difference between the 
two receptors is their interaction with the lipid-surrounding environment which is in the TM7domain. 
CB1 receptor has a hydrophobic surface that is suitable for the specific interaction with cholesterol 
and palmitic acid, while CB2 receptor shows a region of negative charge which is quite unfavorable 
to any lipid interaction, although they present the ability to be activated by the same 
endocannabinoids and they may cause the same signal. The differences between the two receptors 
could be exploited to develop specific ligands. 
22 
 
 
Figure 13: cannabinoid system37 
 
It was also identified a third type of receptor, CB3, present in the brain and endothelial tissues but it 
still has not been well characterized. CB1 cannabinoid receptors are the most abundant and widely 
distributed GPCRs in brain especially in the basal ganglia, globus pallidus and substantia nigra and, 
to a lesser extent, in the cerebellum, hippocampus, caudate nucleus, putamen, hypothalamus and 
amygdala. They have also been identified, but with lower density, in lungs, liver, kidneys, and in both 
male and female cells of the reproductive system. CB1 receptors are absent in the medulla 
oblongata, the part of the nervous system that governs the control of respiratory and cardiovascular 
functions. The role of the receptors is essentially to regulate the release of other neurotransmitters, 
in fact, the activation of CB1 protects the CNS from overstimulation or extra-inhibition caused by 
other neurotransmitters. As for the CB2, it was thought that they were almost exclusively on T cells 
of the immune system, with the highest density in the spleen. However, recent studies have shown 
their presence also at the level of the central nervous system, in particular at the level of glial and 
microglial cells.  
The stimulation of CB2 receptors appears to be primarily responsible for the anti-inflammatory and 
immunomodulatory activity of cannabinoids, through the regulation of cytokine release. Anandamide 
and NADA do not only bind to cannabinoid receptors but as capsaicin, an active ingredient in hot 
peppers, have the ability to bind the vanilloid receptors (TRPV1) (fig. 13). 
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As mentioned before, CB1 and CB2 receptors are G-protein coupled inhibitory; in fact their activation 
involves inhibition of adenylate cyclase, ion channel voltage-dependent Ca2+ N, P/Q and L type. The 
action on these channels and on adenylate cyclase is mediated by the α subunit of the G protein. In 
particular, the activation of CB1 receptors blocks N type presynaptic calcium channels reducing the 
synaptic transmission. It is also probable that the THC induces some of its symptoms at cognitive 
level thanks this molecular mechanism.38 It was then suggested that activation of these receptors 
plays a role in neurogenesis, synaptogenesis and axonal growth even if the molecular mechanisms 
involved in these processes are not yet completely understood. 39 The adenylate cyclase inhibition 
and the consequent decrease of cAMP also leads to a decrease in the activity of the protein kinase 
A (PKA), which leads to a decrease in the phosphorylation of the type D potassium channels. The 
effects of the activation of these receptors include, depending on the dose, the cell type and the 
state of the organism, euphoria, anxiety, dry mouth, muscle relaxation, hunger and pain reduction. 
This means that they not only block the effects of endocannabinoids but they also produce opposite 
effects compared to agonists, such as an increased sensitivity to pain or nausea, suggesting that 
the cannabinoid system is tonically active. This tonic activity may be due to a constant release of 
endocannabinoids by a portion of the receptor that is in a constantly active state. CB receptor 
antagonists are in clinical use for the treatment of obesity and are being tested for the treatment of 
addiction to nicotine and other. CB1 receptor agonists should not overcome the blood-brain barrier, 
in order to avoid the psychotropic action, and the development of compounds that influence the 
levels of endocannabinoids through the inhibition of their membrane transport or hydrolysis (as 
inhibitors of FAAH). For example, blockers of anandamide hydrolysis are able, in animal tests, to 
reduce anxiety, pain, tumor growth and colitis. Currently, for the medical use, two cannabinoid 
receptor agonists are available, dronabinol and nabilone and a cannabis extract (Sativex®). In some 
countries, the possession of small amounts of cannabis for recreational use or treatment is allowed 
or tolerated, as in the Netherlands, Spain, Belgium and some regions of Switzerland. Dronabinol is 
a synthetic ∆9-THC, the primary psychoactive cannabis which is used to treat nausea and vomiting 
associated with cancer chemotherapy who do not respond adequately to conventional antiemetic 
treatments. Rimonabant, with Acomplia trade name, a cannabinoid receptor antagonist, is instead 
used for the treatment of obesity but it was withdrawn from the market owing to its side-effects. The 
high concentration of CB1 and the presence of AEA and 2-AG in regions of the brain involved in 
memory processes are in line with the idea that ECs modulate cognitive processes. The activation 
of these receptors reduces the ACh levels in the hippocampus, followed by a cognitive decline, 
suggesting a function of modulation on ACh release by CB1 receptors.  
Many neurodegenerative diseases are associated with chronic inflammation from the activation of 
microglial cells. Considering that increased proliferation of microglial cells in the brain of patients 
affected by AD, has deleterious effects on surrounding neurons, many studies focused the attention 
on factors that mediate the activation of microglial cells. In this scenario, CB2 receptors seem to 
play a crucial role in inflammatory processes that affect the brain. It is proved that activation of CB2 
receptors causes immunomodulatory effects that lead to many changes in the production of 
substances related to inflammation. The ability of compounds selective for the CB2 receptors in 
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reducing inflammation, can be explained by increasing proliferation and recall of immune cells 
involved in immune-mediated repair of damaged tissues. Thus, CB2 receptors expressed on 
leukocytes in the SCN may be activated by EC which modulates the progression of 
neuroinflammation. Cannabinoids modulate the immune response during inflammatory processes. 
Several animal studies showed that cannabinoids exert their immunomodulatory properties in four 
different ways: the induction of apoptosis, suppression of cell proliferation, inhibition of the 
production of pro-inflammatory cytokines and the increase of anti-inflammatory cytokines and the 
induction of T regulatory cells. The activation of CB2 triggers apoptosis in immune cells; this 
suggests that this receptor may be the target of a new therapeutic approach for the treatment of 
inflammatory and autoimmune diseases. Several studies demonstrated that the expression of CB2 
receptor is upregulated during neuroinflammation and that agonists of this receptor reduce the 
permeability of the blood-brain barrier through the increase in the expression of tight junctions.  
 
1.5.2 Endocannabinoid system and Alzheimer disease 
 
 The probable neuroprotective role of ECs and their modulating action on neurotransmitter 
systems affected by neurodegenerative diseases such as Alzheimer's, Huntington's disease and 
multiple sclerosis are under investigation. Increasing data show an imbalance in the system CEs 
(for example, a decrease of neuronal CB1 receptors, an increase in glial CB2 receptors and an over 
expression of the enzyme FAAH in astrocytes) in experimental models of AD and in post-mortem 
brain tissue of AD patients. The central role of ECs in several diseases of the CNS, such as mood 
disorders and neurodegenerative diseases is confirmed by the high expression of cannabinoid CB1 
receptors in brain areas such as the cortex, cerebellum, hippocampus and basal ganglia affecting 
cognition, motor activities and satiety.40 The EC system plays a dual role in the pathophysiology of 
AD, the first related to its inhibitory action on the release of acetylcholine and the second related to 
its anti-inflammatory action in the CNS.  
Recent studies focused the attention on the possible protective role of ECs in limiting microglia 
activation and inflammation in AD in fact microglia activation leads to in vivo and in vitro 
neurodegeneration and also AD transgenic mouse models develop plaques characterized by 
deposits of Aβ and activated microglia. The role of ECs is important in the modulation of immune 
function and inflammation; endocannabinoids and Δ9-THC affect memory as well as neurochemical 
substrates of the acquisition and consolidation of memory, such as long-term potentiation. 
Cannabinoid receptors are located in immune cells where their expression is modulated by stimuli 
that induce immune activation, although it has been suggested a cannabinoid-independent 
mechanism. Recently, Esposito et al. showed that CB2 is able to attenuate the inflammatory 
responses caused by Aβ in neurotoxicity Aβ models, suppressing IL-1β and inducible nitric oxide 
synthase (iNOS). Although there are still doubts, all components of the EC system that act on 
different nervous cells or neurons and astrocytes, may play a role in normal and pathological 
conditions. 
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The central role of ECs in several diseases of the CNS, such as mood disorders and 
neurodegenerative diseases, is confirmed by the high expression of cannabinoid CB1 receptors in 
brain areas such as cortex, cerebellum, hippocampus and basal ganglia that affect cognition, motor 
activities and satiety. Endocannabinoids, showing an anti-inflammatory and antioxidant action, as 
well as a protective action against excitotoxicity and improvement of neurogenesis, may have 
beneficial effects on Alzheimer's. The involvement of the endocannabinoid system in AD is 
supported by a number of studies done on post-mortem brains of patients that showed a nitrosylation 
and up-regulation of cannabinoid receptors in microglia. Some studies demonstrated that 
cannabinoids can contribute for a neuroprotective effect against toxicity induced by Aβ considering 
that the CB1 receptors are related to the processes of learning and memory and the block of the 
latter by SR141716A, CB1 antagonist, seems to reduce amnesia induced by Aβ plaques in mice.41 
In addition, also membrane transport or FAAH and MAGL enzymes inhibitors (that regulate the 
levels of cannabinoids in the brain) may play an important role for the protection against 
neurodegeneration induced by Aβ. Recent studies showed that Δ9-THC inhibits AChE and prevents 
the aggregation of the peptide induced by the enzyme with a link with the peripheral site. The 
neuroprotective effect is explained by the anti-inflammatory action that these compounds exert in 
the CNS. In fact, CB receptors are located on the membrane of cells belonging to the immune 
system, such as leukocytes; therefore, the protective effect is supported by the fact that CB1 
receptor agonists, such as anandamide and noladin are able, in vitro, to reduce the toxicity induced 
by the peptide and that this effect is reverted by receptor antagonists. The high concentration of CB1 
receptors and the presence of AEA and 2-AG in regions of the brain involved in memory processes 
leads to the hypothesis that this system could play an important role in cognitive processes. The 
activation of these receptors reduces the levels of ACh in the hippocampus, followed by a cognitive 
decline, therefore their block has a positive effect, as demonstrated by studies on rats which 
rimonabant and donepezil were administered.  
In AD the expression of CB1 receptor is reduced and it plays a role in the preservation of cognitive 
function. In addition it was found that the levels of anandamide and its precursor lipid are reduced 
in the frontal and temporal cortices. 
The neuroprotective effect of CB2 agonists is associated with suppression of the activation of 
microglia, inhibiting the release of neurotoxic factors and decreasing neuronal damage. The 
expression of the CB2 is connected with cortical levels of Aβ42 and with the rate of senile plaques; 
they are upregulated in both the brain treated with Aβ, both in the brain suffering from AD. So, it has 
been hypothesized that, in people affected by AD, overexpression of CB2 in microglial cells can be 
regarded as an anti-inflammatory response of the CNS in order to protect neurons from 
degeneration inducing an increase in the proliferation and recruitment of immune cells. 
Regarding the modulation of FAAH, both AEA that 2-AG, even if to a lesser degree, are substrates 
for the enzyme and its degradation leads to the release of arachidonic acid which itself can be 
metabolized to obtain pro-inflammatory molecules, such as prostaglandins. Therefore, inhibition of 
this enzyme may be beneficial in the prevention inflammatory processes associated with the 
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deposition of Aβ. Is important to underline that in brain areas rich in amyloid plaques, levels of FAAH 
are increased. 
 
1.5.3 FAAH enzyme 
 
 Fatty acid amide hydrolase (FAAH) enzyme, responsible for the hydrolysis of endogenous 
ligands of the CB1 and CB2 receptors, was purified and sequenced by Scripps group in 1996; it was 
first isolated from rat liver through its ability to catalyze the hydrolysis of the sleep-inducing lipid, 
oleamide. FAAH is a membrane-bound enzyme and it belongs to the family of amidase proteins. 
They are characterized by a highly conserved region that is rich in serine, glycine and alanine 
residues. This region is common for more than 80 amidases and it corresponds to amino acids 215–
257 in mammalian FAAH.  
 
 
Figure 14: Structure of the integral membrane protein FAAH42 
 
FAAH is generally required for inactivation of endocannabinoids in the brain. The mouse and human 
FAAH genes, each composed of 15 exons, are localized on chromosomes 1 and 4, respectively. 
Recently, the first 2.8 Å X-ray crystal structure of FAAH in a complex with the irreversible inhibitor 
methoxy arachidonyl fluorophosphonate revealed several unusual features of the enzyme. First, the 
catalytic core of FAAH is composed of a serine–serine–lysine catalytic triad (Ser217, Ser241, Lys142), 
in contrast to the serine–histidine–aspartate triad typical of most serine hydrolases. These catalytic 
residues are located deep within the enzyme and can be reached through two narrow channels; one 
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of these is wider and more hydrophilic, thanks to the presence of polar residues, instead the other 
one is longer, narrower and more hydrophobic. 
These results are consistent with previous enzymological studies indicating that S241 and K142 
play key catalytic roles as the nucleophile and acid/base, respectively. The structure of FAAH (fig. 
14) also revealed that this enzyme possesses a significant collection of channels that could allow 
simultaneous access to both the membrane and cytoplasmic compartments of the cell, probably to 
facilitate product release, substrate binding, and catalytic turnover. 43 
These uncommon mechanistic and structural features of FAAH inspired new strategies for the 
design of specific inhibitors (i.e. URB 597) that display high selectivity for this enzyme relative to the 
hundreds of serine hydrolases present in the human proteome. Despite biochemical and cell 
biological studies supporting a role for AEA as an endogenous CB1 agonist, the behavioral effects 
caused by AEA are weak and brief compared with those produced by Δ9-THC. The limited 
pharmacological activity of AEA is may be due to its rapid catabolism in vivo, considering that it is 
hydrolyzed to arachidonic acid within minutes of exogenous administration. However, the relative 
contribution made by FAAH to the hydrolysis of anandamide in vivo was largely unclear until it was 
cloned and a mouse model was generated in which this enzyme was genetically deleted (FAAH-
knockout).  
 
 
Figure 15: Active site of FAAH in complex with the arachidonyl inhibitor methoxy arachidonyl 
fluorophosphonate (MAP) 
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Tissues from FAAH- KO mice were found to display a 50–100-fold reduction in hydrolysis rates for 
AEA and related FAAs. In contrast to FAAH wild-type mice, in which administered AEA failed to 
produce important behavioral effects, FAAH-KO mice showed significant responses to AEA, 
becoming hypomotile, analgesic, cataleptic, and hypothermic.  
Additionally, all of the behavioral effects of AEA in FAAH-KO mice were blocked by pre-treatment 
with the CB1 receptor antagonist SR141716A (rimonabant), indicating that AEA acts as a potent 
and selective CB1 agonist in these animals. Moreover, AEA in brain homogenates from FAAH-KO 
mice showed about 15-fold higher apparent binding affinity for the CB1 receptor. These FAAH-KO 
mice have been shown to have elevated levels (10–15-fold) of AEA and other N-acylethanol-amines 
(NAE) in several brain regions, including the hippocampus, cortex, and cerebellum; those levels are 
correlated with a CB1-dependent reduction in pain sensation in FAAH-KO mice. Considering this 
information, FAAH is a key enzyme involved in the catabolism of AEA and other NAEs in vivo and 
suggest that pain pathways are under the influence of a FAAH-regulated endocannabinoid tone. In 
mouse brain, FAAH is mostly associated with neurons. FAAH appears not to be limited to neuronal 
somata but also extends into the areas surrounding the neural tissue. This is most clearly seen in 
the hippocampal formation where, although the highest concentration of FAAH is clearly located in 
the somata of hippocampal pyramidal cells and granule cells of the dentate gyrus, there is also a 
widespread presence of FAAH in the adjacent layers that contain their axons and dendrites.44 
Recently, there has been an explosion in number and quality of FAAH inhibitors available for 
pharmacological evaluations. The majority of evidence from animal models indicate a 
pharmacological analgesic action associated with these compounds, with different structures and 
mechanisms in different models of pain. It was also demonstrated that the analgesic effect can be 
achieved at lower doses than those required to produce sedation and catalepsy, typically associated 
with the CB1 agonists with analgesic action. Other potential indications for these compounds are 
still being discussed and we were still unsure about the models of anxiety and depression.  
FAAH is present in neuronal and glial elements and shows significant overlap with CB1 receptors, 
especially in areas related to cognitive processes which are involved in extinction learning. The 
FAAH enzymes along with the CB2 receptors modulate inflammation because the protein and the 
FAAH activity, along with the CB2 receptors are overexpressed in glial cells related to inflammatory 
processes typical of AD. Since AEA and 2-AG are partially FAAH substrates, and are converted to 
arachidonic acid, the high presence of FAAH in astrocytes surrounding the neuritic plaques suggests 
that astrocytes, through FAAH, could be a significant source of arachidonic acid and correlated 
proinflammatory substances around these plaques. Thus, inhibition of FAAH may be beneficial in 
the prevention of inflammatory processes associated with the deposition of Aβ. 
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1- PROJECT 1 
 
2.1 Aim of the project: coumarin-based molecules 
 
 The mechanisms underlying AD are not completely clear yet, but genetic, pathological and 
biochemical clues suggest that dysfunction of the basal acetylcholine (ACh) forebrain signaling, 
deposits of β-amyloid protein, τ hyperphosphorylation, oxidative damage and neuroinflammation 
play a significant role in the disease. Considering the multifactorial nature of Alzheimer disease and 
that only palliative treatments are available to date,45,46 we decided to apply a multi-target-directed 
ligand strategy in order to tackle the disease from different paths, considering AChE, BuChE, BACE-
1, FAAH, Aβ aggregation and CB receptors as targets.  
The first strategic line that we adopted concerns carbamates that are usually recognized as 
cholinesterases (AChE and BuChE) inhibitors and are also well known in literature as FAAH 
inhibitors. The research group with whom I did my PhD, has been involved for many years in the 
development of carbamate ChEIs. 
Taking into account this information and considering the recent finding that the eCB anandamide 
and some of its congeners potently inhibit human plasma BuChE, a library of carbamates with the 
general formula shown in figure 16, that was already proven as AChE inhibitors and that was already 
available in house, was tested on the new target FAAH.  
 
 
Figure 16 
 
Tested molecules were constituted of various natural inspired heterocyclic rings like cumarine, 
chromone, flavone, xanthone, azaxanthone; they had different lengths of the spacer chain (from 2 
to 12 carbon atoms) and the carbamic function was formed ranging from a methyl group to a long 
chain and a morpholine was also inserted. 
 
 
Figure 17 
 
The biological results allowed to establish some important structure−activity relationships (fig. 17): 
among the different aryl groups (Ar), coumarin, azaxanthone, and xanthone were preferred; the 
optimal chain length (n) seemed to be of three methylene units; the variation of the length of the 
carbamic N-substituent has a significant effect on the activity of the inhibitors, longer chains 
producing the most active compounds.  
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Starting from these results, considering compounds with the general formula showed in figure 17 
(with the cumarine nucleous and the three methylenes spacer) as the most active ones, the main 
goal was to find the optimal carbamic group for FAAH. Focused on this issue, a lead (fig. 18) with 
activity in the nanomolar range on AChE and FAAH was obtained. Furthermore, it showed to be a 
selective BuChE inhibitor and one of the most potent compounds known to date. 
 
 
Figure 18 
 
This dual activity could make it suitable to effectively counteract the progression of AD or disorders 
characterized by defective cholinergic and endocannabinoid signaling. 
On the basis of previous research work, focused on the development of FAAH and cholinesterase 
inhibitors47 combining all these information and the first promising results, the aim of this thesis was 
the optimization of the activity of the lead in order to both increase the potency and balance the 
biological activities towards the three targets. 
 
2.2 Series 1 
 
 New carbamate-based molecules, able to contrast the three enzymes (cholinesterases and 
FAAH), were designed and synthesized, with the aim of obtaining multi-target compounds. A library 
of 16 compounds (table 1) substituted with natural inspired heterocycles, different lengths of the 
spacer chain and various carbamates has been synthesized, in order to explore the chemical space 
of the enzymes and determine the structural requirements necessary for high activities. 
 
TABLE 1 
 
 
 Ar n R 
1 
 
1 
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2 
 
1 
 
3 
 
1 
 
4 
 
1 
 
5 
 
1 
 
6 
 
1 
 
7 
 
1 
 
8 
 
1 
 
9 
 
1 
 
10 
 
1 
 
11 
 
1 
 
32 
 
12 
 
1 
 
13 
 
3 
 
14 
 
3 
 
15 
 
3 
 
16 
 
3 
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2.3 Biological results series 1 and discussion 
 
Biological results of inhibitory activities against AChE, BuChE and FAAH are collected and showed 
in table 2. 
 
TABLE 2 
 
Compound 
IC
50
hAChE 
(nM) 
IC
50
hBuChE 
(nM) 
IC
50
 on FAAH 
(nM) n≥2 
1 80.5  4.7 2.75  0.13 134.93±5.49 
2 89.9  1.8 1.44  0.06 49.09±38.22 
3 390  24 1.19  0.03 312.17±60.34 
4 125  15 2.06  0.08 249.54±91.49 
5 312  23 1.30  0.07 322.09±36.21 
6 179  12 1.15  0.06 210.69±21.62 
7 900  49 3.51  0.16 265.53±112.49 
8 37.4±1.9 1.36±0.07 28.55±9.74 
9 21.6  0.7 0.271  0.007 306.41±65.96 
10 13.0  0. 6 0.
.
696  0.020 202.14±1.14 
11 3800  540 32.1  2.9 >50000 
12 109  5 2.85  0.14 529.69±166.48 
13 88.1  4.0 1.23  0.10 120.19±38.49 
14 11.3  4.9 0.787  0.044 241.90±38.00 
15 18.3  0.8 0.277  0.010 109.07±6.12 
16 6.92  0.58 0.534  0.032 178.35±15.13 
34 
 
These data highlight some important structure−activity relationships. Regarding AChE, the best 
results were obtained, in ascending order, with the nuclei of the basic coumarin (8, 13, 14), 7,8,9,10-
tetrahydro-6H-benzo [c] chromen-6-one (15) and azaxanthone (16). Undoubtedly, the best carbamic 
function was the one with long linear chain (8-10, 14-16); in addition, the spacer chain with five 
methylene units provided greater activity, probably allowing for the compounds to bind into the gorge 
(14-16). The same goes for BuChE, towards which compounds showed highs activity than AChE 
probably due to the physical properties of the enzyme that, with the channel of greater size, allows 
the molecules to more easily reach the catalytic site. In particular, compounds 9-10 and 14-16 
showed an inhibitory activity toward BuChE in the subnanomolar range.  
Regarding FAAH, all compounds are less potent than the lead, except compound 8, with the 
coumarin core and the carbamate with long linear chain; perhaps these features allow for an easier 
entry of the carbamate in the binding pocket. 
Resuming, 8 boosted the activity at each selected target showing balanced inhibitory activity and 
increased potency against AChE and FAAH by about a half more if compared to the starting lead 
compound.  
For these reasons, we decided to consider compound 8 as the new lead and to continue studies 
about activity optimization. 
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2.4 FAAH docking studies series 1 
 
 Thanks to the group of Marco Mor in Parma, a docking study of the most active compound 
8 on FAAH was performed, taking into account both the neutral and the charged form of the amino 
group. Different conformations of the compound generated through a conformational search have 
been docked into the B chain of FAAH dimer (PDB ID: 1MT5; chain A blue cartoon; chain B white 
cartoon). 
The docking simulation was performed using the Induced Fit Docking protocol of the Schrödinger 
suite. Figure 19 represents one of the best poses obtained for compound 8 in its neutral form (green 
sticks). Docking of 8 showed that the position of the carbamate group is stabilised by polar 
interactions within the oxyanion hole, in proximity of the catalytic triad. While the alkyl moiety of 8 
occupies a portion of region corresponding to that of the arachidonyl chain of MAP, co-crystallised 
with FAAH, the chromenonic head of the molecule spans within the so called “cytosolic port”, a cavity 
characterised by polar amino acids situated at the interface of chain A and chain B. 
The figure on the left clearly shows that in the docking pose the carbamate group of 8 makes 
hydrogen bonds with residues I238 and M191, while the neutral amino group interacts with T236 
forming a hydrogen bond.  
 
 
Figure 19: FAAH dimer is represented with cartoon (chain B –white cartoon; chain A –blue cartoon). 
In the docking pose of 8 (green sticks) the carbamate group is situated in proximity of the catalytic 
triad, while the neutral amino group points towards the side chain of Thr238 forming polar 
interactions with it. 
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2.5 BuChE docking studies series 1 
 
 For each compound a conformational analysis was performed, in order to obtain different 
conformations that can be used for the docking study. Starting from the structure of hBuChE, co-
crystallized in presence of a reversible inhibitor (PDB ID: 4TPK), the docking grid was prepared to 
be centered on the position of the inhibitor located in the crystallized complex, with an amplitude of 
14 Å in each direction. 
Compound 9 (IC
50= 0.271) turned out to be the most active on BuChE. Docking poses of the latter 
showed that the carbamic group makes polar interactions with backbone nitrogen atoms of the 
oxyanion hole (Gly116 and Gly117). The N-heptyl substituent was localized in the region occupied 
by tacrine in the crystallized complex tacrine-hBuChE (4BDS). O-phenyl ring was located in the 
lipophilic pocket delimited by Leu286, Val288 and Trp231 residues, and was perfectly superimposed 
on the second naphthalene ring of the inhibitor of the crystallized complex used for the docking 
study. 
The basic nitrogen and the trimethylene linker were located within the access channel to the catalytic 
site, while the aryl group was located at the entrance of the channel. This conformation was further 
stabilized by the formation of a hydrogen bond between the oxygen of the linker and the side chain 
of Asn289 residue. 
 
 
Figure 20: Binding mode of compound 9 (blue ligand), with two rotated representations along the 
vertical axis. The residues of the catalytic triad and oxyanion hole were represented in green, the 
residues of the acyl binding pocket was blue and the choline binding site residues were orange. 
F297 and F295 residues of hAChE were represented in yellow. 
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Figure 21: Representation of the access channel to the catalytic site of hBuChE. Left panel: the 
ligand 9 occupied a more external portion of the channel than that occupied by donepezil in hAChE 
(PDB: 4EY7). Right panel: the entrance width of the access channel allowed ligands to adopt 
alternative binding modes.  
 
 
Figure 22: Binding mode of 9; the N-heptyl substituent was located in the pocket occupied by tacrine 
(PDB: 4BDS) 
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Docking poses obtained for the other compounds of the series showed similar elements with the 
binding mode of 9. The lipophilic substituents of the carbamic nitrogen tended to occupy the binding 
pocket of tacrine, while the carbamic group was oriented in order to form polar interactions with 
residues of the oxyanion hole. 
A single element of variability was related to the position occupied at the entrance of the access 
channel to the catalytic site by different O-aryl groups. This variability was mainly related to the width 
of this region. 
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2.6 Series 2 
 
 In order to improve the activity, pooling all the data and considering the docking studies 
regarding compound 8 showing that the best pose is in the neutral form, a new series of coumarin 
derivatives (table 3, 4) bearing a triazole moiety as spacer was synthesized. 
 
TABLE 3 
 
 
 Chain position R 
59 para 
 
60 meta 
 
61 para  
62 meta  
 
TABLE 4 
 
 
 Chain position R 
67 para 
 
68 meta 
 
40 
 
69 para  
70 meta  
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2.7 FAAH docking studies series 2 
 
 Docking studies of compound 68 on FAAH enzyme were performed. As shown in picture 
23, the triazole ring of 68 is located in proximity of the side chain of T236, resulting in a different 
arrangement of the cromenonic portion with the formation of a hydrogen bond in the channel that 
leads to the cytosolic port; the terminal phenyl ring is located in the ACB pocket. 
 
 
Figure 23: docking of compound 68 
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2.8 BuChE docking studies series 2 
 
 Docking study on triazole derivatives revealed some important information on the effect 
produced by the presence of the phenyl or benzyl-triazole group, and the meta or para position of 
these groups on the O-phenyl ring of the phenyl-carbamate. 
 
Benzyl-triazole derivatives: 
Benzyl-triazole derivatives, if para-substituted (59 e 61), showed higher power. The resulting 
docking poses of compounds 59 and 61 showed a good overlap of the O-position of the phenyl ring 
with that obtained for compound 9. Docking poses characterized by the positioning of the O-phenyl 
ring in the lipophilic pocket of the acyl binding pocket and by the correct positioning of the carbamic 
group close to the catalytic serum, were also observed for meta-substituted compounds. This result 
suggested that the m-triazolyl-methyl derivatives were less effective at ensuring an optimum 
interaction between carbamate and catalytic triad. 
 
Figure 24: Binding mode of 61 (left panel, orange ligand) and 59 (right panel, green ligand) 
compared with docking of 9 (blue ligand) 
 
Phenyl-triazole derivatives: 
Unlike what was observed for benzyl-triazole compounds, the meta-substituted phenyl-triazole 
derivatives are more powerful than the para-substituted derivatives. Coherently, the docking study 
showed that for 68 and, to a lesser degree, 70, the most frequent and with best score poses located 
the O-phenyl ring in the hydrophobic pocket of the acyl binding pocket. 
On the contrary, this binding mode was not found for compounds 67 and 69, in which the dimensions 
of the triazole ring and the greater stiffness conferred by the absence of methylene bridge prevented 
this type of ligand-protein interaction. 
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Figure 25: Binding mode of 68 (yellow ligand) compared with the laying of 9 (blue ligand) 
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2.9 Biological results series 2 and discussion 
 
TABLE 5 
 
Compound 
AChE IC
50
 
(nM) 
BuChE IC
50
 
(nM) 
FAAH IC
50
 
(nM) n≥2 
FAAH 
% inhibition 
at 10 µM 
59 255 ± 12 1.17 ± 0.12 55.44 ± 10.64 86.44% 
60 941 ± 106 42.7 ± 1.5 51.18 ± 10.65 94.87% 
61 214 ±19 15.9 ± 0.5 6290.30 ± 82.60 80.15% 
62 1044± 82 78.2 ± 4.8 317.55 ± 153.15 94.42% 
67 47900 ± 1400 1230 ± 90 565.97 ± 248.47 83.85% 
68 1175 ± 145 15.2 ± 1.2 12.80 ± 1.33 95.13% 
69 157550 ± 26800 122000 ± 23000 153.15 ± 24.25 86.61% 
70 702 ± 18 71.2 ± 2.9 48.07 ± 14.90 92.35% 
 
 Biological data, shown in table 5, demonstrated a loss of activity on AChE, probably due to 
the rigidity of the structure that could not allow to enter into the narrow gorge, and a decrease in 
inhibitory activity on BuChE, although it is still in the nanomolar range (except for 67 and 69). 
Probably this is due to the fact that the radius of BuChE is wider and it allows the molecules to better 
fit into the gorge. Some compounds improved their activity on FAAH; in particular, compound 68, 
although with limited mobility capabilities, thanks to its spatial arrangement was able to get into the 
binding pocket and interact with FAAH. Moreover, it showed an interesting and balanced activity on 
BuChE and FAAH. Indeed, this is an essential peculiarity for a multi-target molecule. 
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2.10 Series 3 
 
 We then decided to synthesize a new small series of compounds shown in table 6, in which 
the carbamic function was replaced by an amide function. This modification could be suitable to 
obtain reversible cholinesterase and FAAH inhibitors. Moreover, the long chain is closed in a 5 or 6-
membered ring which, could maybe retain the features required to give hydrophobic interactions 
with the binding pockets of the selected enzymes.  
The biological profile of compounds 74 and 75 is now under evaluation. 
 
TABLE 6 
 
 
 R2 
74 
 
75 
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2.11 Chemistry 
 
Compounds 1-16 were prepared according to this scheme: 
 
SCHEME 1 
 
 
 
Reagents and conditions: i) K2CO3, toluene, reflux; ii) NaI, methyl ethyl ketone, reflux; iii) TEA, 
toluene, reflux; iv) NaH, toluene, r.t. 
 
The hydroxyl group of the natural inspired heterocycles was alkylated with bromochloroalkane of 
various length, refluxing the mixture in acetone with K2CO3 in order to achieve the chloro- derivatives. 
Compounds 17-27 were treated with NaI, refluxing in methylethylketone, with the purpose of obtain 
more reactive compounds for the next step of nucleophile substitution. The latter was conducted 
refluxing 3-((methylamino)methyl)phenol in toluene with compounds 40-51; then thanks to a 
carbamylation achieved in presence of NaH and with appropriate isocyanates, we reached final 
compounds from 1 to 16. 
 
SCHEME 2 
 
Reagents and conditions: i) SOCl2, TEA, DCM, reflux; ii) DMF, reflux; iii) hydrazine monohydrate, 
ethanol, reflux; HCl 37%, reflux; iv) COCl2, TEA, toluene, reflux 
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The synthesis starts with an activation of the alkyl alcohol obtained with SOCl2. In order to obtain 
the amino compound 56, thanks to Gabriel synthesis, 54 was treated with potassium phthalimide 
refluxing in DMF, then 55 was refluxed in ethanol with hydrazine monohydrate. The last step, 
refluxing in toluene with phosgene, allowed to the formation of the isocynate,. 
 
 
SCHEME 3 
 
 
 
Reagents and conditions: i) SOCl2, reflux; ii) NaN3, acetone, H2O; benzene, 60°C 
 
Thanks to its previously activation with SOCl2, the acid, combined with NaN3, was heated giving the 
formation of various isocyanates. 
 
 
 R 
53a 
 
53b 
 
53c 
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SCHEME 4 
 
 
 
Reagents and conditions: i) DDQ, dioxane, reflux 
 
The 3-(3-chloropropoxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one was dehydrogenated 
using DDQ (2,3-dichloro-5,6-dicyano-p-benzoquinone) in dioxane, refluxing for 24h. 
 
SCHEME 5 
 
 
 
Reagents and conditions: i) (CH3CO)2O, 180°C; K2CO3; ethanol, reflux 
 
The hydroxyphenyl coumarines are obtained thanks to the classic method of Perkin and Pechmann. 
The selected 2,4-dihydroxybenzaldehyde is condensed with the sodium salt of selected 
phenylacetic acid in acetic anhydride. Then, acetylated phenylcoumarines are hydrolyzed with 
K2CO3 in order to obtain desired compounds 58 a-d. 
 
58a 
 
58b 
 
58c 
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58d 
 
 
SCHEME 6 
 
 
 
Reagents and conditions: i) K2CO3, acetone, reflux; ii) TEA, CuSO4, Sodium ascorbate, DMSO, 
r.t.; iii) BBr3, DCM, N2 atmosphere, r.t. ; iv) NaH, toluene, r.t. 
 
The 7-OH-coumarin was combined with propargyl bromide obtaining 63 then, thanks to a click 
reaction conducted in presence of CuSO4 and sodium ascorbate the triazole was formed. 
Subsequently, the methoxyl group was demethylated with BBr3; finally compounds 66a,b were 
combined with properly isocyanate reaching the various carbamates. 
 
SCHEME 7 
 
 
 
Reagents and conditions: i) NaN3, DMF, 80°C 
 
Azido compounds were obtained combining chlorine derivatives with sodium azide in DMF and 
heating at 80°C. 
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64a 
 
64b 
 
 
SCHEME 8 
 
 
Reagents and conditions: i) K2CO3, acetone, reflux; ii) TEA, CuSO4, Sodium ascorbate, DMSO, 
r.t.; iii) flash chromatography ; iv) NaH, toluene, r.t. 
 
The 7-OH-coumarin was combined with propargyl bromide obtaining 63 then, thanks to a click 
reaction, combining the alkyne-derivative with the azidophenoxy tert-butyl dimethylsilane derivative 
in presence of CuSO4 and sodium ascorbate the triazole was formed. Subsequently, the oxygen 
was deprotected thanks a flash chromatography; finally compounds 72a,b were reacted with 
properly isocyanate reaching the various carbamates. 
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SCHEME 9 
 
 
 
Reagents and conditions: i) imidazole, TBDMS-Cl, DMF, r.t.; ii) H2O, HCl 37%, NaNO2, NaN3 
 
The aminophenol was protected with TBDMS-Cl at room temperature in DMF; at that time, 
previously the diazonium salt was formed adding 73 a,b to NaNO2 in H2O and HCl 37%, then, adding 
NaN3 and the azide was formed. 
 
 
 R 
71a 
 
71b 
 
 
SCHEME 10 
 
 
 
Reagents and conditions: i) K2CO3, acetone, reflux 
 
The last step of synthesis is an alkylation of the phenol with the chloro-derivative in acetone in 
presence of K2CO3. 
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2.12 Conclusions 
 
 As first, we interesting improved the activity of coumarin-core molecules. This study led to 
the identification of a series of compounds showing an inhibitory potency on selected target up to 
nanomolar and subnanomolar range. 
To strongly enhance activity and selectivity toward each target, one derivative was recognized as 
possessing all the structural requirements identified as: 
 
- basic coumarin core  
- spacer chain of three units  
- long seven methylenes carbamic tail 
 
 We found a new lead (compound 8) with increased activity on AChE, BuChE and FAAH. Thus, this 
compound was selected for further development and on this basis, considering docking studies too 
that demonstrated that the best poses were obtained in the neutral form, we projected and 
synthesized second series of compounds. At a first sight the inhibitory activity on AChE and on 
BuChE decreased and maybe it was due to the rigidity caused by the triazole ring; although the 
inhibition of BuChE was reduced, it was still satisfactory. In particular, compound 68 showed potent 
and balanced activity both on BuChE and on FAAH, a researched and fundamental feature for a 
multi-target compound that bodes well for the future potentialities of this molecule. 
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4- PROJECT 2 
 
3.1 Aim of the project: benzofuran-core molecules 
 
 As previously explained, the endocannabinoid system is involved in AD in neuroprotective, 
anti-inflammatory and neurotrophic actions, which can be obtained by activating type 2 cannabinoid 
receptors (CB2), either directly or by endocannabinoid cellular reuptake inhibition.48 It has been 
demonstrated that CB2 receptors are overexpressed in the area of neural plaques; in particular, they 
are located in microglia and astrocytes, that are activated by neuronal damage and beta-amyloid 
plaques. Indeed, an activation of CB2 receptors could reduce microglia activation and prevent the 
inflammatory process. In addition, CB1 receptors activation or inhibition, depending on the stage of 
the disease, was also suggested to be beneficial for AD. Moreover, the inhibition of FAAH could be 
successfully considered as physiologic receptor activation. Considering all this, the second project 
of this thesis had the intention to hit multiple target: AChE, BuChE, BACE-1, FAAH, Aβ aggregation 
and CB receptors. 
The design of this MLTD strategy considers the benzofuran heterocyclic moiety. It is a 
privileged structure and this scaffold is present in many biologically active natural products 
and therapeutics, and thus represents a very important pharmacophore.  
 
 
Figure 26 
 
In previous studies a lead molecule was identified, combining the benzofuran moiety of in 
SKF-64346, an inhibitor of Aβ fibril formation, with an AChEI methylbenzylamino fragment 
previously optimized by the research group were I did the PhD. 
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The lead compound had a remarkable inhibitory activity: besides the important micromolar 
activity on AChE and BuChE, it also showed significant activity for inhibition of the formation 
of Aβ25-35 (a) fibrils to 50% of the control value, for the inhibition of Aβ25-35 (b) peptide toxicity 
in human neuronal SH-SY5Y and for the loss of neuronal viability evoked by Aβ, thus 
providing neuroprotection. Taking into account that the benzofuran framework was present 
in LY320135 (fig. 26) a high affinity antagonist/ inverse agonist at CB1 receptor, the lead 
compound was also tested on CB receptors, demonstrating moderate affinity and good 
selectivity for CB1 receptors. 
 
TABLE 7 
Lead compound biological activities 
hAChE 
IC50 
hBuChE 
IC50 
Aβ25-35 IC50a Aβ25-35 IC50b 
SH-SY5Y 
cells PI 
CB1 EC50 CB2 EC50 
40.7 µM 38.1 µM 12.5 µM 5.6 µM 58.16 % 0.79 µM >10µM 
 
My aim for this project was to optimize and improve the biological activities of this lead, 
focusing on the inhibition of cholinesterases, Aβ aggregation, BACE-1 and FAAH, and on 
the interaction with CB1 and CB2 receptors. Five new series of compounds, depicted in the 
scheme below, have been synthesized (fig. 27). 
 
Figure 27  
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3.2 Series 1, 2, 3, 4, 5: lead optimization 
 
SERIES 1 
 
 
 n 
76 5 
77 4 
78 3 
79 2 
 
In Series 1 the R in the general structure was replaced with an N-methyl benzyl amine 
residue with an ethereal chain of various lengths and R1 was substituted with a methoxyl 
group. 
 
SERIES 2 
 
 
 R2 R3 
100 H 
 
101 
  
 
56 
 
102 H 
 
103 
  
104 H 
 
105 
  
106 H 
 
107 H 
 
108 H 
 
109 H 
 
110 H  
111 H  
112 CH3 
 
 
Series 2, allowed the formation of mono or di-alkylated amine on R, while R1 was still a 
methoxyl group. 
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SERIES 3 
 
 
Series 3 is in fact constituted of only one compound where R was transformed in a 
substituted triazole and R1 was again a methoxyl group. 
 
SERIES 4 
 
 
 R4 
117 
 
118 
 
119 
 
120 
 
121 
 
58 
 
122 
 
123 
 
 
In series 4 various amides were inserted on R, that could contribute for a better affinity with 
BACE-1 or FAAH. 
 
SERIES 5 
 
 
 R5 
124 
 
125 
 
126 
 
127 
 
128 
 
59 
 
129 
 
130 
 
 
In series 5 the triazole was moved from R to R1 and substituted with a benzyl moiety. 
.  
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3.3 Chemistry 
 
SCHEME 11 
 
 
 
Reagents and conditions: i) SnCl4, DCM, 0°C, r.t.; ii) NaI, methylethyl ketone; iii) toluene, reflux 
 
The benzofuran undergoes Friedel Craft acylation, using 80-83 in order to obtain compounds 84-
87, which were treated with NaI to replace the chlorine atom by introducing a better leaving group 
to facilitate the subsequent nucleophilic substitution; the latter was obtained refluxing with 
methylbenzylamine in toluene consequently reaching compounds 76-79. 
 
 
SCHEME 12 
 
 
 
Reagents and conditions: i) K2CO3, acetone, reflux; ii) KOH, ethanol, reflux; iii) SOCl2, reflux 
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The reaction scheme starts with an alkylation of the hydroxyl group of the para-hydroxyethyl 
benzoate in basic conditions with 1-bromo-ω-chloroalkanes in order to obtain various analogues. 
The reaction is chemoselective on brominated position to achieve derivatives 92-95 from which 
thanks to a saponification with potassium hydroxide compounds 96-99 were formed. The acid was 
then transformed into the corresponding chloride by treatment with thionyl chloride. 
 
 n 
80 5 
81 4 
82 3 
83 2 
 
SCHEME 13 
 
 
Reagents and conditions: i) SnCl4, DCM, 0°C; ii) SnCl2, ethanol, reflux; iii) KI, K2CO3, CH3CN, 
110°C, 150W, MW; iv) tetrabutylammonium hydrogensulfate, DCM/NaOH 50%, r.t.; v) tert-butyl 
nitrite, TMSN3, CH3CN, r.t. 
 
The benzofuran ring was derivatized with Friedel Craft acylation using p-nitrobenzoylchloride in 
presence of SnCl4. The nitro group was reduced to the corresponding amine refluxing with SnCl2; 
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then with the aid of microwaves, in presence of KI and K2CO3, mono- and di-alkylated compounds 
(100-109) were obtained. Compound 102 was methylated in a biphasic mixture of DCM/NaOH 50% 
using CH3I in presence of tetrabutylammonium hydrogensulfate; with the same procedure, using the 
appropriate bromo-alkane, we obtained alkylated compounds 110-111. Compound 113 was formed 
using a click reaction, combining 115 with the alkyne 116 in presence of tert-butyl nitrite and TMSN3 
in CH3CN, forming in this way the triazole. 
 
 
SCHEME 14 
 
 
 
Reagents and conditions: i) K2CO3, acetone 
 
The 3-fluorophenol reacted with propargyl bromide in presence of K2CO3 in acetone in order to 
achieve compound 116. 
 
 
 
SCHEME 15 
 
 
Reagents and conditions: i) K2CO3, toluene; ii) DCC, DCM, N2 atmosphere, r.t. 
 
Compounds 117-121 were obtained thanks to an amidation conducted in thermal conditions in 
presence of potassium carbonate in toluene. The amide of compound 122, 123 was formed in 
presence of DCC, in DCM, under nitrogen atmosphere. 
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SCHEME 16 
 
 
Reagents and conditions: i) SnCl4, DCM, 0°C; ii) BBr3, DCM, N2 atmosphere; iii) propargyl 
bromide, K2CO3, toluene, reflux; iv) TEA, CuSO4, sodium ascorbate, DMSO, r.t. 
 
The benzofuran ring was derivatized with Friedel Craft acylation using benzoyl chloride in presence 
of SnCl4. The methoxyl group was deprotecting using BBr3, and then it was functionalized with 
propargyl bromide. Thank a click reaction conducted in presence of CuSO4, sodium ascorbate and 
the various azides, the triazole rings were formed in order to reach compounds 124-130. 
 
 
SCHEME 17 
 
 
 
Reagents and conditions: i) NaN3, DMF, 80°C; or NaN3, DMSO, r.t. 
 
Bromo-benzyl derivatives were converted in benzylazides using sodium azide in DMF at 80°C, or 
using sodium azide in DMSO at room temperature. 
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 R6 R7 R8 R9 
134 H H F H 
135 H F H F 
136 F H F H 
137 H H OCH3 H 
 
 
SCHEME 18 
 
 
 
Reagents and conditions: i) H2O, HCl 37%, NaNO2, NaN3, r.t. 
 
The functionalization of the aniline in azide was performed forming the diazonium salt with NaNO2 
and subsequently adding sodium azide. 
 
 R10 R11 
138 F OCH3 
139 F H 
140 F F 
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3.4 Biological results and discussion 
 
Given the large number of targets for which benzofuran-inspired molecules was designed and the 
fact that the synthesis of the designed molecules was completed close to the end of my PhD, 
currently various biological studies are still ongoing, in particular we are waiting for BACE1 and β-
aggregation biological activities.  
Thus, in this thesis, only preliminary data will be presented and therefore complete biological 
framework is not available. 
 
SERIES 1 
 
 
Ki on CB
1
 
µM m±ds 
CB
1
% 
displacement 
at 10 µM 
Ki on CB
2
 µM 
m±ds 
CB
2 
%displaceme
nt at 10 µM 
AChE 
% inhib 
IC
50 
BuChE 
µM 
76 1.76 ± 0.36 65.34 >10 33.56 11.06 1.09 ± 0.07 
77 0.86 ± 0.13 60.90 >10 35.05 n.a 219 ± 94.0 
78 0.50 ± 0.05 70.23 0.12±0.02 85.07 n.a. 135 ± 6.o 
79 0.43 ± 0.08 80.00 0.69 ± 0.00 73.92 n.a. 14.0 ± 0.9 
 
Biological data showed that 76 and 77 (n = 5 and n = 4, respectively) had moderate affinity 
and good selectivity for CB1 receptors and 76 has also good activity on BuChE.  
With the shortening of the chain the affinity for CBs was increased, but the compounds lost 
their selectivity towards CB1 receptors. Compound 78 (n= 3), in fact, had submicromolar 
affinity both for CB1 and for CB2, but it lost activity on BuChE. Instead, 79 recovers inhibitory 
activity of BuChE. 78 is the compound that proved to have the greatest affinity towards CB2. 
None of the compounds proved to be active on AChE. 
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SERIES 2 
 
 
Ki on CB
1
 
µM m±ds 
CB
1 
%displacement 
at 10 µM 
Ki on CB
2 
µM 
m±ds 
CB
2 
%displaceme
nt at 10 µM 
% inhib 
BuChE 
IC
50
 BuChE 
µM 
100 >10 41.91 168±11.29 78.00   
101 >10 27.05 925.63±60.15 69.29   
102 0.78±0.34 68.64 0.02±0.00 75.57 60.8± 1.1 13.4±0.5 
103 >10 29.14 0.44±0.04 66.30   
104 >10 22.07 0.30±0.06 62.39 <10 n. d. 
105 >10 25.03 >10 26.56   
106 >10 49.90 1.34±0.38 68.48 (25µM) <10 n. d. 
107 >10 38.25 1.02±0.12 67.91 (25µM)   
108 2.60±0.05 92.27 (25µM) 0.025±0.001 79.89 <10 n. d. 
109 0.4±0.17 85.11 0.108±0.015 87.17 23.5±0.6 n. d. 
110 0.085±0.02 87.14 0.069±0.004 83.57   
111 1.67±0.66 69.39 0.401±0.76 74.42   
112 0.02±0.00 90.60 0.002±0.000 96.06 10.1±02 n.d. 
 
Data listed in the table demonstrated that many compounds of series 2 had remarkable biological 
properties. First of all, regarding CB1 receptors, we noticed that 100, which has the benzyl ring 
without substituents, does not show affinity at all. The introduction of a fluoro or cyano substituent 
in para position of the benzyl ring (102 and 108, respectively), appeared to be important for a 
significant affinity, while the introduction of a methoxyl (107) led to the loss of affinity. Positive was 
also the introduction of methylcyclopropane (109).  
The introduction of an alkyl chain (110-111) present in anandamide and THC too, provided 
interesting affinity for the compounds best being where the derivative was with a 5 carbon chain. 
The most potent compound in the series is derivative 112 with the tertiary nitrogen, but with a small 
substituent.  
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Although almost all the substituents demonstrated more or less affinity for CB2 receptors, the same 
SAR of CB1, relating to the para substituted benzyl, in particular with fluorine and cyano substituents, 
also applies for CB2, although showing affinity values much more noticeable.  
In particular, compounds 102 and 108 have Ki of 20 and 25 nM, respectively; on the other hand, the 
introduction of a 5 units alkyl chain gives to 110 a Ki of 69 nM, demonstrating high selectivity and 
affinity. 
Selectivity is more pronounced towards the CB2 receptors, for which Ki values were quite lower than 
those for CB1. Of particular interest appeared to be the central role of the tertiary amine; in fact 
compound 112 clearly showed that the affinities towards the CB1 and CB2 increased 39 times and 
10 times respectively. However, of greater importance appears to be the small size of the substituent 
on the nitrogen, in fact a methyl group gives to compound 112 a nanomolar affinity. This is also 
demonstrated by the affinity of the disubstituted compounds 103 and 105 for CB2: the first one 
shows acceptable affinity while, the second one, with a bulkier substituent, totally lost the affinity. 
Finally, only 102 had activity on BuChE and all compounds are inactive towards AChE; maybe it is 
due to the rigidity of the structure that hinders the molecules to enter in the gorges.  
 
SERIES 3 
 
 
Ki on CB
1
 
µM m±ds 
CB
1 
%displacement 
at 10 µM 
Ki on CB
2 
µM m±ds 
CB
2 
%displaceme
nt at 10 µM 
% inhib 
BuChE 
IC
50
 BuChE 
µM 
113 >10 29.18 >10 21.07 <10 n. d. 
 
Compound 113 showed no activity and affinity towards the selected targets. 
 
SERIES 4 
 
 
Ki on CB
1
 µM 
m±ds 
CB
1 
%displacement 
at 10 µM 
Ki on CB
2 
µM 
m±ds 
CB
2 
%displacement 
at 10 µM 
117 >10000 23.11% >10000 11.54% 
118 >10000 23.56.% >10000 22.10% 
119 >10000 14.69% >10000 28.15% 
120 >10000 36.95% >10000 22.89% 
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121 597.90±69.13 75.52% >10000 37.02% 
122 >10000 33.18% >10000 37.24% 
123 >10000 34.48% >10000 33.16% 
 
Compounds of series 4 turned out to have no affinity for CBs. However, their amide group was 
inserted to obtain activity on BACE1; unfortunately biological results for the latter are not available 
yet. 
 
 
SERIES 5 
 
 
Ki on CB
1
 
µM m±ds 
CB
1 
%displacement 
at 10 µM 
Ki on 
CB
2 
µM 
m±ds 
CB
2 
%displacement 
at 10 µM 
IC
50
 on 
FAAH 
(µM) n≥2 
%inib 
BuChE 
124 >10 32.95 >10 34.61 n.a.  
125 0.45±0.19 79.65 >10 26.03 3.01±0.13 24.4±0.1 
126 >10 47.58 >10 43.27 n.a.  
127 2.67±0.13 85.14 >10 45.02 n.a.  
128 >10 20.00 >10 23.46 n.a.  
129 >10 37.86 >10 35.87 n.a.  
130 >10 38.13 >10 32.86 n.a.  
 
Biological results of series 5 showed that only 125 and 127 had affinity for CB1 receptors. No 
compounds of this series shows affinity for CB2s and activity on BuChE. 125, the most potent one, 
also showed a promising inhibitory action on FAAH. 
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3.5 Conclusions 
 
 In continuing our studies on the design of new multi-target compounds for the treatment of 
AD, several modifications of the promising lead, previously identified among a new series of hybrid 
molecules based on the frameworks of our AChE/ BuChE inhibitors and of SKF-64346, were 
performed. With the aim of further optimizing this scaffold and broadening the biological profile of 
the molecules by investigating their potential action on additional targets involved in AD, five small 
series of compound were designed and synthesized. The different modifications introduced in the 
structure of the lead compound led to an increase in activity towards one or more of the selected 
targets for various compounds. 
Some compounds of series 1 showed interesting increased activity, in particular compound 79, if 
compared with the lead molecule, improved the affinity for CB1 and gained affinity for CB2; moreover 
it enhanced the activity on BuChE. 78 acquired instead an interesting affinity for CB2 receptors. 
Structure activity relationships suggest that, with the shortening of the alkyl chain, the affinity for the 
CB tends to increase 
Biological results of series 2 demonstrated that the insertion of the para-fluorine seems to be 
essential. In fact, fluorine atoms were also introduced in the amine backbone, in order to evaluate 
their possible role in activity. Indeed the fluorine atom, due to its small size and high electronegativity, 
has recently received increasing interest in medicinal chemistry, since its introduction into potential 
drugs or diagnostic could improve pharmacokinetic and physical-chemical properties, such as 
metabolic stability or membrane permeation. 49 Furthermore, a greater affinity of fluorinated 
compounds for the different target proteins has been documented. 50  
Moreove,r with compound 112 the importance of the fundamental role of the tertiary amine, if 
substituted with a not bulky group (methyl group) has been demonstrated. 
In series 5 the first compound with interesting activity on FAAH (compound 125), which also appears 
to have affinities with the CB1 was identified. 
Finally, these studies showed that it is possible to obtain compounds able to modulate both classic 
and novel emerging targets involved in AD. These new compounds can be considered as a platform 
for further studies aimed at improving their multifaceted activities for the identification of new 
molecular entities. 
In conclusion, these studies could demonstrate that drug discovery paradigm is shifting from one-
drug–one-target strategy to one-drug-multiple-targets strategy. The diverse targets can be hit not 
only by multiple components but also by one compound or even by a single pharmacophore. Thanks 
to the advancement in high throughput drug screening and computer-aided drug design, there is 
less and less technical hurdle in finding more multipotent agents to fulfill the new strategy. 
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CHAPTER 2 
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4 INTRODUCTION 
 
 Ten months out of the three years of PhD were spent at the "Institute of Medical Sciences", 
Aberdeen, UK, under the supervision of Professor Matteo Zanda. During this period, I was involved 
in different projects. One of these was entitled: “Mapping the Brain with PET Radiolabeled 
Cannabinoid (CB1) Ligands PET brain”. 
As explained before, Cannabinoid receptors are members of G-protein coupled receptors 
(GPCRs).51, 52 Two types of cannabinoid receptor were discovered so far, CB1 and CB2, and both 
of them were widely studied. CB2 receptors are more expressed in peripheral nervous system (PNS) 
cells53 while CB1 receptors are mostly localized in the brain.54 Some studies showed the presence 
of CB1 in the PNS55 and of CB2 in the central nervous system, although in low density56. Moreover, 
CB1 receptors were associated with many disorders like depression,57 anxiety,58 Alzheimer disease, 
chronic pain59 and obesity.60 Consequently, several cannabinoid ligands were developed as drug 
candidates.  
 
PROJECT 3 
 
4.1 Aim of project 3 
 
 The work was based on the concept that the study of the role of the cannabinoid system in 
the brain is still largely unexplored; moreover, the relationship between CB1 receptors functional 
modification, density and distribution and the onset of a pathological state is still not well understood.  
 
 
Figure 28: Uptake of [18F] MK-9470, inverse agonist (human IC50, 0.7 nM) for the cannabinoid 
CB1 receptor in human brain. Baseline images (120–180 min after tracer injection, day 1 of subject 
1) show the regional distribution of tracer binding was consistent with labelling CB1R and with rhesus 
monkey images. Color scale corresponds to SUV units.61 
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Taking this into account, the development of radio-ligands suitable for in vivo PET (positron emission 
tomography) functional imaging of CB1 receptors remains an important area of research in medicine 
and drug development and may lead to the development of new therapeutic strategies for the early 
stages of AD. We decided to synthesize radioligands for CB1 receptors, which, through the PET (fig. 
28), could provide reliable measurements of density and distribution of CB1 receptors in the brain. 
PET would allow the in vivo determination of specific biomarkers; in this way, the accuracy of the 
diagnosis of AD would be improved. 
To date, few radiotracers were synthesized based on the structure of SR141716 (Rimonabant), (fig. 
29), a potent pyrazole-core inverse agonist of CB1 receptors discovered by Sanofi-Synthelabo (now 
Sanofi-Aventis) in 1994. This drug was marketed in Europe as an anti-obesity drug but subsequently 
withdrawn from the market owing to its side-effects, which included severe depression and suicidal 
thoughts. Until today, most of the derivatives that were synthesized and tested in vivo demonstrated 
unsatisfactory brain imaging results due to their poor ability to cross the blood-brain barrier.  
 
Figure 29  
 
Extensive theoretical and experimental structure-activity relationship studies were performed on 
Rimonabant analogues for identifying a general pharmacophore. The two aromatic rings in positions 
1 and 5 of the pyrazole ring favourably interrelate with hydrophobic interactions with 
Trp279/Phe200/Trp356 and Tyr275/Trp255/Phe278 respectively (fig. 30) and, at the same, the 
aminopiperidine cyclohexyl could interact with the cavity constituted by Val196/Phe170/Leu387 and 
Met384.62 In addition, the hydrogen bond between the ligand’s amidic oxygen and the receptor 
residue Lys192 plays a key role in the binding, giving the inverse agonism of Rimonabant. 
The aim of this work was the design and synthesis of analogues of Rimonabant that could be used 
as tracers for PET imaging and that might also be developed into a theranostic or multi-modal 
imaging tool by radioiodination. 
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Figure 30: structure-activity relationship Rimonabant and Rimonabant analogues 
 
Considering these information we decided to replace the carbonyl-aminopiperidine residue in 
position 3 with a 4-(1,2,3-triazolyl) function, since any of the triazolyl sp2 nitrogen atoms could act 
as hydrogen bond acceptor with Lys192. The 1,2,3-triazole would carry a N-(4-fluorobutyl) group, 
which should be used for [18F]radiofluorination and could be located in the lipophilic pocket. Many 
compounds had an iodine atom in position 5 of the triazole; this substitution could be useful for 
radioiodination. Finally, we planned to replace the 4-chlorophenyl group in 5-position with a 5-
substituted 2-thiophenyl residue, which was previously shown to be an advantageous structural 
modification leading to high-affinity CB1 ligands. Four compounds, shown in table 8, were 
synthesized.63 
 
TABLE 8 
 
 
 
 R R1 
131 I 
 
132 I 
 
74 
 
133 I  
142 H  
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4.2 Chemistry 
 
SCHEME 19 
 
 
 
Reagents and conditions: i) EtONa/EtOH, r.t., overnight; ii) 2,4-dichlorophenylhydrazine 
hydrochloride, EtOH, reflux, overnight; iii) NBS, CH3CN, from 0 8C to r.t., overnight; iv) DIBAL-H, 
DCM, -78 °C, 4 h; v) dimethyl 1-diazo-2-oxopropylphosphonate, K2CO3, MeOH, r.t., overnight; vi) 4-
iodomorpholine, CuI, THF, r.t. 1 h; vii) azido-compound, CuI, TEA, THF, r.t, 72 h 
 
The synthesis started from 1-(thiophen-2-yl) propan-1-one which was condensed with diethyl 
oxalate in presence of sodium ethylate to give, in 85% yield, the 1,3-diketoester (135)as a tautomeric 
mixture, predominantly containing the alkenylidene structure. Subsequently, tricarbonyl compound 
and 2,4-dichlorophenylhydrazine were heated in ethanol to afford the pyrazole 136 in rather modest 
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yield (32%). The latter was regioselectively brominated, employing NBS, to afford the corresponding 
bromothiophene 137 in good yield (83%). The following conversion was accomplished through a 
DIBAL-H hydride reduction, providing the aldehyde 138 which was homologated under Bestmann-
Ohira alkynylation conditions to generate the alkyne 139 in a moderate yield (55%).  
The intermediate 139 was iodinated in a good yield (74%) using 4-iodomorpholine as iodine source. 
Next, a copper-catalysed azide-iodoalkyne cycloaddition afforded the desired compound 131-134 
in moderate yield. 
 
SCHEME 20 
 
 
 
Reagents and conditions: i) iodine, CH3OH, r.t. 
 
Iodomorpholine was obtained treating morpholine with iodine in methanol.  
 
SCHEME 21 
 
 
 
Reagents and conditions: i) NaN3, H2O/Acetone (1:4), r.t. or NaN3, DMF, r.t. 
 
Azido-compounds were formed combining the selected bromoderivative, dissolved in H2O/Acetone 
or DMF, with sodium azide. 
 
 R1 
141 a 
 
142 b 
 
143 c  
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SCHEME 22 
 
 
 
Reagents and conditions: i) 1-azido-4-fluorobutane, CuI, sodium ascorbate, tert-BuOH/H2O, r.t, 
overnight 
 
The triazole in 142 was achieved by means of a copper-catalyzed azide-alkyne cycloaddition 
protocol, in presence of sodium ascorbate in tert-BuOH/H2O with an acceptable yield.  
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4.3 Biological results and discussion 
 
 At the moment only biological results about compound 131 are available. To present a 
clearer framework, in table 9 are shown also biological data of Rimonabant and of the non-
iodinated analogue of 131 (fig. 31), previously synthesized. 
 
 
Figure 31: non-iodinated analogue of 131 
 
TABLE 9 
 
 
hCB1 CHO cells 
Ki (95% CL) 
nM 
hCB1 CHO cells 
% Max 
displacement 
(95% CLb)= 
hCB2 CHO 
cells 
Ki (95% CL) 
nM 
hCB1 CHO cells 
% Max 
displacement 
(95% CLb)= 
131 
422 (235–757) 
nM 
71.8 (65.6–77.9) n. a. n. a. 
non-iodinated 
analogue of 
131 
312 (113–862) 100 (81.0–120) 
1.02 x 103 
(603–1.72 x 
103) 
92.0 (79.7–104) 
Rimonabant 18.7 (11.1–31.4) 90.2 (85.0–95.3) 
1.40 x 103 
(500–3.70 x 
103) 
92.4 (70.4–114) 
 
Biological data show that the non-iodinated analogue of 131 is affine CB for the receptors although 
with less intensity than Rimonabant. On the other hand, compound 131 loses almost totally the 
affinity. This could explain that the polarized C5-H bond of the triazole, that can act as a hydrogen 
bonding donor, deems to be essential for the affinity on CBs. 
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PROJECT 4 
 
4.4 Aim of project 4 
 
 The aim of this project was the design and the synthesis of a series of novel 5-aryl-4-
alkylpyrazole compounds, related to the potent and selective CB1 antagonist NESS-0327 (fig. 32),64, 
65,66 with the aim of obtaining different analogues, suitable as radioligands for PET imaging. 
 
 
Figure 32 
 
The strategy was to modify NESS-0327in two different portions (fig. 33) 
- the amidic portion (A)  
- the aromatic substituent of the tricyclic moiety (B)  
 
 
Figure 33 
 
Various triazoles analogues (table 10) bearing a fluoro alkynyl chain, suitable for radiolabelling with 
19F radioisotope, replacing the bromine at position 8 of the tricyclic moiety, were designed; the amidic 
portion was replaced with an N-substituited triazole ring. 
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TABLE 10 
 
 R2 
152 
 
153 
 
154 H 
155 CH3 
 
As known, triazole group displays structural similarity with the amide bond, mimicking a Z or an E 
amide bond depending on its substitution pattern.67 
The 1,4-disubstituted triazole moiety can be compared with the Z-amide bond. In fact, the lone pair 
of the 3-nitrogen mimics the one of the carbonyl oxygen of the amide bond, the polarized C5-H bond 
can act as a hydrogen bonding donor, just like the amide N–H bond, and the electrophilic and 
polarized C4 is electronically similar to the carbonyl carbon (fig. 34). 
 
 
Figure 34 
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Moreover, the triazole was inserted considering the easiness of its synthesis: in general, the 
Sharpless click chemistry proves to be highly reproducible, quickly, cheap and simple to perform. 
The chlorine was changed with the bromine considering that in literature this substitution in NESS-
0327 does not produce a large difference in terms of potency, activity and selectivity (CB1 vs CB2)68, 
moreover bromine is more attractive from a synthetic point of view. In fact, a common intermediate 
for the syntheses of various analogues bearing the original chlorine was less useful in comparison 
to the one substituted with the bromine. 
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4.5 Chemistry 
 
The key intermediate 144 was obtained with the following scheme of synthesis. 
 
SCHEME 23 
 
 
Reagents and conditions: i) tBuOK, DMSO, r.t.; ii) Pd/C, H2, AcOEt, r.t.; iii) COCl2, DCM, DMF 
(cat), 50°C, 2h; AlCl3, r.t., overnight; iv) diethyloxalate, N2, EtOH, r.t.; v) 2,4-dichloroaniline 
hydrochloride salt, EtOH, 80°C; vi) LiAlH4, THF, 0°C to rt; vii) DMP, DCM, 0°C to r.t.; viii) Bestmann 
Ohira reagent, CH3OH, K2CO3, r.t. 
 
The synthesis of 144 started from the commercially available 3-bromobenzaldehyde, following the 
procedures previously published.69 The aldehyde was submitted to a Wittig condensation with the 
phosphonium bromide by means of t-BuOK in DMSO to yield the pentenoic acid derivatives 145. 
Then, the double bond was reduced using Pd/C, AcOEt, 1 atm of H2, affording the desired product 
146. The subsequent transformation of 146 into the corresponding acyl chloride was carried out 
using thionyl chloride, while the ring closure was achieved via an intramolecular Friedel-Crafts 
acylation under standard conditions, affording the benzosuberone derivative 147. After that, the 
reaction with diethyl oxalate NaOEt in EtOH provided diketoester 148 which was allowed to react 
with 2,4-dichlorophenylhydrazine hydrochloride to obtain compound 149. 
The aldehyde 151,was reached with the total reduction of the ester of 149 using LiAlH4 at 0ºC to 
give alcohol 150 and the following re-oxidation to aldehyde 151 using DMP at 0ºC. Finally, 
Bestmann-Ohira alkynylation was employed to obtain compound 144. 
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SCHEME 24 
 
 
 
Reagents and conditions: i) azido-compound, CuSO4, sodium ascorbate, tBuOH/H2O; ii) propargyl 
alcohol, Pd(PhP)2Cl2, TBAF, 80°C; iii) Pd/C, EtOH, H2 1 atm, r.t.; iv) DAST 
 
Compound 144 was submitted to a click reaction using the properly azide in order to obtain analogue 
157 a-d. The copper/amine/solvent - free Sonogashira alkynylation70 that was carried out using 
Pd(PPh)2Cl2, TBAF, 80⁰C obtaining 158 a-d. Then, the triple bond was hydrogenated before the 
deoxofluorination step, in order to avoid a side reaction that occurs using DAST on a similar 
substrate. In fact, previously, the formation of a side elimination product was observed. It was due 
to the creation of a propargyl cation intermediate71 which reacts with toluene (employed as solvent) 
through a Friedel-Crafts propargylation, leading to an undesired product. Without the triple bond, no 
radical side process should take place. 
As already published, the switch from a single bond to a triple bond, on similar substrate, does not 
affect the activity and the selectivity against the CB1 receptor.72 
Unfortunately, during the hydrogenation the two chlorine atoms were lost and the last step of the 
synthesis was not performed. 
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SCHEME 25 
 
 
 
Reagents and conditions: i) NaN3, acetone/H2O, 60°C or NaN3, DMSO, 80°C or NaN3, DMF, 65°C 
 
The synthesis of the azides starts from the corresponding bromide, using sodium azide in 
acetone/H2O or in DMSO.  
 
 R2 
156 a  
156 b 
 
156 c 
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4.6 Conclusions 
 
 
Figure 35 
 
 The hydrogenation of the triple bond had as a consequence the unexpected loss of the two 
chlorine atoms located on the aromatic ring (fig. 35). This event was confirmed by NMR and mass 
spectra. Unfortunately, considering the limited time spent at Institute of medical sciences, it was not 
possible to solve the problem and achieve the synthesis of the prefixed compounds. The work was 
after completed by Zanda’s group. 
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5 INTRODUCTION 
 
5.1 Magnetic resonance imaging 
 
 NMR is the most powerful technique for molecule characterization. However, it suffers some 
weaknesses, such as low sensitivity due to Boltzmann distribution, according to which only 1 spin 
in 31,200 is NMR active at a magnetic field of 9.4 T (normal magnetic field for MRI). In order to 
enhance the signal, several hyperpolarization techniques, able to modify the Boltzmann distribution 
making the technique more sensitive, have been reported.73 
Magnetic Resonance Imaging (MRI) thanks to imaging nuclei atoms inside the body provides to the 
visualization in detail of internal structures. MRI generally allows seeing the body structures rather 
than the pharmacokinetics or metabolism. This technique considers the magnetic properties of 
atomic nuclei, in particular the hydrogen (present in water molecules), the most abundant one in our 
bodies. Thanks to a different water concentration in each tissue, there is a dissimilar response to 
the applied magnetic field and, consequently, a different grey gradient in the final picture (fig. 36). 
 
 
Figure 36 
 
MRI scanner is a device in which the patient lies within a large, powerful magnet and the magnetic 
field is used to align the magnetization of some atomic nuclei in the body. Radio frequency magnetic 
fields are applied to systematically alter the alignment of this magnetization. Consequently, nuclei 
produce a rotating magnetic field that is detected by the scanner and the information is recorded in 
order to form an image of the desired area of the body.74 Magnetic field gradients cause nuclei at 
different locations to precess at different speeds, which allows spatial information to be recovered 
using Fourier analysis of the measured signal. By using gradients in different directions, 2D images 
or 3D volumes can be obtained. MRI affords good contrast of different soft tissues of the body, which 
makes it useful in imaging brain, heart, muscles and cancers compared with other medical imaging 
techniques such as computed tomography (CT) or X-rays. The adverse side is the long scan times 
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to acquire a proper image. Some contrast agents have been used based on gadolinium, which 
changes the relaxation times of the molecules in the body, to enhance the signal and overcome the 
sensitivity problem. These agents alter the relaxation times of atoms within body tissues after oral 
or intravenous administration. In fact, MRI and NMR is quite an insensitive technique: for example, 
it is quite representative the difference in concentration in the preparation of a sample to be 
submitted to a normal 1H-NMR experiment versus the amount of a compound submitted to an MS 
analysis. Another example is the time and concentration requested to run a normal 13C-NMR 
experiment. Several scans are needed in order to achieve a good to optimal Signal-to-Noise: at least 
4 for normal 1H-NMR, while 50 for 13C-NMR. That is due to the signal intensity that is related to 
relative populations of the magnetic levels probed during the experiment; this mechanism is called 
polarization. At thermal equilibrium the energy levels are close and there is little energy needed to 
promote the transition from one level to the other one. Moreover, the Boltzman distribution predicts 
that almost an equal number of nuclei will be in the two different energy levels, even in highest 
magnetic fields. An altered distribution of the nuclei population in the two levels would increase NMR 
signal because more nuclei are subjected to transition. This mechanism is called hyperpolarization.  
 
5.2 Para Hydrogen Induced Polarisation 
 
 Para Hydrogen Induced Polarisation (PHIP) is a technique that induce polarisation into 
molecules. This method was used for the generation of PHIP enhanced contrast agents in Magnetic 
Resonance Imaging.75 In the H2 molecule the two hydrogen nuclei have spin = 1/2 and the molecule 
is NMR active. The two spins can couple and generate four spin isomers for the molecule as a triply 
degenerate and symmetric with respect to the exchange of nuclei state (orthohydrogen), finally, the 
remaining configuration corresponding at the parahydrogen, is antisymmetric with respect to 
exchange of nuclei and results in a singlet state. Even if these spin configurations are close in energy 
and basically equally at room temperature, p-H2 is the most stable isomer and it is prevalent at low 
temperatures. The transformation from one isomer to the other is forbidden in fact, spins cannot 
simply flip from one state to another even if the thermodynamics are favorable. Thus is necessary a 
paramagnetic catalyst like charcoal, Fe2O3 or Fe(OH)3.  
When hydrogen reacts and its symmetry is broken in an oxidative addition reaction to a metal center, 
novel NMR effects can be seen thanks to the reaction that proceeds in a spin correlated manner.  
In nature hydrogen is diffused in equal numbers of molecules in each of its four spin configurations, 
also the four possible configurations in the oxidative addition product of hydrogen on the metal 
center are equally populated. 
Considering that the intensity of an NMR signal is proportional to the population difference among 
the energy levels (very low in this case), the number of nuclei able to undergoing the transition is 
very low and low intensity signals are detected (fig. 37). On the other hand, if it is possible to populate 
selectively only one of the spin configurations of the molecular hydrogen, the αβ-βα state or p-H2, 
after the oxidative addition to the metal center only one of the spin states in the product would be 
selectively populated, with a resulting hyperpolarisation. In this case, the populations of each energy 
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level are very different to the usual Boltzmann distribution and the resultant NMR signals of the 
product show an enhancement.  
 
 
 
Figure 37: Boltzmann-derived distribution and resulting transitions and NMR signals 
 
The enhancement worked if the resultant signals are antiphase: one set in absorption and the other 
in emission (fig. 38). After its embranchment, the sample relaxes back to thermal equilibrium.  
 
 
Figure 38: p-H2 - distribution of population and resulting NMR signal 
 
ALTADENA (Adiabatic Longitudinal Transport After Dissociation Engenders Nuclear Alignment) and 
PASADENA (Parahydrogen And Synthesis Allow Dramatically Enhanced Nuclear Alignment) are 
two old techniques used to obtain the p-H2 -induced polarization. Their fundamental requirement is 
that the molecule has to present a proton acceptor (double or triple bond). 
SABRE (signal amplification by reversible exchange) a new method developed at the University of 
York, UK, in the group of Professor Simon Duckett, can achieve the PHIP without any chemical 
modification of the substrate. 76,77  
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Figure: 39 
 
More in detail, there is no chemical modification of the hyperpolarized material: it generates long 
lived spin states and then the polarization can be transferred to the heteronuclei through a suitable 
NMR sequence. SABRE is based on the transfer of the polarization present in the para-hydrogen to 
a pyridine or pyridyl moiety within a molecule through a catalyst center based on iridium metal (fig. 
39). Probably the metal center has the function of a template and allows the p-H2 and the substrate 
molecule to get close and participate in the magnetization exchange. All this process happens at 
low magnetic fields, and signal enhancement >100-fold could be observed.78  
 
5.3 Nitric Oxide Synthases and arginine 
 
 Arginine, a natural amino acid among the 20 proteinogenic L-amino acids, is one of the most 
basic residues, with a pKa of 12.48. Arginine is the substrate for Nitric Oxide Synthases (NOS) 
enzyme, a class composed by three different isozyme forms (the Neuronal NOS, the Endothelial 
NOS and the Inducible NOS) with the function of the conversion of arginine to citrulline and nitric 
oxide (fig. 40). 
 
 
Figure 40 
 
NO, produced in neuronal tissues with the function of intracellular second messenger for 
neurotransmission, is involved in the regulation of smooth muscle relaxation and blood pressure in 
the endothelial tissue; moreover, in macrophage cells, NO acts as an answer to inflammatory stimuli. 
NO has also an important role in cardiovascular diseases, such as hypertension. 
Many inhibitors are based on L-arginine; but a simple modification of the scaffold or capping an 
amine functionality could target only one of the different isoforms of the NOS enzyme.79 
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5.4 Aim of project 5 
 
 This project was developed in collaboration with the group of Professor Matteo Zanda at the 
University of Aberdeen, UK, the group of Professor Michael Frenneaux and doctor Dana Dawson at 
the University of Aberdeen and the group of Professor Simon B. Duckett at the University of York. 
The aim was the synthesis of arginine analogues with a pyridyl/pycolyl moiety that could be potential 
substrate for eNOS enzyme and also could be suitable substrate for the transfer of polarization by 
p-H2 molecules through SABRE technique.  
In fact, considering that peculiar analogues and peptides involved in the catalytic process of the 
synthesis of the Nitric Oxide could be detected through Magnetic Resonance Imaging, synthesized 
compounds could be source of their NMR signal. For these reasons, the goal was to develop 
arginine analogues that could work as MRI contrasting agents which are target specific due to their 
exclusively location into NOS enzymes. This could result in the MRI technique as a more sensitive 
and faster technique.  
For these reasons, five compounds were synthesized (table 11) 
 
TABLE 11 
 
 
 Salt R R1 
160 ∙3HCl H 
 
162 ∙3HCl H 
 
164 ∙3HCl CH3 
 
166 ∙3HCl H 
 
92 
 
168 ∙3HCl H 
 
 
Moreover, five compounds, already synthesized, were converted in hydrochloride salt (table 12). 
 
TABLE 12 
 
 
 Salt R2 R3 
171 ∙3HCl H 
 
172 ∙3HCl H 
 
173 ∙3HCl H 
 
174 ∙3HCl CH3 
 
175 ∙3HCl H 
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5.5 Chemistry 
 
Compounds showed in table 11 were synthesized following synthetic procedures explained in 
schemes 26-31. 
 
SCHEME 26 
 
 
 
Reagents and conditions: i) HATU, TEA, DCM, r.t.; ii) CF3COOH, r,t,; HCl 1N 
 
The small peptide 161 was obtained by simple coupling of the Boc-Pbf protected arginine with 
pyridin-3-ylmethanamine in presence of HATU and TEA; then the aminoacid derivative was 
deprotected using TFA. Finally, in order to reach the hydrochloride salt, compound was treated with 
HCl 1N and crystals of 160 were obtained thanks to freeze drying. Using the same procedure were 
obtained compounds 162, 164, 166 too. 
 
 
 
SCHEME 27 
 
 
Reagents and conditions: i) HATU, TEA, DCM, r.t.; ii) CF3COOH, r,t,; HCl 1N 
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SCHEME 28 
 
 
Reagents and conditions: i) HATU, TEA, DCM, r.t.; ii) CF3COOH, r,t,; HCl 1N 
 
SCHEME 29 
 
 
Reagents and conditions: i) HATU, TEA, DCM, r.t.; ii) CF3COOH, r,t,; HCl 1N 
 
SCHEME 30 
 
 
 
Reagents and conditions: i) HATU, TEA, DCM, r.t.; ii) LiOH, THF, H2O; iii) CF3COOH, r,t,; HCl 1N 
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Thanks to a saponification with LiOH the acid 169 was formed then, the aminoacid derivative was 
deprotected using TFA. Finally, in order to reach the hydrochloride salt, compound was treated with 
HCl 1N and crystals of 168 were obtained with the afford of the freeze drying. 
 
SCHEME 31 
 
 
 
Reagents and conditions: i) SOCl2, CH3OH, r.t. 
 
2-amino-3-(pyridin-3-yl)propanoic acid was methylated using SOCl2, in methanol, affording 
compound 165. 
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5.6 Results and discussion 
 
 Compounds of Table 11 and Table 12 were tested with the eNOS enzyme according to a 
protocol based on a standard Nitrate-Nitrite colorimetric assay protocol by Dana Dawson’s research 
group at the Institute of Medical Sciences, Aberdeen, UK.  
 
Polarisation Tests 
During a period as a visiting PhD student at The Centre for Hyperpolarisation in Magnetic 
Resonance (CHyM), York, UK, SABRE experiments of 160, 164, 171 and 174 were performed. 
Considering previous studies, that demonstrated that the presence of the triflic acid as counterion 
interacted strongly with the catalyst causing an insignificant enhancement, all synthesized 
compounds were converted in hydrochloride salts. Unfortunately, HCl salts still interacted with the 
catalyst. For this reason why we had to remove it before reading out the results. 
 
In order to analyze the enhancement of 171 we followed this procedure: 
The reaction mixture was prepared dissolving approximately 10 to 20 mg of 171 in 0.6 mL of 
deuterated methanol, because its appearance is a very sticky oil, and it was impossible to weight 
out, adding 2 mg of the catalyst Ir(cod)(IMes)Cl. This solution was filtered through a home-made 
cartridge of K2CO3 to get rid of the HCl, which is known to deactivate the catalyst. Then the cartridge 
was washed out with 0.1 mL of the same solvent. Unfortunately, during the neutralization process, 
water was formed (fig. 41) causing the precipitation of an amount of catalyst.  
 
2 HCl + K2CO3  2 KCl + H2O + CO2 
Figure 41 
 
Even though, we were able to achieve the experiments listed below: 
 
 1H thermal spectrum (fig. 42) 
 1H Hyperpolarised spectrum, that showed 50.68-fold enhancement signal at 70 gauss (fig. 43) 
 OPSY experiments at 0 gauss (fig. 44) and 70 gauss, that showed greater enhancement signal 
at 0 gauss; no enhancement for any proton in the arginine chain was observed but only on 
aromatic region. 
 13C hyperpolarized spectrum at 0 gauss, that showed no enhancement. 
 
NMR tube prepared was first degassed then, the para-hydrogen was introduced in the headspace, 
and the tube was shaken with the “shake-and-drop” technique close to the NMR instrument, where 
the magnetic field is approximately 70 G. The distance to the instrument where there is a 70 gauss 
magnetic field was calculated using a gauss meter. 
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In vitro, 171 indicated the highest activity among all ten tested compounds (about as twice active as 
native arginine). It also showed the best enhancement in the SABRE polarization tests.  
The enhancement of 174 was analyzed following this procedure:  
Even if 174 did not show an excellent activity in vitro, it was tested with SABRE method in order to 
observe the effect of the methyl substituent on the nitrogen. 
The sample was prepared dissolving 2 mg of the catalyst Ir(cod)(IMes)Cl and 10.7 mg of 174 in 0,6 
mL of deuterated methanol. Then, the solution was filtered through a K2CO3 home-made cartridge 
to get rid of the HCl part of the salt. Catalyst needed to be activated overnight. 
Indeed, enhancement was lower than that of 171, being only 17.25-fold. In the OPSY spectra no 
proton for the arginine chain was observed and only protons of the pyridyl moiety can be detected. 
0 gauss gave better enhancement than 70 gauss, therefore 13C spectrum was collected 
hyperpolarizing at that magnetic field, but no enhancement was observed.  
 
 
 
 
Figure 42 
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Figure 43 
 
 
Figure 44 
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The enhancement of 160 was analyzed following this procedure:  
10.1 mg of 160 were dissolved with 0.6 mL of deuterated methanol and 2 mg of the catalyst 
Ir(cod)(IMes)Cl. Then, it was filtered through the K2CO3 cartridge. Enhancement shown was of 
39.47-fold, spread in the four protons of the pyridyl moiety (o: o: p: m are 12.62: 14.73: 9.17: 2.95). 
OPSY was found to be better at 0 gauss, but 13C was not even read out, because it was supposed 
the enhancement of the protons was not enough to be transferred to the carbon. 
 
The enhancement of 164 was analyzed following this procedure:  
9.7 mg of the 164 were dissolved in a solution of 2 mg of the catalyst Ir(cod)(IMes)Cl in 0.6 mL of 
deuterated methanol. Some spectra were recorded like that, after degassing the tube, showing 
enhancement only on the first read out and only 0.4 on the ortho protons, and no signal for the 
hydrides was observed. The reason could be that this compound could form a very stable complex 
with the catalyst that did not dissociate, so catalyst is saturated, and therefore blocked. If this 
happens, the guanidine moiety of the arginine is the most likely part to be blocking the Ir center. 
Moreover it could be due to a too slow or quick exchange. To rule out that possibility, 
hyperpolarization was achieved at 9oC and at 35oC, but still the same spectrum could be observed. 
This indicates the temperature and the rapidity of the polarization transfer is most likely not the cause 
of the lack of polarization within the molecule. 
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5.7  Conclusions 
 
 Previous work showed that no data were available for unprotected compounds, with the 
triflic acid as counterion that interacted with the catalyst; therefore hyperpolarisation process could 
not be properly performed. In this project, with the use of the free amine, we obtained interesting 
results in particular for 171 that showed a 53-fold enhancement in the signal, also for both protons 
ortho and meta even if 13C NMR did not show any enhancement. 
The results obtained in York constitute a significant step forward showing an enhancement almost 
as strong as the picolyl moiety itself as previous studies demonstrated. This means that optimization 
can be now performed, with the goal of obtaining a much greater enhancement. 
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6 EXPERIMENTAL SECTION 
 
Chemistry 
 
General Methods.  
 
 Melting points were measured in glass capillary tubes on a Büchi SMP-20 apparatus and 
are uncorrected. Direct infusion ES-MS spectra were recorded on a Waters Micromass ZQ 4000 
apparatus. 1H, 13C, 19F NMR experiments were recorded in CDCl3, unless differently indicated, on 
Varian VXR 400 MHz instrument. Chemical shifts are reported in parts per million (ppm) relative to 
tetramethylsilane (TMS), and spin multiplicities are given as s (singlet), d (doublet), t (triplet) or m 
(multiplet). Chromatographic separations were performed on silica gel columns (Kieselgel 40, 0.040-
0.063 mm; Merck) by flash chromatography. Compounds were named following IUPAC rules as 
applied by Beilstein-Institut AutoNom (version 2.1), a PC integrated software package for systematic 
names in organic chemistry. HPLC-MS: Agilent Technologies HP1100 instrument, equipped with a 
ZOBRAX-Eclipse XDB-C8 Agilent Technologies column, mobile phase: H2O/CH3CN, 0.4 mL/min, 
gradient from 30 to 80% of CH3CN in 8min, 80% of CH3CN until 25min, coupled with an Agilent 
Technologies MSD1100 single-quadrupole mass spectrometer: full scan mode from m/z = 50 to 
2600, scan time 0.1s in positive ion mode, ESI spray voltage 4500V, nitrogen gas 35psi, drying gas 
flow 11.5 mL/min, fragmentor voltage 20V. 
 
 
PROJECT 1 
 
3-(3-chloropropoxy)-6H-benzo[c]chromen-6-one (57) 
To a suspension of 2.58g (11.37 mmol, 3eq) of DDQ (2,3-dichloro-5,6-dicyano-p-benzoquinone) in 
30 mL of anhydrous dioxane, 1.1g (3.79 mmol, 1eq) of 3-(3-chloropropoxy)-7,8,9,10-tetrahydro-6H-
benzo[c]chromen-6-one were added and the mixture was stirred and refluxed for 24h. The solution 
was concentrated under vacuum, then water was added and the aqueous phase was extracted with 
ethyl acetate. The combined organic layers were dried over anhydrous Na2SO4 and concentrated 
under vacuum. The crude was purified via flash chromatography: petroleum ether/ethyl acetate 3:2. 
0.23g of 57 were obtained. Yield: 21.10% M.P.: 84-85° C; 1H-NMR δ 8.35 (d, J = 8.8 Hz, 1H), 8.11 
- 7.95 (m, 2H), 7.83 (t, J = 8.2 Hz, 1H), 7.55 (t, J = 6.4 Hz, 1H), 7.09- 6.81 (m, 2H), 4.19 (t, J = 11.2 
Hz, 2H), 3.78 (t, J = 15.6 Hz, 2H), 2.35 – 2.26 (m, 2H) 
 
7-hydroxy-3-phenyl-2H-chromen-2-one (58a)  
0.17g (7.35 mmol) of Na were dissolved in methanol. The solution was added to 1.0g (7.35 mmol) 
of phenylacetic acid previously dissolved in methanol. The mixture was concentrated under vacuum, 
then ethanol was added and it concentrated again. 1.01g (7.350 mmol) of 2,4-
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dihydroxybenzaldehyde and an excess of acetic anhydride were added to the reaction flask that was 
stirred and heated at 180 °C for 5h. The reaction was poured in a solution of sodium 
bicarbonate(10%), then it was filtered and allowed to dry. The solid was dissolved in DCM then was 
washed with NaOH 2N and water; the organic phase was concentrated under vacuum. The 
compound was further purified via flash chromatography: petroleum ether/ethyl acetate 7:3. 
Obtained compound was deacetylated with an excess of K2CO3 in acetone warming up to reflux. 
0.65g of neat compound 58a were obtained. Yield: 37.14% M.P.: 175.5-177° C; 1H NMR δ 9.49 (s, 
1H), 8.05 (s, 1H), 7.79 (d, J = 8.8 Hz, 2H), 7.63 (d, J = 8.4 Hz, 1H), 7.48 - 7.54 (m, 3H), 6.91 (d, J = 
10.8 Hz, 1H), 6.81 (s, 1H) 
 
7-hydroxy-3-(4-methoxyphenyl)-2H-chromen-2-one (58b)  
Compund 58b was obtained following the same procedure described for compound 58a using p-
methoxy phenylacetic acid and 2,4-dihydroxybenzaldehyde. Yield: 8,7 %; M.P.:158.7-160.8° C; 1H-
NMR δ 9.49 (s, 1H), 8.05 (s, 1H), 7.79 (d, J = 8.8 Hz, 2H), 7.63 (d, J = 8.4 Hz, 1H), 7.08 (dd, J = 8.4 
Hz, 2H), 6.91 (d, J = 10.8 Hz, 1H), 6.81 (s, 1H),  3.92 (s, 3H) 
 
6-hydroxy-3-(4-methoxyphenyl)-2H-chromen-2-one (58c)  
Compund 58c was obtained following the same procedure described for compound 58a using p-
methoxy phenylacetic acid and 2,5-dihydroxybenzaldehyde. Yield: 49.7% M.P.: 186.6-187.3° C. 1H-
NMR δ 9.49 (s, 1H), 8.11 (s, 1H), 7.63 (d, J = 8.8 Hz, 2H), 7.48 - 7.32 (m, 3H), 7.08 - 6.91 (m, 2H), 
3.68 (s, 3H) 
 
3-(4-chlorophenyl)-7-hydroxy-2H-chromen-2-one (58d)  
Compund 58d was obtained following the same procedure described for compound 58a using p-
chlorophenylacetic acid and 2,4-dihydroxybenzaldehyde. Yield: 48.27% M.P.: >250° C; 1H-NMR δ 
9.49 (s, 1H), 8.11 (s, 1H), 7.79 (d, J = 8.8 Hz, 2H), 7.62 (d, J = 8.4 Hz, 1H), 7.48 (dd, J = 8.4 Hz, 
2H), 6.91 (d, J = 10.8 Hz, 1H), 6.81 (s, 1H) 
 
7-(3-chloropropoxy)-4-methyl-2H-chromen-2-one (17)  
To a solution of 1.26g (7.16 mmol) of 7-hydroxy-4-methyl-2H-chromen-2-one in acetone (100 mL), 
2.47g (17.89 mmol, 2.5eq) of K2CO3 and 1.67g (10.738 mmol, 1.5eq, d=1.592) of 1-bromo-3-
chloropropane were added. The reaction was refluxed for 24h, then it was filtered hot and 
concentrated under vacuum. The crude was crystallized with petroleum ether. 1.42g of neat 
compound 17. Yield: 79% M.P.: 79-80° C; 1H NMR δ 7.58 (d, J = 8.2 Hz, 1H), 6.95 - 6.81 (m, 2H), 
6.15 (s, 1H),.4.19 (t, J = 11.2 Hz, 2H), 3.78 (t, J = 15.6 Hz, 2H), 2.45 (s, 3H), 2.35 – 2.26 (m, 2H) 
 
3-(3-chloropropoxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one (18)  
Compound 18 was obtained following the same procedure described for compound 17 using 3-
hydroxy-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one as starting material. Yield: 78% M.P.: 99.8-
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101.0° C. 1H NMR δ 7.44 (d, J = 8.8 Hz, 1H). 6.90 - 6.70 (m, 2H), 4.07 (t, J = 12.4 Hz, 2H), 3.85 - 
3.70 (m, 2H), 2.75 (t, J = 11.6 Hz, 2H), 2.57-2.54 (m, 2H), 2.00 – 1.97 (m, 2H), 1.86 – 1.78 (m, 4H) 
 
7-(3-chloropropoxy)-3-phenyl-2H-chromen-2-one (19) 
Compound 19 was obtained following the same procedure described for compound 17 using 
compound 58a as starting material. Yield: 48.78% M.P.: 108-110° C; 1H NMR δ 7.75 (s, 1H), 7.68 
(d, J = 8.8 Hz, 2H), 7.45 – 737 (m, 4H), 6.87 (d, J = 10 Hz, 2H), 4.19 (t, J = 11.6 Hz, 2H),3.76 (t, J = 
12.8 Hz, 2H), 2.31 – 2.26 (m, 2H) 
 
7-(3-chloropropoxy)-3-(4-methoxyphenyl)-2H-chromen-2-one (20)  
Compound 20 was obtained following the same procedure described for compound 17 using 
compound 58b as starting material. Yield: 51.97% M.P.: 108-114.5° C; 1H NMR δ 7.81 (s, 1H), 7.51 
- 7.25 (m, 4H), 7.01 - 6.87 (m, 3H), 4.19 (t, J = 11.2 Hz, 2H), 3.92 (s, 3H), 3.78 (t, J = 15.6 Hz, 2H), 
2.35 – 2.26 (m, 2H) 
 
6-(3-chloropropoxy)-3-(4-methoxyphenyl)-2H-chromen-2-one (21)  
Compound 21 was obtained following the same procedure described for compound 17 using 
compound 58c as starting material. Yield: 49.53% M.P.: 113.9-116.2° C; 1H NMR 7.89 (s, 1H), 7.64 
(d, J = 8.8 Hz, 2H), 7.49 - 7.31 (m, 3H), 7.08 - 6.91 (m, 2H), 4.19 (t, J = 11.2 Hz, 2H), 3.95 (s, 3H), 
3.78 (t, J = 15.6 Hz, 2H), 2.35 – 2.26 (m, 2H) 
 
3-(4-chlorophenyl)-7-(3-chloropropoxy)-2H-chromen-2-one (22)  
Compound 22 was obtained following the same procedure described for compound 17 using 
compound 58d as starting material. Yield: 74.38% M.P.: 157° C; 1H NMR δ 7.76 (s, 1H), 7.66 (dd, J 
= 8.4 Hz, 2H), 7.46-7.40 (m, 3H), 6.89-6.87 (m, 2H), 4.22-4.18 (m, 2H), 3.79-3.75 (m, 2H), 2.31-2.26 
(m, 2H) 
 
7-(3-chloropropoxy)-2H-chromen-2-one (23)  
Compound 23 was obtained following the same procedure described for compound 17 using 7-
hydroxycoumarin as starting material. Yield: 95.92% M.P.: 104.3° C; 1H NMR δ 7.60 (d, J = 9.5 Hz, 
1H), 7.33 (d, J = 8.6 Hz, 1H), 6.80 (dd, J = 8.6, 2.4 Hz, 1H), 6.76 (d, J = 2.3 Hz, 1H), 6.20 (d, J = 9.5 
Hz, 1H), 4.13 (t, J = 5.8 Hz, 2H), 3.71 (t, J = 6.3 Hz, 2H), 2.23 (p, J = 6.0 Hz, 2H) 
 
8-(3-chloropropoxy)-5H-chromeno[2,3-b]pyridin-5-one (24)  
Compound 24 was obtained following the same procedure described for compound 17 using 8-
hydroxy-5H-chromeno[2,3-b]pyridin-5-one as starting material. Yield: 95.92% M.P.: 104.3° C; 1H 
NMR δ 8.72 (d, J = 8 Hz, 2H), 8.252 (d, J = 8.8 Hz, 1H), 7.45 – 7.42 (m, 1H), 7.03 – 6.98 (m, 2H), 
4.28 (t, J = 12 Hz, 2H), 3.79 (t, J = 12.4 Hz, 2H), 2.35 – 2.31 (m, 2H) 
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7-((5-chloropentyl)oxy)-2H-chromen-2-one (25) 
Compound 25 was obtained following the same procedure described for compound 17 using 7-
hydroxycoumarin and 1-Bromo-5-chloropentane as starting materials. Yield: 51.21% M.P.: 52-54° 
C; 1H NMR δ 7.60 (d, J = 9.5 Hz, 1H), 7.33 (d, J = 8.6 Hz, 1H), 6.80 (dd, J = 8.6, 2.4 Hz, 1H), 6.76 
(d, J = 2.3 Hz, 1H), 6.20 (d, J = 9.5 Hz, 1H), 4.13 (t, J = 5.8 Hz, 2H), 3.71 (t, J = 6.3 Hz, 2H), 1.98-
1.89 (m, 4H), 1.69-1.68 (m, 2H) 
 
3-((5-chloropentyl)oxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one (26)  
Compound 26 was obtained following the same procedure described for compound 17 using 3-
hydroxy-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one and 1-Bromo-5-chloropentane as starting 
materials. Yield: 96.15%; yellow oil; 1H NMR δ 7.38 (d, J = 8.8 Hz, 1H), 6.76 (d, J = 8.8 Hz, 1H), 
6.70 (s, 1H), 3.94 (t, J = 12.4 Hz, 2H), 3.50 (t, J = 12.8 Hz, 2H), 2.67 – 2.56 (m, 2H), 2.49 – 2.48 (m, 
2H), 1.83 - 1.61 (m, 8H), 1.55 – 1.52 (m, 2H) 
 
8-((5-chloropentyl)oxy)-5H-chromeno[2,3-b]pyridin-5-one (27)  
Compound 27 was obtained following the same procedure described for compound 17 using 8-
hydroxy-5H-chromeno[2,3-b]pyridin-5-one and 1-Bromo-5-chloropentane as starting materials. 
Yield: 67.86% M.P.: 109.8-110.5° C; 1H NMR δ 8.72-8.69 (m, 2H), 8.24 (dd, J = 7.6 Hz, 1H), 7.45 
(dd, J = 12.4 Hz, 1H), 6.99 (d, J = 10Hz, 2H), 4.12 (t, J = 12.8 Hz, 2H), 3.61 (t, J = 13.2 Hz, 2H), 
1.92-1.87 (m, 4H), 1.69-1.68 (m, 2H) 
 
7-(3-iodopropoxy)-4-methyl-2H-chromen-2-one (28)  
A mixture of 1.42g (5.63 mmol) of 17 and 0.84g (5.63 mmol) di NaI in 75 mL of methyl ethyl ketone 
was refluxed for 3h, then it was concentrated under reduced pressure. The crude was dissolved in 
DCM and washed with water. The organic layer was collected and the solvent was evaporated under 
reduced pressure. Compound 28 was used for the next reaction without any further purification. 
1.53g of neat compound.Yield: 79.27% 
 
3-(3-iodopropoxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one (29)  
Compound 29 was obtained following the same procedure described for compound 28 using 
compound 18 as starting material. Yield: 88.49% M.P.: 99.8-101.0° C. 1H NMR: δ 1.5-2.0 (m,5H), 
2.1-2.4 (m,2H), 2.5 (s,2H), 2.7 (s,2H), 3.3 (t,1H), 3.7 (t,1H), 4.0-4.4 (m,2H), 6.7-6.9 (m,2H), 7.1-7,4 
(m,1H), 7.4 (d,1H). 
 
7-(3-iodopropoxy)-3-phenyl-2H-chromen-2-one (30)  
Compound 30 was obtained following the same procedure described for compound 28 using 
compound 19 as starting material. Yield: 86.96% 
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7-(3-chloropropoxy)-3-(4-methoxyphenyl)-2H-chromen-2-one (31)  
Compound 31 was obtained following the same procedure described for compound 28 using 
compound 20 as starting material. Yield: 87.79%  
 
6-(3-iodopropoxy)-3-(4-methoxyphenyl)-2H-chromen-2-one (32)  
Compound 32 was obtained following the same procedure described for compound 28 using 
compound 21 as starting material. Yield: 73.45%  
 
3-(4-chlorophenyl)-7-(3-chloropropoxy)-2H-chromen-2-one (33)  
Compound 33 was obtained following the same procedure described for compound 28 using 
compound 22 as starting material. Yield: 91.15%  
 
7-(3-iodopropoxy)-2H-chromen-2-one (34)  
Compound 34 was obtained following the same procedure described for compound 28 using 
compound 23 as starting material. Yield: 86.92%;  
 
8-(3-iodopropoxy)-5H-chromeno[2,3-b]pyridin-5-one (35)  
Compound 35 was obtained following the same procedure described for compound 28 using 
compound 24 as starting material. Yield: 94.93%  
 
7-((5-iodopentyl)oxy)-2H-chromen-2-one (36)  
Compound 36 was obtained following the same procedure described for compound 28 using 
compound 25 as starting material. Yield: 86.56%  
 
3-((5-iodopentyl)oxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one (37)  
Compound 37 was obtained following the same procedure described for compound 28 using 
compound 26 as starting material. Yield: 86.49%; yellow oil 
 
8-((5-iodopentyl)oxy)-5H-chromeno[2,3-b]pyridin-5-one (38)  
Compound 38 was obtained following the same procedure described for compound 28 using 27 as 
starting material. Yield: 70.96% M.P.: 97.2-97.8° C 
 
3-(3-iodopropoxy)-6H-benzo[c]chromen-6-one (39)  
Compound 39 was obtained following the same procedure described for compound 28 using 57 as 
starting material. Yield: 70.96%  
 
7-(3-((3-hydroxybenzyl)(methyl)amino)propoxy)-4-methyl-2H-chromen-2-one (40)  
A mixture composed by 1.53g (4.461 mmol) of 28, 0,61g (4.461 mmol) of 3-
((methylamino)methyl)phenol (0,004 moli) and 0,404g (4.461 mmol) of TEA in 20 mL of toluene was 
refluxed for 48h. The organic phase was washed with water, then the organic layer was anhydrified 
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with anhydrous Na2SO4 and it was concentrated under reduced pressure. The crude was purified by 
flash chromatography: toluene/acetone 3:2. 0.44g of neat compound were obtained. Yield: 28.02% 
M. P.: 133-135° C; 1H NMR δ 7.58 (d, J = 8.2 Hz, 1H), 7.15 (t, J = 15.6 Hz , 1H), 6.95 - 6.79 (m, 5H), 
6,15 (s, 1H),.4.19 (t, J = 11.2 Hz, 2H), 3.50 (s, 2H), 2.63 – 2.58 (m, 2H), 2.45 (s, 3H), 2.25 (s, 3H), 
2.15 – 1.89 (m, 2H) 
 
3-(3-((3-hydroxybenzyl)(methyl)amino)propoxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-
one (41)  
Compound 41 was obtained following the same procedure described for compound 40 using 
compound 29 as starting material. Yield: 41.17%; purple oil; 1H NMR δ 7.44 (d, J = 8.8 Hz, 1H), 7.14 
(t, J = 15.6 Hz, 1H), 6.91 – 6.79 (m, 4H), 6.75 (dd, J = 10.4 Hz, 1H), 4.07 (t, J = 12.4 Hz, 2H), 3.45 
(s, 2H), 2.57 (t, J = 11.6 Hz, 2H), 2.57 – 2.52 (m, 4H), 2.23 (s, 3H), 2.00 (m, 2H), 1.86- 1.78 (m, 4H) 
 
7-(3-((3-hydroxybenzyl)(methyl)amino)propoxy)-3-phenyl-2H-chromen-2-one (42)  
Compound 42 was obtained following the same procedure described for compound 40 using 
compound 30 as starting material. Yield: 85.10%; oil;  1H NMR δ 7.77 (s, 1H), 7.71 (d, J = 8.8 Hz, 
2H), 7.48-7.38 (m, 4H), 7.15 (t, J = 15.6 Hz, 1H), 6.92 (d, J = 8 Hz, 2H), 6.85 (d, J = 10.4 Hz, 2H), 
6.74 (d, J = 10.4 Hz, 1H), 4.11 (t, J = 12.8 Hz, 2H), 3.47 (s, 2H), 2.55 (t, J = 13.6 Hz, 2H), 2.24 (s, 
3H), 2.01 (t, J = 13.2 Hz, 2H) 
 
7-(3-((3-hydroxybenzyl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-2H-chromen-2-one 
(43)  
Compound 43 was obtained following the same procedure described for compound 40 using 
compound 31 as starting material. Yield: 39.21%; oil; 1H NMR δ 7.82 -7.78 (m, 3H),. 7.42 (d, J = 9.2 
Hz, 1H), 7.15 (m, 2H), 7.02 (d, , J = 8 Hz, 2H), 6.95 - 6.76 (m, 5H), 4.11 (t, J = 12.8 Hz, 2H), 3.89 
(s, 3H), 3.47 (s, 2H), 2.55 (t, J = 13.6 Hz, 2H), 2.24 (s, 3H), 2.01 (t, J = 13.2 Hz, 2H) 
 
6-(3-((3-hydroxybenzyl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-2H-chromen-2-one 
(44)  
Compound 44 was obtained following the same procedure described for compound 40 using 
compound 32 as starting material. Yield: 37.07%; oil; 1H NMR δ 7.75 (s, 1H), 7.43 - 7.05 (m, 5H), 
6.98 - 6.65 (m, 6H), 4.14 (t, J = 12.8 Hz, 2H), 3.87 (s, 3H), 3.46 (s, 2H), 2.57 (t, J = 13.6 Hz, 2H), 
2.22 (s, 3H), 2.07 (t, J = 13.2 Hz, 2H) 
 
3-(4-chlorophenyl)-7-(3-((3-hydroxybenzyl)(methyl)amino)propoxy)-2H-chromen-2-one (45)  
Compound 45 was obtained following the same procedure described for compound 40 using 
compound 33 as starting material. Yield: 38.09% M.P.: 144-145° C; 1H NMR δ 7.79 (s,1H), 7.66 (d, 
J = 8.4 Hz, 2H), 7.44-7.41 (m, 3H), 7.15 (d, J = 15.6 Hz, 1H),  6.94 (d, J = 14.4 Hz, 2H), 6.85-6.83 
(m, 2H), 4.13 (t, J = 12.8 Hz, 2H), 3.47 (s, 2H), 2.56 (d, J = 12.8 Hz, 2H), 2.24 (s, 3H), 2.04-2.00 (m, 
2H) 
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7-(3-((3-hydroxybenzyl)(methyl)amino)propoxy)-2H-chromen-2-one (46)  
Compound 46 was obtained following the same procedure described for compound 40 using 
compound 34 as starting material. Yield: 31.05%; brown oil; 1H NMR δ 7.65 (d, J = 9.6 Hz, 1H), 7.36 
(d, J = 8.4 Hz, 1H), 7.26 (s, 1H), 7.13 (t, J = 15.6, 2.4 Hz, 1H), 6.86-6.79 (m, 3H), 6.74 (dd, J = 7.6 
Hz, 1H), 6.26 (d, J = 9.6 Hz, 1H), 4.07 (t, J = 12.8 Hz, 2H), 3.46 (s, 2H), 2.55 (t, J = 13.6 Hz, 2H), 
2.23 (p, J = 6.0 Hz, 2H), 2.24 (s, 3H), 2.01-1.98 (m, 2H) 
 
88-(3-((3-hydroxybenzyl)(methyl)amino)propoxy)-5H-chromeno[2,3-b]pyridin-5-one (47)  
Compound 47 was obtained following the same procedure described for compound 40 using 
compound 35 as starting material. Yield: 73.62%; oil; 1H NMR δ 8.65 (d, J = 12 Hz, 2H), 8.13 (d, J 
= 8.8 Hz, 1H), 7.38 (dd, J = 12.4 Hz, 1H), 7.17 -7.07 (m, 3H), 6.88 (dd, J = 10.8 Hz, 1H), 6.75 (d, J 
= 7.2 Hz, 1H), 6.71 (d, J = 8 Hz, 1H), 4.16 (t, J = 12.4 Hz, 2H), 3.41 (s, 2H), 2.52 (t, J = 13.2 Hz, 
2H), 2.18 (s, 3H), 1.99 – 1.96 (m, 2H) 
 
77-((5-((3-hydroxybenzyl)(methyl)amino)pentyl)oxy)-2H-chromen-2-one (48)  
Compound 48 was obtained following the same procedure described for compound40 using 
compound 36 as starting material. Yield: 17.99%; oil; 1H NMR δ 7.60 (d, J = 9.5 Hz, 1H), 7.33 (d, J 
= 8.6 Hz, 1H), 7.25 - 7.11 (m, 1H), 6.68-6.79 (m, 5H) 6.20 (d, J = 9.5 Hz, 1H), 4.13 (t, J = 5.8 Hz, 
2H), 3.44 (s, 2H), 3.71 (t, J = 6.3 Hz, 2H), 2.24 (s, 3H), 1.98-1.89 (m, 4H), 1.69-1.68 (m, 2H) 
 
3-((5-((3-hydroxybenzyl)(methyl)amino)pentyl)oxy)-7,8,9,10-tetrahydro-6H-
benzo[c]chromen-6-one (49)  
Compound 49 was obtained following the same procedure described for compound 40 using 
compound 37 as starting material. Yield: 36.80%; yellow oil; 1H NMR δ 7.42 (d, J = 8.8 Hz, 1H), 7.14 
(t, J = 8.0 Hz, 1H), 6.85 – 6.78 (m, 3H), 6.73 (dd, J = 10.2, 2.0 Hz, 2H), 3.96 (t, J = 6.5 Hz, 2H), 3.45 
(s, 2H), 2.74 (t, J = 5.8 Hz, 2H), 2.55 (t, J = 5.7 Hz, 2H), 2.47 – 2.38 (m, 2H), 2.21 (s, 3H), 1.88 – 
1.73 (m, 6H), 1.58 (dd, J = 14.8, 7.6 Hz, 2H), 1.48 (dd, J = 14.9, 7.9 Hz, 2H) 
 
8-((5-((3-hydroxybenzyl)amino)pentyl)oxy)-5H-chromeno[2,3-b]pyridin-5-one (50)  
Compound 50 was obtained following the same procedure described for compound 40 using 38 as 
starting material. Yield: 64.27%; yellow oil; 1H NMR δ 8.72 (d, J = 6.4 Hz, 2H), 8.21 (d, J = 8.8 Hz, 
1H), 7.45 (dd, J = 5.2 Hz, 1H), 7.26 (s, 1H), 7.16 (t, J = 15.6 Hz, 1H), 6.97-6.93 (m, 2H), 6.88 (s, 
1H), 6.84 (d, J = 7.2 Hz, 1H), 6.78 (d, J = 9.6 Hz, 1H), 4.06 (t, J = 12.8 Hz, 2H), 3.49 (s, 2H), 2.45 
(d, J = 14 Hz, 2H), 2.25 (s, 3H), 1.87-1.79 (m, 2H), 1.66 (m, 2H), 1.55-1.48 (m, 2H) 
 
3-(3-((3-hydroxybenzyl)amino)propoxy)-6H-benzo[c]chromen-6-one (51)  
Compound 51 was obtained following the same procedure described for compound 40 using 39 as 
starting material. Yield: 48.67%; yellow pale oil; 1H NMR δ 8.35 (d, J = 8.8 Hz, 1H), 8.11 - 7.95 (m, 
2H), 7.83 (t, J = 8.2 Hz, 1H), 7.55 (t, J = 6.4 Hz, 1H),7.22 -7.09 (m, 3H), 6.95 - 6.72 (m, 3H), 4.09 (t, 
J = 11.2 Hz, 2H), 3.45 (s,2H), 2.5 (m, 2H), 2.15 (s, 3H), 2.05 - 1.89 (m, 2H), 
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3-((methyl(3-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)propyl)amino)methyl)phenyl (5-
phenylpentyl)carbamate (1)  
A mixture of 0.12g (0.34 mmol) of 40 and a catalytic amount of NaH in anhydrous toluene (20 mL) 
was stirred for 10 minutes. 0.06g (0.339 mmol) of 53a were added to the mixture and the reaction 
was stirred at r.t. for 48h; then it was quenched with water and extracted with DCM. Compound 1 
was purified via flash chromatography: toluene/acetone 4:1. Yield: 43.32%; M.P.: 82° C; 1H NMR δ 
7.45 - 7.05 (d, J = 9.2 Hz 1H), 7.38 (m, 8H), 6.95 (d, J = 8 Hz,1H), 6.70-6.9 (m, 2H), 6.12 (s, 1H), 
5.35 (broad, 1H), 4.05 (t, J = 13.2 Hz, 2H), 3.50 (s, 2H), 3.20-3.38 (m, 2H), 2.45-2.70 (m, 4H), 2.38 
(s, 3H), 2.25 (s, 3H), 1.85-2.05 (m, 2H), 1.52-1.73 (m, 4H), 1.3-1.5 (m, 2H); 13C NMR δ 162.26, 
161.49, 155.29, 152.72, 151.22, 142.43, 141.52, 137.98, 128.89, 128.36, 128.25, 128.66, 126.33, 
125.35, 121.96, 120.33, 113.32, 112.98, 111.67, 101.22, 66.89, 62.12, 53.03, 42.44, 40.52, 35.77, 
31.04, 29.69, 23.91, 26.35, 18.65; ES-MS m/z: 543 (M + H+), 565 (M + Na)  
 
3-((methyl(3-((6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl)oxy)propyl)amino)methyl) 
phenyl (5-phenylpentyl)carbamate (2)  
Compound 2 was obtained following the same procedure described for compound 1 using 41 and 
53a as starting materials. Yield: 67.56% M.P.: 82° C; 1H NMR δ 7.43 (d, J = 8.8 Hz, 1H), 7.28-7.22 
(m, 3H), 7.18-7.13 (m, 4H), 7.10 (d, J = 7.2 Hz, 1H), 6.99 (d, J = 8Hz, 2H), 6.81-6.79 (m, 2H), 5.30 
(broad, 1H), 4.3 (t, J = 12.8 Hz, 2H), 3.5 (s, 2H), 3.28 (dd, J = 6.8 Hz, 2H), 2.76-2.73 (m, 2H), 2.63-
2.50 (m, 6H), 2.25 (s, 3H), 1.96 (t, J = 13.2 Hz, 2H), 1.85-1.79 (m, 4H), 1.68-1.61 (m, 4H), 1.43-1.38 
(m, 2H); 13C NMR δ 162.26, 161.49, 155.29, 152.72, 151.22, 142.43, 141.52, 137.98, 128.89, 
128.36, 128.25, 128.66, 126.33, 125.35, 121.96, 120.33, 119.59, 113.32, 112.98, 101.22, 67.17, 
63.93, 55.78, 43.22, 41.65, 36.78, 29.87, 29.51, 27.26, 27.23, 26.54, 24.65, 24.40, 24.27; ES-MS 
m/z: 583 (M + H+), 605 (M + Na) 
 
3-((methyl(3-((6-oxo-6H-benzo[c]chromen-3-yl)oxy)propyl)amino)methyl)phenyl (5-
phenylpentyl)carbamate (3)  
Compound 3 was obtained following the same procedure described for compound 1 using 51 and 
53a as starting materials. Yield: 27.03%; M.P.: 79° C; 1H NMR δ 8.37 (d, J = 8 Hz, 1H), 8.02 (d, J = 
8.4 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.78 (t, J = 15.2 Hz, 1H), 7.50 (t, J = 15.2 Hz, 1H), 7.28-7.23 
(m, 4H), 7.18-7.15 (m, 3H), 7.11 (d, J = 7.6 Hz, 1H), 6.99 (d, J = 7.6 Hz, 1H), 6.89 (d, J = 8.8 Hz, 
2H), 5.21 (broad, 1H), 4.07 (t, J = 12.8 Hz, 2H), 3.51 (s, 2H), 3.26-3.24 (m, 2H), 2.61 (t, J = 15.2 Hz, 
2H), 2.53 (t, J = 13.2 Hz, 1H), 2.27 (s, 3H), 1.67-1.58 (m, 4H), 1.41-1.37 (m, 2H); 13C NMR δ 163.49, 
158.20, 152.56, 151.20, 142.43, 136.54, 135.31, 134.86, 130.51, 128.91, 128.36, 128.25, 127.62, 
126.33, 125.67, 124.38, 123.63, 121.95, 121.05, 120.30, 119.88, 113.11, 110.87, 102.06, 66.72, 
62.11, 53.13, 41.18, 40.50, 35.78, 31.06, 30.08, 29.67, 26.44; ES-MS m/z: 579 (M + H+), 601 (M + 
Na) 
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3-((methyl(3-((2-oxo-3-phenyl-2H-chromen-7-yl)oxy)propyl)amino)methyl)phenyl (5-
phenylpentyl) carbamate (4)  
Compound 4 was obtained following the same procedure described for compound 1 using 42 and 
53a as starting materials. Yield: 27.52%; oil; 1H NMR δ 7.76 (s, 1H), 7.69 (d, J = 7.1 Hz, 2H), 7.47 
– 7.35 (m, 4H), 7.30 – 7.22 (m, 3H), 7.17 (t, J = 7.4 Hz, 4H), 7.09 (d, J = 7.3 Hz, 1H), 6.99 (d, J = 
7.4 Hz, 1H), 6.83 (m, 2H), 5.24 (broad, 1H), 4.06 (t, J = 6.5 Hz, 2H), 3.51 (s, 2H), 3.26 (dd, J = 13.4, 
6.7 Hz, 2H), 2.66 – 2.58 (m, 2H), 2.52 (t, J = 6.5 Hz, 2H), 2.27 (s, 3H), 2.03 – 1.93 (m, 2H), 1.70 – 
1.57 (m, 4H), 1.45 – 1.38 (m, 2H); 13C NMR δ 161.80, 160.94, 155.20, 154.50, 151.29, 142.37, 
140.07, 134.96, 129.39, 128.81, 128.43, 128.41, 128.35, 128.25, 126.40, 125.66, 124.71, 122.78, 
121.36, 119.87, 114.22, 113.34, 113.02, 101.04, 66.35, 54.84, 53.76, 52.85, 41.20, 35.75, 31.02, 
29.24, 26.33, 14.10; ES-MS m/z: 605 (M + H+), 627 (M + Na) 
 
3-(((3-((3-(4-methoxyphenyl)-2-oxo-2H-chromen-7-yl)oxy)propyl)(methyl) amino)methyl) 
phenyl (5-phenylpentyl)carbamate (5)  
Compound 5 was obtained following the same procedure described for compound 1 using 43 and 
53a as starting materials. Yield: 42.85 %; M.P.: 123-124° C; 1H NMR δ 7.71 (s, 1H), 7.66 (d, J = 8.7 
Hz, 2H), 7.39 (d, J = 8.6 Hz, 1H), 7.27 (s, 3H), 7.18 (t, J = 7.2 Hz, 5H), 6.99 (t, J = 9.1 Hz, 3H), 6.87 
– 6.80 (m, 2H), 5.26 (broad, 1H), 4.08 (t, J = 6.5 Hz, 2H), 3.86 (s, 3H), 3.52 (s, 2H), 3.34 – 3.19 (m, 
2H), 2.67 – 2.58 (m, 2H), 2.58 – 2.49 (m, 2H), 2.28 (s, 3H), 2.08 – 1.95 (m, 2H), 1.63 (m, 4H), 1.46 
– 1.39 (m, 3H); 13C NMR δ 161.94, 161.25, 159.79, 155.06, 154.71, 151.21, 142.43, 140.87, 138.89, 
136.38, 129.60, 128.90, 128.46, 128.35, 128.25, 127.43, 125.61, 124.12, 121.96, 120.30, 113.86, 
113.38, 113.25, 100.77, 66.89, 62.13, 55.33, 53.06, 42.44, 41.18, 40.54, 35.77, 31.03, 26.93, 26.42; 
ES-MS m/z: 635 (M + H+), 657 (M + Na) 
 
3-(((3-((3-(4-methoxyphenyl)-2-oxo-2H-chromen-6-yl)oxy)propyl)(methyl) amino) methyl) 
phenyl (5-phenylpentyl) carbamate (6)  
Compound 6 was obtained following the same procedure described for compound 1 using 44 and 
53a as starting materials. Yield: 29.58 %; M.P.: 83.2-84 ° C; 1H NMR δ 7.77 (s, 1H), 7.44 – 7.33 (m, 
2H), 7.29 – 7.24 (m, 6H), 7.21 – 7.13 (m, J = 7.3 Hz, 4H), 7.13 – 7.09 (m, 1H), 7.00 (d, J = 7.4 Hz, 
1H), 6.94 (d, J = 7.8 Hz, 1H), 6.84 (d, J = 8.7 Hz, 2H), 5.25 (s, 1H), 4.07 (t, J = 6.7 Hz, 2H), 3.86 (s, 
3H), 3.52 (s, 2H), 3.27 (dd, J = 6.0 Hz, 2H), 2.68 – 2.58 (m, 2H), 2.58 – 2.47 (m, 2H), 2.28 (s, 3H), 
2.04 – 1.91 (m, 2H), 1.72 – 1.59 (m, 4H), 1.47 – 1.33 (m, 3H).; 13C NMR δ 162.28, 160.91, 159.33, 
155.33, 154.70, 151.21, 142.42, 140.87, 140.27, 136.39 ,129.40, 128.91, 128.72, 128.36, 128.25, 
125.65, 124.29, 121.95, 120.76, 120.30, 114.07, 113.47, 113.04, 100.78, 66.93, 62.14, 55.32, 53.05, 
42.45, 41.19, 35.77, 31.03, 29.69, 26.93, 26.35; ES-MS m/z: 635 (M + H+) 
 
3-(((3-((3-(4-chlorophenyl)-2-oxo-2H-chromen-7-yl)oxy)propyl)(methyl)amino)methyl)phenyl 
(5-phenylpentyl)carbamate (7)  
Compound 7 was obtained following the same procedure described for compound 1 using 45 and 
53a as starting materials. Yield: 23.47 %; M.P.: 76-77° C; 1H NMR δ 7.75 (s, 1H), 7.66 (d, J = 8 Hz, 
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2H), 7.49 (d, J = 8.2 Hz,  2H), 7.14-7.16 (m, 4H), 7.22-7.24 (m, 3H), 7.10 (d, J = 7.7 Hz,  2H), 6.99 
(d, J = 7.7 Hz,  2H), 6.85 (d, J = 8 Hz,  2H), 5.22 (broad, 1H), 4.06 (t, 2H), 3.27 (s, 2H), 3.27 (dd, J 
= 6.8 Hz, 2H), 2.61 (t, J = 15.2 Hz, 2H), 2.52 (t, J = 13.2 Hz, 2H), 2.27 (s, 3H), 1.98 (t, J = 13.6 Hz, 
2H) 1.62-1.55 (m, 4H), 1.49-1.38 (m, 2H); 13C NMR δ 162.46, 160.80, 155.39, 154.68, 151.20, 
142.39, 140.82, 140.20, 134.38, 133.45, 129.64, 128.91, 128.76, 128.60, 128.35, 128.25, 125.67, 
125.61, 123.24, 121.95, 120.29, 113.62, 112.92, 100.82, 66.95, 62.12, 53.04, 42.44, 41.17, 35.76, 
31.02, 29.67, 26.91, 26.33; ES-MS m/z: 639 (M + H+), 661 (M + Na) 
 
3-((methyl(3-((2-oxo-2H-chromen-7-yl)oxy)propyl)amino)methyl)phenyl heptylcarbamate (8) 
Compound 8 was obtained following the same procedure described for compound 1 using 46 and 
53b as starting materials. Yield: 80 %; M.P.: 84-85° C; 1H NMR δ 7.61 (d, J = 9.4 Hz, 1H), 7.31 (d, 
J = 9.0 Hz, 1H), 7.22 (dd, J = 13.9, 6.2 Hz, 1H), 7.10 (s, 1H), 7.06 (d, J = 7.4 Hz, 1H), 6.96 (d, J = 
7.8 Hz, 1H), 6.77 (d, J = 4.8 Hz, 2H), 6.21 (d, J = 9.4 Hz, 1H), 5.32 (broad, 1H), 4.01 (t, J = 6.3 Hz, 
2H), 3.47 (s, 2H), 3.22 (dd, J = 13.2, 6.6 Hz, 2H), 2.49 (t, J = 6.5 Hz, 2H), 2.23 (s, 3H), 2.01 – 1.90 
(m, 2H), 1.60 – 1.48 (m, 2H), 1.37 – 1.17 (m, 8H), 0.84 (t, J = 5.8 Hz, 3H); 13C NMR δ 162.39, 
161.42, 155.85, 154.72, 151.18, 143.58, 140.59, 128.90, 128.61, 125.62, 122.02, 120.32, 113.20, 
112.72, 112.29, 101.21, 66.84, 62.05, 53.05, 42.36, 41.27, 31.71, 29.79, 28.91, 26.83, 26.76, 22.56, 
14.05; ES-MS m/z: 481 (M + H+), 503 (M + Na) 
 
3-((methyl(3 -((6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl)oxy)propyl) amino) 
methyl)phenyl heptylcarbamate (9)  
Compound 9 was obtained following the same procedure described for compound 1 using 41 and 
53b as starting materials. Yield: 61.42 %; M.P.: 86-87° C ; 1H NMR δ 7.43 (d, J = 9.2 Hz, 1H), 7.24 
(t, J = 17.6 Hz, 1H), 7.13 (s, 1H), 7.09 (d, J = 7.2 Hz, 1H), 6.99 (d, J = 8 Hz, 1H), 6.81 (d, J = 6.4 Hz, 
2H), 5.29 (broad, 1H), 4.03 (t, J = 12.8 Hz, 2H), 3.49 (s, 2H), 3.28-3.23 (dd, J = 20.4 Hz, 1H), 2.75 
(m, 2H), 2.57-2.49 (m, 4H), 2.25 (s, 3H), 1.99-1.95 (m, 2H), 1.85-1.79 (m, 4H), 1.56 (t, 2H), 1.31-
1.28(m, 8H), 0.88 (t, J = 13.2 Hz, 3H); 13C NMR δ 162.27, 160.99, 154.72, 153.51, 151.23, 147.37, 
140.83, 128.87, 125.54, 123.94, 121.94, 120.26, 119.88, 113.52, 112.57, 101.05, 66.71, 62.10, 
53.19, 42.38, 41.27, 31.72, 29.81, 28.91, 26.97, 26.69, 25.20, 23.81, 22.55, 21.69, 21.39, 14.03; 
ES-MS m/z: 535 (M + H+), 557 (M + Na) 
 
3-((methyl(3-((5-oxo-5H-chromeno[2,3-b]pyridin-8-yl)oxy)propyl)amino)methyl)phenyl 
heptylcarbamate (10) 
Compound 10 was obtained following the same procedure described for compound 1 using 47 and 
53b as starting materials. Yield: 74.07 %; M.P.: 68° C; 1H NMR δ 8.76 – 8.67 (m, 2H), 8.22 (d, J = 
8.9 Hz, 1H), 7.45 (dd, J = 7.4, 4.9 Hz, 1H), 7.33 – 7.21 (m, 1H), 7.16 – 7.05 (m, 2H), 7.05 – 6.87 (m, 
3H), 5.34 (broad, 1H), 4.14 (t, J = 6.5 Hz, 2H), 3.52 (s, 2H), 3.26 (dd, J = 13.5, 6.8 Hz, 2H), 2.54 (t, 
J = 6.5 Hz, 2H), 2.29 (s, 3H), 2.10 – 1.91 (m, 2H), 1.58 – 1.49 (m, 2H), 1.39 – 1.24 (m, 8H), 0.88 (t, 
J = 6.8 Hz, 3H); 13C NMR δ 176.86, 165.69, 160.93, 157.87, 153.68, 151.56, 142.41, 137.59, 129.25, 
128.41, 125.96, 122.35, 121.33, 120.64, 119.88, 117.33, 115.51, 114.86, 101.56, 67.43, 62.53, 
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53.27, 42.82, 41.64, 41.02, 32.07, 30.19, 29.30, 27.14, 22.91, 14.39; ES-MS m/z: 532 (M + H+), 554 
(M + Na) 
 
3-((methyl(3-((2-oxo-2H-chromen-7-yl) oxy)propyl) amino)methyl)phenyl (4-hexylphenyl) 
carbamate (11)  
Compound 11 was obtained following the same procedure described for compound 1 using 46 and 
53c as starting materials. Yield: 42.86 %; M.P.: 93-94° C; 1H NMR δ 7.61 (d, J = 9.6 Hz, 1H), 7.39 
(d, J = 8 Hz, 2H), 7.32 (d, J = 10.8 Hz, 1H), 7.26 (d, J = 8 Hz, 1H), 7.20 (s, 2H), 7.14-7.11 (m, 2H), 
7.04 (dd, J = 8 Hz, 1H), 6.81 (d, J = 10 Hz, 1H), 6.24 (d, J = 9.2 Hz, 1H), 4.06 (t, J = 12.8 Hz, 2H), 
3.51 (s, 2H), 2.58-2.51 (m, 4H), 2.26 (s, 3H), 1.98-1.95 (m, 2H), 1.60-1.57 (m, 2H), 1.33-1.29 (m, 
6H), 0.88 (t, J = 13.6 Hz, 3H); 13C NMR δ 162.46, 161.51, 155.89, 150.80, 143.54, 142.41, 141.09, 
138.16, 135.12, 128.99, 128.92, 128.60, 125.96, 121.98, 120.30, 118.88, 118.68, 113.25, 112.75, 
112.30, 101.28, 66.79, 62.11, 53.02, 42.44, 35.27, 31.69, 31.46, 28.88, 26.91, 22.58, 14.06; ES-MS 
m/z: 543 (M + H+), 565 (M + Na) 
 
3-((methyl(3-((2-oxo-2H-chromen-7-yl) oxy)propyl)amino) methyl)phenyl (6-phenylhexyl) 
carbamate (12) 
Compound 12 was obtained following the same procedure described for compound 1 using 46 and 
52 as starting materials. Yield: 34.84 %; oil; 1H NMR δ 7.63 (d, J = 9.2 Hz, 1H), 7.34 (d, J = 8.8 Hz, 
1H), 7.29-7.24 (m, 3H), 7.17-7.13 (m, 4H), 7.09 (d, J = 8 Hz, 1H), 6.97 (d, J = 8 Hz, 1H), 6.81 (d, J 
= 7.6 Hz, 2H), 6.25 (d, J = 9.6 Hz, 1H), 5.23 (broad, 1H), 4.04 (t, J = 13.2 Hz, 2H), 3.49 (s, 2H), 3.27-
3.23 (m, 4H), 2.60 (t, J = 15.6 Hz, 2H), 2.51 (t, J = 13.2 Hz, 2H), 2.26 (s, 3H), 1.98 (dd, J = 13.2 Hz, 
2H), 1.64-1.38 (m, 4H), 1.38-1.34 (m, 6H), 1.13 (t, J = 14.4 Hz, 2H); 13C NMR δ 162.43, 155.91, 
151.21, 143.54, 142.62, 128.91, 128.60, 128.35, 128.22, 128.20, 125.64, 125.60, 125.57, 122.01, 
120.33, 119.81, 113.24, 112.76, 112.30, 101.23, 66.88, 62.07, 53.02, 42.39, 41.22, 35.83, 31.37, 
29.75, 28.88, 26.84, 13.85; ES-MS m/z: 543 (M + H+), 565 (M + Na) 
 
3-((methyl(5-((2-oxo-2H-chromen-7-yl) oxy)pentyl) amino)methyl)phenyl (5-phenylpentyl) 
carbamate (13) 
Compound 13 was obtained following the same procedure described for compound 1 using 48 and 
53a as starting materials. Yield: 35.02 %; oil; 1H NMR δ 7.63 (d, J = 9.2 Hz, 1H), 7.36 (d, J = 8.8 Hz, 
1H), 7.28-7.24 (m, 3H), 7.19-7.10 (m, 5H), 7.01 (d, J = 7.6 Hz, 1H), 6.84-6.80 (m, 2H), 6.25 (d, J = 
9.6 Hz, 1H), 5.01 (broad, 1H), 3.99 (t, J = 12.8 Hz, 2H), 3.47 (s, 2H), 3.27 (dd, J = 20.4 Hz, 2H), 2.62 
(t, J = 15.2 Hz, 2H), 2.41 (t, J = 14 Hz, 2H), 2.19 (s, 3H), 1.81 (t, J = 14.4 Hz, 2H), 1.68-1.47 (m, 
8H), 1.41-1.38(m, 2H); 13C NMR δ 162.38, 161.27, 155.88, 154.62, 151.08, 143.44, 142.35, 140.80, 
128.90, 128.66, 128.35, 128.26, 125.68, 122.01, 120.10, 119.81, 112.94, 112.85, 112.34, 101.33, 
68.51, 61.95, 57.14, 42.27, 41.15, 35.75, 31.01, 29.68, 28.79, 27.02, 26.32, 23.70 
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3-((methyl(5-((2-oxo-2H-chromen-7-yl)oxy)pentyl)amino)methyl)phenyl heptylcarbamate (14) 
Compound 14 was obtained following the same procedure described for compound 1 using 48 and 
53b as starting materials. Yield: 50.60%; oil; 1H NMR δ 7.64 (d, J = 9.2 Hz, 1H), 7.36 (d, J = 8 Hz, 
1H), 7.27 (t, J = 15.6 Hz, 1H), 7.14-7.10 (m, 2H), 7.01 (d, J = 7.6 Hz, 1H), 6.83-6.79 (m, 2H), 5.17 
(broad, 1H), 3.99 (t, J = 12.8 Hz, 2H), 3.47 (s, 2H), 3.26-3.21 (dd, J = 7.0 Hz, 2H), 2.39 (t, J= 13.6 
Hz, 2H), 2.19 (s, 3H), 1.84-1.77 (m, 2H), 1.57-1.46 (m, 6H), 1.32-1.28 (m, 8H), 0.88 (t, J= 13.2 Hz, 
3H); 13C NMR δ 162.38, 161.31, 155.86, 154.66, 151.09, 143.50, 128.89, 128.69, 125.66, 122.02, 
120.11, 119.83, 112.93, 112.83, 112.33, 101.30, 68.51, 61.96, 57.15, 42.28, 41.25, 31.71, 29.81, 
28.91, 28.80, 27.04, 26.69, 23.70, 22.56, 14.06; ES-MS m/z: 509 (M + H+), 531 (M + Na), 547 (M + 
K) 
 
3-((methyl(5-((5-oxo-5H-chromeno[2,3-b]pyridin-8-yl)oxy)pentyl)amino)methyl)phenyl 
heptylcarbamate (15)  
Compound 15 was obtained following the same procedure described for compound 1 using 49 and 
53b as starting materials. Yield: 74.91%; M.P.: 73° C; 1H NMR δ 7.43 (d, J = 8.7 Hz, 1H), 7.31 – 
7.27 (m, 1H), 7.16 – 7.08 (m, 2H), 7.00 (d, J = 7.3 Hz, 1H), 6.85 – 6.76 (m, 2H), 5.05 (broad, 1H), 
3.98 (t, J = 6.4 Hz, 2H), 3.48 (s, 2H), 3.24 (dd, J = 13.2, 6.6 Hz, 2H), 2.74 (t, J = 5.6 Hz, 2H), 2.56 
(t, J = 5.6 Hz, 2H), 2.39 (t, J = 6.9 Hz, 2H), 2.18 (s, 3H), 1.92 – 1.71 (m, 6H), 1.61 – 1.42 (m, 6H), 
1.37 – 1.24 (m, 8H), 0.88 (t, J = 6.4 Hz, 3H); 13C NMR δ 162.12, 160.87, 153.41, 151.00, 147.20, 
140.84, 128.80, 125.57, 123.92, 121.89, 120.26, 119.97, 119.81, 113.48, 112.23, 101.04, 68.27, 
61.89, 57.11, 42.21, 41.17, 31.63, 29.73, 28.82, 27.00, 26.61, 25.12, 23.73, 23.65, 22.48, 21.62, 
21.31, 17.79, 13.96; ES-MS m/z: 563 (M + H+), 585 (M + Na) 
 
3-(((5-((5-oxo-5H-chromeno[2,3-b]pyridin-8-yl)oxy)pentyl)amino)methyl)phenyl 
heptylcarbamate (16)  
Compound 16 was obtained following the same procedure described for compound 1 using 50 and 
53b as starting materials. Yield: 56.23%; oil; 1H NMR δ 8.71 (d, J = 6.8 Hz, 2H), 8.23 (d, J = 8.8 Hz, 
1H), 7.44-7.41 (dd, J = 5.2 Hz, 1H), 7.28 (m, 1H), 7.14-7.11 (m, 2H), 7.01-6.96 (m, 3H), 5.03 (broad, 
1H), 4.09 (t, J= 13.2 Hz, 2H), 3.48 (s, 2H), 3.27-3.22 (dd, J = 6.8 Hz, 2H), 2.40 (t, J= 13.6 Hz, 2H), 
2.20 (s, 3H), 1.88-1.82 (m, 2H), 1.57-1.53 (m, 6H), 1.31-1.28 (m, 8H), 0.88 (t, J= 13.2 Hz, 3H); 13C 
NMR δ 176.49, 165.30, 160.49, 157.72, 154.59, 153.42 ,151.12, 137.18, 128.93, 128.16, 125.73, 
122.06, 120.95, 120.17, 119.81, 116.94, 115.20, 114.28, 101.26, 68.76, 61.91, 57.05, 42.21, 41.26, 
31.69, 29.81, 28.88, 28.73, 26.94, 26.68, 23.69, 22.53, 14.01; ES-MS m/z: 560 (M + H+), 582 (M + 
Na) 
 
(6-chlorohexyl)benzene (54)  
To a cold solution of 1.00g (5.62 mmol, d=0.953) of 6-phenyl-1-hexanol and 0.57g (5.62 mmol, 
d=0.726) of TEA in 30 mL of DCM, 0.67g (5.62 mmol, d=1.631) of SOCl2 were added. The solution 
was stirred at 0° C for 1h, then it was stirred at r.t. for 48h. The solvent was removed under reduced 
pressure, then the solution was alkalinized with Na2CO3 and 54 was extracted with DCM. 0.90g of 
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neat compound were obtained. Yield: 81.81%; oil; 1H NMR δ 7.25 – 7.21 (m, 2H), 7.14 – 7.12 (m, 
3H), 3.44 (t, J = 13.2 Hz, 2H), 2.59 (t, J = 15.2 Hz, 2H), 1.72 - 1.68 (m, 2H), 1.61 – 1.57 (m, 2H), 
1.43 – 1.39 (m, 2H), 1.34 – 1.28 (m, 2H) 
 
2-(6-phenylhexyl)isoindoline-1,3-dione (55)  
0.91g (4.65 mmol, 1.1eq) of 54 were dissolved in 2.5 mL of DMF and 0.78g (4.23 mmol) of K-
phthalimide were added to the solution. The reaction was refluxed for 2h; then it was poured in water 
and the suspension was filtered. 1.15g of neat compound were obtained. Yield: 88.60% M.P.: 40-
41° C; 1H NMR δ 7.85 – 7.83 (m, 1H), 7.71 – 7.69 (m, 1H), 7.27 – 7.26 (m, 4H), 7.17 – 7.14 (m, 3H), 
3.67 (t, J = 14.8 Hz, 2H), 2.59 (t, J = 15.6 Hz, 2H), 1.67 – 1.59 (m, 4H), 1.38 – 1.36 (m, 4H) 
 
6-phenylhexan-1-amine (56)  
1.15g (3.75 mmol) of 55 were dissolved in ethanol, then 0.37g (11.61 mmol, d=1.029, 3.1eq) of 
hydrazine monohydrate were added. The reaction was refluxed for 5h, then it was allowed to cool. 
1.3 mL of HCl 37% were added to the mixture and the solution was refluxed for 30 minutes, then it 
was concentrated under reduced pressure. The mixture was washed with water and 56 was 
extracted with DCM. 0.69g of neat compound. Yield: 96.53%; oil; 1H NMR δ 7.27 – 7.25 (m, 2H), 
7.17 – 7.14 (m, 4H), 2.71 (t, J = 14 Hz, 2H), 2.58 (t, J = 15.2 Hz, 2H), 1.62 – 1.58 (m, 2H), 1.48 – 
1.43 (m, 2H), 1.37 – 1.33 (m, 4H) 
 
(6-isocyanatohexyl)benzene (52)  
0.57g (5.84 mmol, 1.5eq) of phosgene solution 20% in toluene were added dropwise to a solution 
of 0.69g (3.89 mmol, 1eq) of 56 and 2.83 mL of TEA in toluene at 0° C. The solution was stirred for 
2h at r.t.; 0.57g (5.84 mmol, 1.5eq) of phosgene solution 20% in toluene were added again and the 
solution was stirred for 90 minutes. The reaction was bubbled with N2, then it was washed with 
water. The solvent was removed. Compound 52 was used crude for next step of reaction. 
 
(5-isocyanatopentyl)benzene (53a)  
A mixture of 1g (5.21 mmol) of 6-phenylhexsanoic acid and 10 mL of SOCl2 was refluxed for 5h, 
then SOCl2 was removed. To an ice-cold mixture of 0.42g (7.28 mmol, 1.4eq) of NaN3 in 2 mL of 
water, a solution of 6-phenylhexanoyl chloride in 2 mL of acetone was added, keeping the 
temperature below 10° C. The mixture was stirred for 1h, then the layers were separated and the 
lower acqueous layer was discarded; the upper layer was slowly and dropwise added to 30 mL of 
benzene heated to 60° C and the mixture was kept at 60-70° C until gas production ceased; then it 
was filtered and the solvent was removed. Compound 54a was used crude, without any further 
purification, for next step of reaction; oil 
 
1-isocyanatoheptane (53b)  
Compound 53b was obtained following the same procedure described for compound 53a using 
octanoic acid as starting material; oil 
115 
 
1-hexyl-4-isocyanatobenzene (53c)  
Compound 53c was obtained following the same procedure described for compound 53a using 4-
hexylbenzoic acid as starting material; oil 
 
7-(prop-2-yn-1-yloxy)-2H-chromen-2-one (63)  
To a solution of 1.00g (6.17 mmol) of 7-hydroxycoumarin in 40 mL of acetone, 0.88g (7.40 mmol, 
1.2 eq, d=1.335) of propargyl bromide and 1.00g of anhydrous K2CO3 were added. The mixture was 
stirred and refluxed for 8h, then it was filtered hot and it was concentrated under reduced pressure. 
The crude was crystallized with petroleum ether. 1.22g of neat compound 63 were obtained. Yield: 
97%; M.P.: 120-121° C; 1H NMR δ 7.26 (d, J = 9.5 Hz, 1H), 7.01 (d, J = 8.5 Hz, 1H), 6.87 (s, 1H), 
6.56 (d, J = 2.3 Hz, 1H), 6.52 (dd, J = 8.5, 2.4 Hz, 1H), 5.89 (d, J = 9.5 Hz, 1H), 4.37 (d, J = 2.4 Hz, 
2H), 2.19 (t, J = 2.4 Hz, 1H). 
 
7-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one (65a)  
To a solution of 0.50g (2.497 mmol, 1 eq) of 63 in 15 mL of DMSO, 0.53g (3.247 mmol, 1.3eq) of 
64a and 0.02g (0.250 mmol, 1/10eq, d=0.726) of TEA were added. 0.04g (0.250 mmol, 1/10eq) of 
CuSO4 and 0.25g (1.249 mmol, ½eq) of sodium ascorbate were dissolved in water and were stirred 
for 5 min; the solution was added to the reaction flask and it was stirred at r.t. for 24h. A saturated 
solution of NH4Cl was added to the reaction and the organic compound was extracted with ethyl 
acetate. The mixture was purified via flash chromatography: toluene/acetone 4:1; 0.89g of neat 
compound 65a were obtained. Yield: 98%; M.P.: 134-136° C; 1H NMR (200 MHz, CDCl3,) δ 7.63 (d, 
J = 9.4 Hz, 1H), 7.54 (s, 1H), 7.37 (d, J = 8.4 Hz, 1H), 7.25 (d, J = 8.4 Hz, 2H), 6.91 (m, 4H), 6.26 
(d,  J = 9.4 Hz, 1H) , 5.48 (s, 2H), 5.22 (s, 2H), 3.81 (s, 3H) 
 
7-((1-(3-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one (65b)  
Compound 65b was obtained following the same procedure described for compound 65a using 63 
and 64b as starting materials. Yield: 94.81%; M.P.: 101-102° C; 1H NMR (400 MHz, CDCl3,) δ 7.59 
(m, 2H), 7.33 (d, J = 8.4 Hz, 1H), 7.25 (t, J= 15.6 Hz, 1H), 6.88-6.76 (m, 4H), 6.20 (d, J= 9.6 Hz, 
1H), 5.47 (s, 2H), 5.18 (s, 2H), 3.73 (s, 3H) 
 
7-((1-(4-hydroxybenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one (66a)  
0.89g (2.449 mmol) of 65a were dissolved in anhydrous DCM under nitrogen atmosphere in a two 
neck flask. The temperature was allowed to 0° C. 4.0 mL of BBr3 were added dropwise to the reaction 
that was stirred at r.t. for 48h. The reaction was quenched with water and it was washed with brine. 
The organic layer was concentrated under reduced pressure. The crude was purified via flash 
chromatography: toluene/acetone 4:1; 0.32g neat of compound 66a were obtained. Yield: 37%; 
yellow oil; 1H NMR (400 MHz, CDCl3,) δ 7.49 (d, J = 9.4 Hz, 1H), 7.54 (s, 1H), 7.37 (d, J = 8.4 Hz, 
1H), 7.18  (d, J = 8.4 Hz, 2H), 6.88 (m, 4H), 6.26 (d,  J = 9.4 Hz, 1H), 5.98 (s, 1H), 5.46 (s, 2H), 5.21 
(s, 2H) 
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7-((1-(3-hydroxybenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one (66b)  
Compound 66b was obtained following the same procedure described for compound 66a using 65b 
as starting material. Yield: 20.83%; M.P.: 65-66° C; 1H NMR (401 MHz, cdcl3) δ 7.61 (m, 2H), 7.34 
(d, J = 11.2 Hz, 1H), 7.24 (t, 1H), 6.85 (m, 4H), 6.24 (d, J = 9.4 Hz, 1H), 5.47 (s, 2H), 5.18 (s, 2H) 
 
4-((4-(((2-oxo-2H-chromen-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)phenyl (5-
phenylpentyl)carbamate (59)  
To a reaction flask with 0.13g (0.372 mmol)of 66a dissolved in anhydrous toluene a catalytic amount 
of NaH was added and the reaction was stirred for 10 min. 0.07g (0.372 mmol) compound 53a were 
added. The solution was stirred at r.t. for 60h, then it was poured in water and extracted with DCM. 
Compound 59 was purified via flash chromatography: toluene/acetone 4:1; then it was crystalized 
at cold conditions with methanol. 0.04g of neat compound 59 were obtained. Yield: 20%; M.P.: 
129.8-130.1° C; 1H NMR δ 7.61 (d, J = 9.5 Hz, 1H), 7.54 (s, 1H), 7.35 (d, J = 8.5 Hz, 1H), 7.26 (m, 
4H), 7.19 – 7.07 (m, 4H), 6.95 – 6.82 (m, 2H), 6.24 (d, J = 9.5 Hz, 1H), 5.50 (s, 2H), 5.20 (s, 2H), 
5.04 (br, J = 5.4 Hz, 1H), 3.23 (dd, J = 13.3, 6.8 Hz, 2H), 2.61 (t, J = 7.6 Hz, 2H), 1.72 – 1.49 (m, 
4H), 1.38 (m, 2H); 13C NMR δ 161.27, 161.06, 155.68, 154.16, 151.46, 143.29, 142.29, 131.05, 
129.23, 128.87, 128.35, 128.28, 125.72, 122.86, 122.37, 113.44, 112.97, 112.73, 102.10, 62.30, 
53.73, 41.20, 35.74, 30.99, 29.64, 26.28  
 
3-((4-(((2-oxo-2H-chromen-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)phenyl (5-
phenylpentyl)carbamate (60)  
Compound 60 was obtained following the same procedure described for compound 59 using 66b 
and 53a as starting materials. Yield: 21.73%; oil; 1H NMR δ 7.61 (s, 1H), 7.58 (d, J = 7.8 Hz, 1H), 
7.33 (t, J = 8.2 Hz, 2H), 7.25 (dd, J = 9.6, 5.4 Hz, 2H), 7.16 (3H), 7.13 – 7.00 (m, 3H), 6.89 (m, 2H), 
6.23 (d, J = 9.5 Hz, 1H), 5.51 (s, 2H), 5.20 (s, 2H), 5.13 (broad, 1H), 3.23 (dd, J = 13.3, 6.8 Hz, 2H), 
2.61 (t, J = 7.7 Hz, 2H), 1.62 (m, 4H), 1.39 (t, 2H); 13C NMR δ 161.31, 161.13, 155.71, 154.24, 
151.60, 143.36, 142.35, 135.59, 130.10, 128.92, 128.40, 128.33, 125.76, 124.81, 123.08, 122.24, 
121.42, 113.47, 113.01, 112.86, 102.12, 62.36, 53.90, 41.26, 35.79, 31.04, 29.67, 26.35 
 
4-((4-(((2-oxo-2H-chromen-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)phenyl 
heptylcarbamate (61)  
Compound 61 was obtained following the same procedure described for compound 59 using 66a 
and 53b as starting materials. Yield: 22.22%; M.P.:152.2-152.6° C; 1H NMR δ 7.61 (d, J = 9.5 Hz, 
1H), 7.54 (s, 1H), 7.35 (d, J = 8.7 Hz, 1H), 7.30 – 7.20 (m, 3H), 7.13 (d, J = 8.3 Hz, 2H), 6.90 (d, J 
= 7.6 Hz, 2H), 6.24 (d, J = 9.5 Hz, 1H), 5.51 (s, 2H), 5.21 (s, 2H), 5.02 (broad, 1H), 3.24 (dd, J = 
13.4, 6.7 Hz, 2H), 1.28 (m, 8H), 0.87 (t, J = 6.6 Hz, 3H); 13C NMR δ 161.26, 161.06, 155.66, 154.16, 
153.37, 152.26, 151.47, 143.30, 131.01, 129.22, 128.8, 122.3, 113.41, 112.95, 112.73, 102.07, 
62.25, 53.80, 41.30, 31.69, 29.74, 28.88, 26.66, 22.55, 14.04; ES-MS m/z: 491 (M + H+), 513 (M + 
Na) 
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3-((4-(((2-oxo-2H-chromen-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)phenyl 
heptylcarbamate (62)  
Compound 62 was obtained following the same procedure described for compound 59 using 66b 
and 53b as starting materials. Yield: 32.46%; M.P.:>250° C; 1H NMR δ 7.62 (d, J = 9.5 Hz, 1H), 7.58 
(s, 1H), 7.35 (t, J = 9.4 Hz, 2H), 7.15 – 7.04 (m, 3H), 6.94 – 6.86 (m, 2H), 6.25 (d, J = 9.5 Hz, 1H), 
5.52 (s, 2H), 5.22 (s, 2H), 5.14 (broad, 1H), 3.24 (dd, J = 13.4, 6.7 Hz, 2H), 1.40 – 1.20 (m, 8H), 
0.88 (t, J = 6.2 Hz, 3H); 13C NMR δ 161.23, 161.05, 155.64, 154.16, 151.55, 143.38, 143.28, 135.50, 
130.02, 128.84, 124.72, 122.95, 122.16, 121.36, 113.40, 112.93, 112.77, 102.04, 62.29, 53.82, 
41.28, 31.67, 29.72, 28.86, 26.65, 22.53, 14.02; ES-MS m/z: 491 (M + H+), 513 (M + Na), 529 (M + 
K) 
 
1-(azidomethyl)-4-methoxybenzene (64a)  
To a mixture of 0.548g (3.500 mmol, 1eq, d=1.155) of 4-methoxybenzylchloride dissolved in 15 ml 
of anhydrous DMF, 0.46g (7.000 mmol, 2eq) of NaN3 were added. The mixture was stirred at 80° C 
for 6h. The reaction was quenched with water and the crude was extracted with diethyl ether. The 
compound was used without any further purification for the next step; 0.53g of compound 64a were 
obtained. Yield: 93%; colorless oil; 1H NMR (400 MHz, CDCl3,) δ 7.23 (d, J = 7.2 Hz, 2H), 6.88 (d, J 
= 7.2 Hz, 2H), 4.24 (s, 2H), 3.79 (s, 3H) 
 
1-(azidomethyl)-3-methoxybenzene (64b)  
Compound 64b was obtained following the same procedure described for compound 64a using 3-
methoxybenzylchloride as starting material. Yield: 92.73%; oil; 1H NMR (400 MHz, CDCl3,) δ 6.99 
(t, J = 8 Hz, 1H), 6.60-6.56 (m, 3H), 4.01 (s, 2H), 3.50 (s, 3H) 
 
 
7-((1-(4-hydroxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one (72a)  
To a solution of 0.43g (2.161 mmol, 1 eq) of 63 in 15 mL of DMSO, 0.70g (2.809 mmol, 1.3eq) of 
71a and 0.02g (0.216 mmol, 1/10eq, d=0.726) of TEA were added. 0.04g (0.216 mmol, 1/10eq) of 
CuSO4 and 0.25g (1.081 mmol, ½eq) of sodium ascorbate were dissolved in water and were stirred 
for 5 min; the solution was added to the reaction flask and it was stirred at r.t. for 24h. A saturated 
solution of NH4Cl was added to the reaction and the organic compound was extracted with ethyl 
acetate. The nmr of the crude product showed that the reaction had occurred. The mixture was 
purified via flash chromatography: toluene/acetone 4:1; During purification the molecule was 
deprotected, therefore peaks corresponding to the TBDMS disappeared from the NMR spectrum. 
0.18g of neat compound 72a were obtained. Yield: 25%; M.P.: 239° C; 1H NMR (DMSO) δ 9.97 (s, 
1H), 8.81 (s, 1H), 8.00 (d, J = 9.5 Hz, 1H), 7.66 (dd, J = 8.8, 2.6 Hz, 2H), 7.19 (s, 1H), 7.06 (d, J = 
8.7 Hz, 1H), 6.93 (d, J = 8.7 Hz, 2H), 6.31 (d, J = 9.6 Hz, 1H), 5.33 (s, 2H) 
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7-((1-(3-hydroxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one (72b)  
Compound 72b was obtained following the same procedure described for compound 72a using 63 
and 71b as starting materials. Yield: 62.90%; M.P.: 218° C; 1H NMR (400 MHz, DMSO) δ 10.07 (s, 
1H), 8.94 (s, 1H), 8.01 (d, J = 9.5 Hz, 1H), 7.66 (d, J = 8.6 Hz, 1H), 7.38 (t, J = 8.3 Hz, 1H), 7.33 – 
7.28 (m, 2H), 7.20 (d, J = 1.8 Hz, 1H), 7.06 (dd, J = 8.6, 2.0 Hz, 1H), 6.89 (d, J = 8.1 Hz, 1H), 6.32 
(d, J = 9.5 Hz, 1H), 5.34 (s, 2H) 
 
4-(4-(((2-oxo-2H-chromen-7-yl) oxy)methyl)- 1H-1,2,3-triazol-1-yl) phenyl (5-phenylpentyl) 
carbamate (67)  
To a mixture of 0.10g (0.298 mmol) of 72a in anhydrous toluene, a catalytic amount of NaH was 
added and the reaction was stirred for 10 min. 0.06g (0.298 mmol) compound 53a were added, then 
the solution was stirred at r.t. for 60h; it was poured in water and extracted with DCM. Compound 
67 was crystalized with methanol. 0.08g of neat compound 67 were obtained. Yield: 50%; M.P.: 
168.4-168.6° C; 1H NMR δ 8.06 (s, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.65 (d, J = 9.5 Hz, 1H), 7.45 – 
7.37 (m, 1H), 7.31 (m, 4H), 7.20 (t, J = 6.8 Hz, 3H), 6.98 (d, J = 5.5, 2.3 Hz, 2H), 6.29 (d, J = 9.5 Hz, 
1H), 5.35 (s, 2H), 5.09 (broad, J = 5.7 Hz, 1H), 3.29 (dd, J = 13.3, 6.8 Hz, 2H), 2.65 (t, J = 7.6 Hz, 
2H), 1.66 (m, 4H), 1.51 – 1.37 (m, 2H); 13C NMR δ 161.18, 160.99, 155.71, 153.89, 151.34, 143.71, 
143.24, 142.26, 133.79, 128.93, 128.34, 128.28, 125.72, 122.89, 121.64, 121.24, 113.54, 113.07, 
112.69, 102.14, 62.23, 41.24, 35.73, 30.97, 29.63, 26.27 
 
3-(4-(((2-oxo-2H-chromen-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl (5-
phenylpentyl)carbamate (68)  
Compound 68 was obtained following the same procedure described for compound 67 using 72b 
and 53a as starting materials. Yield: 51.28%; M.P.:132.1-132.3° C; 1H NMR δ 8.09 (s, 1H), 7.65 (d, 
J = 9.5 Hz, 1H), 7.60 (d, J = 6.8 Hz, 2H), 7.51 (t, J = 8.2 Hz, 1H), 7.41 (d, 1H), 7.32 – 7.15 (m, 6H), 
6.97 (d, J = 6.4 Hz, 2H), 6.28 (d, J = 9.5 Hz, 1H), 5.35 (s, 2H), 5.11 (broad, 1H), 3.28 (dd, J = 13.3, 
6.8 Hz, 2H), 2.65 (t, J = 7.6 Hz, 2H), 1.73 – 1.61 (m, 4H), 1.43 (dd, J = 15.2, 8.1 Hz, 2H); 13C NMR 
δ 161.15, 160.99, 155.72, 153.73, 151.91, 143.84, 143.24, 137.35, 130.44, 128.95, 128.35, 128.29, 
125.73, 122.10, 121.21, 117.12, 114.34, 113.56, 113.09, 112.67, 102.19, 62.24, 41.26, 35.73, 30.97, 
29.62, 26.27; ES-MS m/z: 525 (M + 1) 
 
4-(4-(((2-oxo-2H-chromen-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl heptylcarbamate (69)  
Compound 69 was obtained following the same procedure described for compound 67 using 72a 
and 53b as starting materials. Yield: 64.29%; M.P.:180-181° C; 1H NMR δ 8.05 (s, 1H), 7.71 (d, J = 
8.8 Hz, 2H), 7.64 (d, J = 9.5 Hz, 1H), 7.43 – 7.36 (m, 1H), 7.31 (d, J = 8.8 Hz, 2H), 6.97 (dd, J = 4.4, 
2.2 Hz, 2H), 6.27 (d, J = 9.5 Hz, 1H), 5.33 (s, 2H), 5.11 (broad, 1H), 3.28 (dd, J = 13.4, 6.7 Hz, 2H), 
1.58 (m, 2H), 1.31 (m, 8H), 0.89 (t, J = 6.6 Hz, 3H); 13C NMR δ 161.18, 161.02, 155.69, 153.92, 
151.36, 143.68, 143.28, 133.72, 128.94, 122.90, 121.62, 121.35, 113.51, 113.05, 112.70, 102.10, 
62.21, 41.35, 31.69, 29.73, 28.88, 26.67, 22.55, 14.03; ES-MS m/z: 499 (M + Na) 
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3-(4-(((2-oxo-2H-chromen-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl heptylcarbamate (70)  
Compound 70 was obtained following the same procedure described for compound 67 using 72b 
and 53b as starting materials. Yield: 41.17%; M.P.:127°; 1H NMR δ 8.09 (s, 1H), 7.63 (d, J = 9.5 Hz, 
1H), 7.57 (m, 2H), 7.48 (t, J = 8.1 Hz, 1H), 7.39 (d, J = 8.5 Hz, 1H), 7.22 (d, J = 8.0 Hz, 1H), 6.94 
(m, 2H), 6.26 (d, J = 9.4 Hz, 1H), 5.32 (s, 2H), 5.21 (broad, 1H), 3.26 (d, J = 6.3 Hz, 2H), 1.58 (m, 
3H), 1.29 (m, 8H), 0.88 (s, 3H); 13C NMR δ 161.15, 161.03, 155.68, 153.83, 151.94, 143.75, 143.28, 
137.34, 130.42, 128.95, 122.10, 121.27, 117.04, 114.31, 113.50, 113.06, 112.67, 102.13, 62.20, 
41.36, 31.69, 29.72, 28.88, 26.66, 22.55, 14.04; ES-MS m/z: 477 (M + H+), 499 (M + Na) 
 
4-((tert-butyldimethylsilyl)oxy)aniline (73a)  
To a solution of 0.50g (4.582 mmol, 1eq) of p-aminophenol in 10 mL of DMF, 0.94g (13.746 mmol, 
3eq) of imidazole and 0.83g (5.498 mmol, 1.2eq) of TBDMS-Cl were added. The mixture was stirred 
at r.t. for 12h, then the solution was poured in water and it was extracted with ether. Compound 73a 
was purified via flash chromatography: petroleum ether/ethyl acetate 4:1; 0.82g of neat compound 
were obtained. Yield: 58.42%; dark red oil; 1H NMR δ 6.64 (d, J = 8.5 Hz, 2H), 6.56 (d, J = 8.5 Hz, 
2H), 0.93 (s, 9H), 0.13 (s, 6H). 
 
3-((tert-butyldimethylsilyl)oxy)aniline (73b)  
Compound 73b was obtained following the same procedure described for compound 73a using 3-
aminophenol as starting material. Yield: 79.92%; brow oil; 1H NMR δ 7.01 (t, J = 16 Hz, 1H), 6.32 – 
6.26 (m, 2H), 6.21 (s, 1H), 3.61 (s, 1H), 0.99 (s, 9H), 0.21 (s, 6H). 
 
(4-azidophenoxy)(tert-butyl)dimethylsilane (71a)  
0.82g (3.661 mmol, 1eq) of 73a, 9.5 mL of water and 2.85 mL of HCl 37% were added to a round-
bottom flask that was cooled at 0° C in a ice bath. A solution of 0.25g (3.661 mmol, 1eq) of NaNO2, 
in H2O, was added dorpwise to the reaction flask. The mixture was stirred for 10’. 0.29g (4.392 
mmol, 1.2eq) of NaN3 were added in portions and the reaction was stirred for 1h. The reaction was 
quenched with water and compound 71a was extracted with ethyl acetate. 0.06g of neat compound 
were obtained. Yield: 58.83%; black oil; 1H NMR δ 6.89 – 6.76 (m, 4H), 0.90 (s, 9H), 0.09 (s, 6H). 
 
(3-azidophenoxy)(tert-butyl)dimethylsilane (71b)  
Compound 71b was obtained following the same procedure described for compound 71a using 73b 
as starting material. Yield: 65.93%; oil; 1H NMR δ 7.18 (t, J = 6.8 Hz, 1H), 6.60 (d, J = 7.8 Hz, 2H), 
6.49 (d, J = 8.9 Hz, 1H), 0.90 (s, 9H), 0.09 (s, 6H) 
 
N-cyclopentyl-2-(3- ((methyl(3- ((2-oxo-2H-chromen-7-yl)oxy) propyl) amino) methyl) 
phenoxy)acetamide (74)  
To a solution of 0.35g (1.032 mmol, 1eq) of 46 in 20 mL of acetone, 0.25g (1.366 mmol, 1.3eq) of 
2-chloro-N-cyclopentylacetamide and 0.70g of K2CO3 were added and the mixture was stirred and 
refluxed for 12h, then the solution was concentrated under reduced pressure. Compound 74 was 
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purified via flash chromatography: toluene/acetone 3:2; 0,00g of neat compound were obtained. 
Yield: oil 1H NMR δ 7.60 (d, J = 9.5 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 7.18 (t, J = 7.9 Hz, 1H), 6.92 
(d, J = 7.6 Hz, 1H), 6.87 (s, 1H), 6.79 – 6.72 (m, 3H), 6.40 (d, J = 7.9 Hz, 1H), 6.20 (d, J = 9.5 Hz, 
1H), 4.47 (s, 2H), 4.13 – 4.03 (m, 2H), 3.50 (s, 2H), 2.97 – 2.83 (m, 1H), 2.55 (dd, J = 13.0, 6.6 Hz, 
2H), 2.16 (s, 3H), 2.07 – 1.95 (m, 2H), 1.73 – 1.58 (m, 4H), 1.51 – 1.36 (m, 4H); 13C NMR δ 167.07, 
162.20, 161.14, 157.23, 155.78, 143.35, 141.26, 129.41, 128.63, 122.48, 115.08, 113.06, 112.88, 
112.68, 112.36, 101.40, 67.79, 67.14, 63.89, 55.92, 54.32, 43.01, 35.65, 27.25, 24.64 
 
N-cyclohexyl-2- (3- ((methyl(3- ((2-oxo-2H-chromen-7-yl) oxy) propyl) amino) methyl) 
phenoxy) acetamide (75)  
Compound 75 was obtained following the same procedure described for compound 74 using 2-
chloro-N-cyclohexylacetamide as starting material. Yield: 65.93%; oil; 1H NMR δ 7.60 (d, J = 9.5 Hz, 
1H), 7.32 (d, J = 8.4 Hz, 1H), 7.18 (t, J = 7.9 Hz, 1H), 6.92 (d, J = 7.6 Hz, 1H), 6.87 (s, 1H), 6.79 – 
6.72 (m, 3H), 6.40 (d, J = 7.9 Hz, 1H), 6.20 (d, J = 9.5 Hz, 1H), 4.38 (s, 2H), 4.04 (dd, J = 7.9, 4.6 
Hz, 2H), 3.89 – 3.74 (m, 1H), 3.45 (s, 2H), 2.52 (t, J = 6.9 Hz, 2H), 2.20 (s, 3H), 2.01 – 1.93 (m, 2H), 
1.93 – 1.83 (m, 2H), 1.72 – 1.62 (m, 2H), 1.62 – 1.53 (m, J = 9.2, 3.8 Hz, 1H), 1.40 – 1.26 (m, 2H), 
1.20 – 1.07 (m, 2H); 13C NMR δ 167.07, 162.20, 161.14, 157.23, 155.78, 143.35, 141.26, 129.41, 
128.63, 122.48, 115.08, 113.06, 112.88, 112.68, 112.36, 101.40, 67.29, 66.53, 62.21, 53.47, 47.74, 
42.21, 32.90, 26.90, 25.36, 24.71 
 
PROJECT 2 
 
ethyl 4-((5-chloropentyl)oxy)benzoate (92)  
To a mixture of 1.00g (6.024 mmol, 1eq) of 4-hydroxybenzoate dissolved in acetone, 1.67g (9.036 
mmol, 1.5eq) of 1-Bromo-5-chloropenthane and 2.13g of K2CO3 were added. The reaction was 
refluxed and stirred for 10h, then it was filtered hot and concentrated under vacuum. Compound 92 
was purified via flash chromatography thanks to a mobile phase of toluene. 1.60g of neat compound 
were obtained. Colorless oil. Yield: 98.40%; 1H NMR δ 7.99 (d, J = 8.8 Hz, 2H), 6.91 (d, J = 9.2 Hz, 
2H), 4.37-4.32 (m, 2H), 4.02 (t, J = 12.4 Hz, 2H), 3.56 (t, J = 13.2 Hz, 2H), 1.89-1.80 (m, 4H), 1.67-
1.61 (m, 2H), 1.38 (t, J = 14.4 Hz, 3H) 
 
ethyl 4-(4-chlorobutoxy)benzoate (93)  
Compound 93 was obtained following the same procedure described for compound 92 using 1-
Bromo-4-chlorobutane as starting material. Yield: 91.44%; oil; 1H NMR δ 8.01 (d, J = 8.4 Hz, 2H), 
6.92 (d, J = 8.8 Hz, 2H), 4.38-4.33 (m, 2H), 4.08 (t, J = 12.4 Hz, 2H), 3.64 (t, J = 11.2 Hz, 2H), 2.00-
1.98 (m, 4H), 1.39 (t, J = 14 Hz, 3H) 
 
ethyl 4-(3-chloropropoxy)benzoate (94) 
Compound 94 was obtained following the same procedure described for compound 92 using 1-
Bromo-3-chloropropane as starting material. Yield: 96.09%; colorless oil; 1H NMR δ 8.02 (d, J = 9.2 
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Hz, 2H), 6.94 (d, J = 8.4 Hz, 2H), 4.38-4.33 (m, 2H), 4.19 (t, J = 11.6 Hz, 2H), 3.76 (t, J = 12.8 Hz, 
2H), 2.30-2.56 (m, 2H), 1.39 (t, J = 14.4 Hz, 3H) 
 
ethyl 4-(2-chloroethoxy)benzoate (95)  
Compound 95 was obtained following the same procedure described for compound 92 using 1-
Bromo-2-chloroethane as starting material. Yield: 85.79%; oil; 1H NMR δ 8.02 (d, J = 9.2 Hz, 2H), 
6.95 (d, J = 9.2 Hz, 2H), 4.39-4.33 (m, 2H), 4.29 (t, J = 11.6 Hz, 2H), 3.85 (t, J = 11.6 Hz, 2H), 1.39 
(t, J = 14.4 Hz, 3H) 
 
4-((5-chloropentyl)oxy)benzoic acid (96) 
To a solution of 1.58g (5.85 mmol, 1eq) of 92 in 40 mL of ethanol, a solution of 0.49g (8.78 mmol, 
1.5eq) of KOH in 2 mL of H2O was added and the mixture was stirred and refluxed for 3h. The 
ethanol was evaporated under vacuum then, 20 mL of HCl 1:1 were added to the reaction flask. A 
white solid precipitate was formed and it was filtrated. 1.37g of neat compound 96 were obtained. 
Yield: 96.75%; M.P.: 103.8° C; 1H NMR δ 8.06 (d, J = 9.2 Hz, 2H), 6.94 (d, J = 8.8 Hz, 2H), 4.06-
4.02 (m, 2H), 3.58 (t, J = 13.2 Hz, 2H), 1.90-1.82 (m, 4H), 1.68-1.61 (m, 2H) 
 
4-(4-chlorobutoxy)benzoic acid (97)  
Compound 97 was obtained following the same procedure described for compound 92 using 93 as 
starting material. Yield: 92.43%; M.P.: 113° C; 1H NMR δ 8.05 (d, J = 8.8 Hz, 2H), 6.94 (d, J = 8.4 
Hz, 2H), 4.09-4.06 (m, 2H), 3.63 (t, J = 12 Hz, 2H), 2.00-1.98 (m, 4H) 
 
4-(3-chloropropoxy)benzoic acid (98)  
Compound 98 was obtained following the same procedure described for compound 92 using 94 as 
starting material. Yield: 87.14%; M.P.: 102° C; 1H NMR δ 8.04 (d, J = 9.2 Hz, 2H), 6.94 (d, J = 8.8 
Hz, 2H), 4.17 (t, J = 11.6 Hz, 2H), 3.74 (t, J = 12.4 Hz, 2H), 2.25 (t, J = 12 Hz, 2H), 
 
4-(2-chloroethoxy)benzoic acid (99)  
Compound 99 was obtained following the same procedure described for compound 92 using 95 as 
starting material. Yield: 91.77%; M.P.: 176-178° C; 1H NMR 8.03 (d, J = 9.2 Hz, 2H), 6.95 (d, J = 8.8 
Hz, 2H), 4.35 (t, J = 11.6 Hz, 2H), 3.91 (t, J = 12.4 Hz, 2H) 
 
4-((5-chloropentyl)oxy)benzoyl chloride (80)  
1.36g (5.62 mmol) of 96 were dissolved in 18 mL of SOCl2; the reaction flask was stirred and refluxed 
for 5h, then the solvent was removed with a trap. 1.40g of compound 80 were obtained and it was 
used for the next reaction without any further purification. Yield: 95.89%; yellow oil. 
 
4-(4-chlorobutoxy)benzoyl chloride (81)  
Compound 81 was obtained following the same procedure described for compound 80 using 97 as 
starting material. Yield: 96.00%; oil 
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4-(3-chloropropoxy)benzoyl chloride (82)  
Compound 82 was obtained following the same procedure described for compound 80 using 98 as 
starting material. Yield: 98.33%; yellow oil. 
 
4-(2-chloroethoxy)benzoyl chloride (83)  
Compound 83 was obtained following the same procedure described for compound 80 using 99 as 
starting material. Yield: 91.77%; oil. 
 
(4-((5-chloropentyl)oxy)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone (84)  
A mixture of 1.00g (4.49 mmol, 1eq) of 2-(4-methoxyphenyl)benzofuran and 1.40g (5.38 mmol, 
1.2eq) of 80, previously dissolved in anhydrous DCM under nitrogen atmosphere, were cooled to 0° 
C. 1.40g (5.38 mmol, 1.2eq) of SnCl4 were added dropwise to the reaction flask then, the mixture 
was stirred at r.t. overnight. The reaction was quenched with ice and the organic compound was 
extracted with DCM. Compound 84 was purified via flash chromatography: petroleum ether/ethyl 
acetate 3:2. 1.42g of neat compound 84 were obtained. Yield: 73.27%; yellow oil; 1H NMR δ 7.86 
(d, J = 9.2 Hz, 2H), 7.69 (d, J = 9.2 Hz, 2H), 7.53 (d, J = 8.4 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.29 
(t, J = 15.6 Hz, 1H), 7.21 (t, J = 15.6 Hz, 1H), 6.84 - 6.78 (m, 4H), 3.95 (t, J = 12.8 Hz, 2H), 3.76 (s, 
3H), 3.52 (t, J = 13.2 Hz, 2H), 1.84 – 1.74 (m, 4H), 1.61 – 1.55 (m, 2H) 
 
(4-(4-chlorobutoxy)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone (85)  
Compound 85 was obtained following the same procedure described for compound 84 using 81 as 
starting material. Yield: 70.90%; oil; 1H NMR δ 7.86 (d, J = 9.2 Hz, 2H), 7.69 (d, J = 9.2 Hz, 2H), 
7.55 (d, J = 8 Hz, 1H), 7.46 (d, J = 7.2 Hz, 1H), 7.30 (t, J = 15.2 Hz, 1H), 7.23 (t, J = 14.8 Hz, 1H), 
6.84 - 6.79 (m, 4H), 3.99 (t, J = 10.8 Hz, 2H), 3.78 (s, 3H), 3.59 (t, J = 12.4 Hz, 2H), 1.96 – 1.92 (m, 
4H) 
 
(4-(3-chloropropoxy)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone (86)  
Compound 86 was obtained following the same procedure described for compound 84 using 82 as 
starting material. Yield: 40.00%; yellow pale oil; 1H NMR δ 7.88 (d, J = 9.2 Hz, 2H), 7.71 (d, J = 9.2 
Hz, 2H), 7.55 (d, J = 8 Hz, 1H), 7.46 (d, J = 7.2 Hz, 1H), 7.30 (t, J = 15.2 Hz, 1H), 7.23 (t, J = 14.8 
Hz, 1H), 6.87 (dd, J = 11.6 Hz, 4H), 4.15 (t, J = 10.8 Hz, 2H), 3.81 (s, 3H), 3.74 (t, J = 12.8 Hz, 2H), 
2.31 – 2.20 (m, 2H) 
 
(4-(2-chloroethoxy)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone (87)  
Compound 87 was obtained following the same procedure described for compound 84 using 83 as 
starting material. Yield: 61.11%; oil; 1H NMR δ 7.88 (d, J = 8.4 Hz, 2H), 7.69 (d, J = 8.8 Hz, 2H), 
7.57 (d, J = 8.4 Hz, 1H), 7.49 (d, J = 8 Hz, 1H), 7.33 (t, J = 15.2 Hz, 1H), 7.23 (t, J = 14.8 Hz, 1H), 
6.86 (dd, J = 8.4 Hz, 4H), 4.24 (t, J = 11.2 Hz, 2H), 3.79 (s, 3H), 1.26 (t, J = 15.2 Hz, 2H) 
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(4-((5-iodopentyl)oxy)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone (88)  
A mixture of 2.50g (5.58 mmol, 1eq) of 84 and 0.84g (5.58 mmol, 1.2eq) of NaI in 70 mL of methyl 
ethyl ketone was stirred and refluxed for 5h. The solvent was removed under reduced pressure, 
then the organic compound was dissolved in DCM and it was washed trice with water. Collected 
organic layers were concentrate under vacuum. 2.38g of compound 88 were obtained and it was 
used for the next reaction without any further purification. Yield: 79.07%; oil. 
 
(4-(4-iodobutoxy)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone (89)  
Compound 89 was obtained following the same procedure described for compound 88 using 85 as 
starting material. Yield: 93.37%; oil. 
 
(4-(3-iodopropoxy)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone (90)  
Compound 90 was obtained following the same procedure described for compound 88 using 86 as 
starting material. Yield: 89.23%; oil. 
 
(4-(2-iodoethoxy)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone (91)  
Compound 91 was obtained following the same procedure described for compound 88 using 87 as 
starting material. Yield: 90.77%; oil. 
 
(4-((5-(benzyl(methyl) amino) pentyl)oxy) phenyl)(2-(4-methoxyphenyl) benzofuran-3-
yl)methanone (76)  
A mixture of 0.84g (1.56 mmol, 1eq) of 88mand 0.38g (3.12 mmol, 2eq) of N-benzylmethylamine in 
28 mL of toluene was stirred and refluxed for 60h; then the reaction mixture was washed thrice with 
water and the organic layers were concentrated under vacuum. Compound 76 was purified via flash 
chromatography: toluene/acetone 4:1; 0.48g of neat compound were obtained. Yield: 57.83%; dark 
yellow oil; 1H NMR δ 7.86 (d, J = 8.8 Hz, 2H), 7.70 (d, J = 8.8 Hz, 2H), 7.55 (d, J = 8 Hz, 1H), 7.46 
(d, J = 7.2 Hz, 1H), 7.32-7.19 (m, 7H), 6.84-6-78 (dd, 4H), 3.96 (t, J = 12.8 Hz, 2H), 3.78 (s, 3H), 
3.47 (s, 2H), 2.37 (t, J = 14.4 Hz, 2H), 2.18 (s, 3H), 1.79-1.59 (m, 2H), 1.57-1.53 (m, 2H), 1.51-1.45 
(m, 2H); 13C NMR δ 190.97, 163.34, 160.63, 156.66, 153.51, 139.22, 132.28, 130.50, 129.66, 
128.98, 128.91, 128.16, 126.87, 124.75, 123.49, 122.17, 121.12, 115.06, 114.16, 113.96, 110.99, 
68.14, 62.38, 57.22, 55.29, 42.25, 28.96, 27.13, 23.78; ES-MS m/z: 534 (M + H+), 556 (M + Na) 
 
(4- (4- (benzyl (methyl) amino) butoxy)phenyl) (2-(4-methoxyphenyl) benzofuran- 3-yl) 
methanone (77)  
Compound 77 was obtained following the same procedure described for compound 76 using 89 as 
starting material. Yield: 68.34%; yellow oil; 1H NMR δ 7.85 (d, J = 8.8 Hz, 2H), 7.70 (d, J = 9.2 Hz, 
2H), 7.53 (d, J = 8.4 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.30-7.13 (m, 7H), 6.82-6-76 (dd, 4H), 3.92 
(t, J = 13.2 Hz, 2H), 3.74 (s, 3H), 3.46 (s, 2H), 2.38 (t, J = 14.4 Hz, 2H), 2.17 (s, 3H), 1.82-1.75 (m, 
2H), 1.67-1.61 (m, 2H); 13C NMR δ 190.95, 163.35, 160.67, 156.67, 153.55, 139.24, 132.29, 130.53 
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, 129.69, 129.00, 128.22, 126.93, 125.31, 124.79, 123.54, 122.19, 121.15, 115.09, 114.21, 113.99, 
111.03, 68.00, 62.39, 56.73, 55.28, 42.19, 26.84, 23.70; ES-MS m/z: 520 (M + H+), 542 (M + Na) 
 
(4-(3-(benzyl(methyl)amino)propoxy)phenyl)(2-(4-methoxyphenyl)benzofuran-3-
yl)methanone (78)  
Compound 78 was obtained following the same procedure described for compound 76 using 90 as 
starting material. Yield: 58.34%; yellow oil; 1H NMR δ 7.86 (d, J = 8.8 Hz, 2H), 7.70 (d, J = 8.8 Hz, 
2H), 7.55 (d, J = 8 Hz, 1H), 7.47 (d, J = 7.2 Hz, 1H), 7.32-7.15 (m, 7H), 6.84-6-78 (dd, 4H), 4.03 (t, 
J = 12.4 Hz, 2H), 3.76 (s, 3H), 3.49 (s, 2H), 2.51 (t, J = 13.6 Hz, 2H), 2.14 (s, 3H), 1.94 (m, 2H); 13C 
NMR δ 190.98, 163.29, 160.63, 156.65, 153.52, 139.02, 132.26, 130.49, 129.66, 128.91, 128.87 , 
128.19, 126.94, 124.76, 123.50, 122.16, 121.11, 115.04, 114.19, 113.96, 111.00, 66.27, 62.43, 
55.28, 53.45, 42.25, 27.04; ES-MS m/z: 506 (M + H+), 528 (M + Na) 
 
(4-(2-(benzyl(methyl)amino)ethoxy)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone 
(79)  
Compound 79 was obtained following the same procedure described for compound 76 using 91 as 
starting material. Yield: 28.38%; oil; 1H NMR δ 7.84 (d, J = 8.4 Hz, 2H), 7.68 (d, J = 8.4 Hz, 2H), 
7.54 (d, J = 8.4 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.13-7.28 (m, 4H), 7.25-7.21 (m, 3H), 6.81 (t, J = 
17.6 Hz, 4H), 4.09 (t, J = 11.6 Hz, 2H), 3.77 (s, 3H), 3.61 (s, 2H), 2.82 (t, J = 12 Hz, 2H), 2.33 (s, 
3H); 13C NMR 190.91, 162.87, 160.57, 156.73, 153.45, 138.30, 132.18, 130.62, 129.63, 128.99, 
128.79, 128.24, 127.13, 124.71, 123.46, 122.04, 121.05, 114.92, 114.15, 113.88, 110.94, 66.43, 
62.62, 55.30, 42.88, 30.84; ES-MS m/z: 492 (M + H+), 514 (M + Na) 
 
(2- (4-methoxyphenyl) benzofuran-3-yl) (4-nitrophenyl) methanone (114)  
A mixture of 1.10g (4.95 mmol, 1eq) of 2-(4-methoxyphenyl)benzofuran, and 1.10g (5.85 mmol, 1.2 
eq) of 4-nitrobenzoyl chloride in anhydrous DCM under nitrogen atmosphere was cooled at 0° C, 
then 1.55g (5.95 mmol, 1.2 eq) of SnCl4 were added dropwise to the flask. The reaction was stirred 
at r.t. for 10h, then it was quenched with ice and the organic compound was extracted with DCM. 
1.44g of neat compound 114 were obtained. Yield: 78.26%; M.P.: 146° C; 1H NMR δ 8.12 (d, J = 8.2 
Hz, 2H), 7.89 (d, J = 8.2 Hz, 2H), 7.64 (d, J = 7.7 Hz, 1H), 7.59 – 7.48 (m, 3H), 7.37 (t, J = 7.7 Hz, 
1H), 7.29 (t, J = 7.5 Hz, 1H), 6.77 (d, J = 8.3 Hz, 2H), 3.77 (s, 3H) 
 
(4-aminophenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone (115)  
To a solution of 1.44g (3.86 mmol) of 114 in 100 mL of ethanol, 10.85g (48.25 mmol, 12.5 eq) of 
SnCl2 were added and the reaction was refluxed for 2h; then it was cooled to r.t. and 40 mL of NaOH 
were added. The organic compound was exctracted with ethyl acetate. Compound 115 was purified 
via flash chromatography: petroleum ether/ethyl acetate 4:1; 1.18g of neat compound were 
obtained. Yield: 89.39%; M.P.: 183° C; 7.77 (d, J = 8.6 Hz, 2H), 7.73 (d, J = 8.9 Hz, 2H), 7.55 (d, J 
= 8.2 Hz, 1H), 7.46 (d, J = 7.7 Hz, 1H), 7.31 (t, J = 8.3 Hz, 1H), 7.22 (t, J = 7.6 Hz, 1H), 6.87 (d, J = 
8.9 Hz, 2H), 6.57 (d, J = 8.7 Hz, 2H), 4.13 (s, 2H), 3.82 (s, 3H) 
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(4-(benzylamino)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone (100) and (4-
(dibenzylamino)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone (101)  
To a solution of 0.10g (0.29 mmol, 1eq) of 115 in 3 mL of CH3CN, 0.05g (0.29 mmol, 1eq) of 
benzylbromide, 0.02g (0.10 mmol, 1/3 eq) of KI and 0.02g (0.10 mmol, 1/3 eq) of K2CO3 were added. 
The reaction was carried out with the microwave at 110° C, 150W, for 10 minutes; then it was poured 
in water and organic compounds were extracted in DCM. Compound 100 and 101 were separated 
and purified via flash chromatography: petroleum ether/ethyl acetate 7:3; 0.04g of 100 and 0.10g of 
101 were obtained. compound 100: yield: 31.85%; yellow oil; 1H NMR δ 7.77 (d, J = 8.6 Hz, 2H), 
7.71 (d, J = 8.7 Hz, 2H), 7.51 (d, J = 8.2 Hz, 1H), 7.43 (d, J = 7.7 Hz, 1H), 7.38 – 7.23 (m, 6H), 7.18 
(t, J = 7.5 Hz, 1H), 6.84 (d, J = 8.7 Hz, 2H), 6.50 (d, J = 8.6 Hz, 2H), 4.63 (s, 1H), 4.35 (d, J = 3.8 
Hz, 2H), 3.79 (s, 3H); 13C NMR δ 190.38, 160.37, 155.43, 153.40, 152.33, 138.00, 132.64, 129.29, 
129.15, 128.75, 127.56, 127.36, 127.04, 124.51, 123.27, 122.36, 121.00, 115.31, 113.91, 111.62, 
110.87, 55.26, 47.51; compound 101: yield: 65.93%; yellow oil; 1H NMR δ 7.77 (d, J = 9.0 Hz, 2H), 
7.71 (d, J = 5.8 Hz, 2H), 7.52 (d, J = 8.1 Hz, 1H), 7.47 (d, J = 7.7 Hz, 1H), 7.33 (m, 4H), 7.27 (m, 
3H), 7.19 ( m, J = 14.6, 7.3 Hz, 5H), 6.86 (d, J = 8.9 Hz, 2H), 6.64 (d, J = 9.0 Hz, 2H), 4.67 (s, 4H), 
3.81 (s, 3H).; 13C NMR δ 190.19, 160.30, 155.38, 153.34, 153.06, 136.97, 132.48, 129.27, 129.10, 
128.74, 127.22, 126.34, 126.26, 124.46, 123.21, 122.37, 120.99, 115.35, 113.83, 111.20, 110.82, 
55.21, 53.84 
 
(4-((4-fluorobenzyl)amino)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone (102) and 
(4-(bis(4-fluorobenzyl)amino)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone (103) 
Compound 102 and 103 were obtained following the same procedure described for compound 100 
using 115 and 4-fluorobenzyl bromide as starting materials. Yield: 57.80%; Compound 102: yield: 
38.05%; yellow oil; 1H NMR δ 7.71 (d, J = 8.8 Hz, 2H), 7.66 (d, J = 8.8 Hz, 2H), 7.46 (d, J = 8.4  Hz, 
1H), 7.38 (d, J 7.6  Hz, 1H), 7.24-7.18 (m, 3H), 7.13 (t, J = 15.2 Hz, 1H), 6.95 (t, J = 17.2 Hz, 2H), 
6.79 (d, J = 8.4 Hz, 2H), 6.44 (d, J = 8.8 Hz, 2H), 4.75 (broad,1H), 4.27 (d, J = 5.6 Hz, 2H), 3.74 (s, 
3H); 13C NMR δ 190.30, 163.27, 160.81, 160.39, 153.45, 152.65, 132.54, 129.43, 129.08, 128.06, 
127.98, 126.74, 124.57, 123.31, 122.34, 121.04, 115.82, 115.61, 113.85, 111.29, 110.90, 55.27, 
53.21; ES-MS m/z: 452 (M + H+), 474 (M + Na); Compound 102: yield: 24.68%; yellow oil; 1H NMR 
δ 7.70 (d, J = 8.8 Hz, 2H), 7.63 (d, J = 8.8 Hz, 2H), 7.45-7.39 (dd, J = 8 Hz, 4H), 7.22 (t, J = 14.4 
Hz, 1H), 7.13 (t, J = 15.2 Hz, 1H), 7.06-7.03 (m, 4H), 6.94 (t, J = 17.2 Hz, 4H), 6.79 (d, J = 8.8 Hz, 
2H), 6.56 (d, J = 9.2 Hz, 2H), 4.54 (s, 4H), 3.75 (s, 3H); 13C NMR δ 190.36, 163.19, 160.39, 153.44, 
152.65, 132.54, 129.43, 129.04, 128.06, 127.98, 126.74, 124.57, 123.31, 122.41, 121.05, 115.82, 
115.61, 113.85, 112.01, 111.29, 110.90, 55.27, 53.22; ES-MS m/z: 560 (M + H+), 582 (M + Na) 
 
(4-((3,5-difluorobenzyl)amino)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone (104) 
and (4-(bis(3,5-difluorobenzyl)amino)phenyl)-(2-(4-methoxyphenyl)benzofuran-3-
yl)methanone (105) 
Compound 104 and 105 were obtained following the same procedure described for compound 100 
using 115 and 3,5-difluorobenzyl bromide as starting materials. Yield: 57.18%; Compound 104: 
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yield: 73.02%; yellow oil; 1H NMR δ 7.76 (d, J = 8.4 Hz, 2H), 7.70 (d, J = 8.8 Hz, 2H), 7.51 (d, J = 8 
Hz, 1H), 7.42 (d, J = 7.6 Hz, 1H), 7.28 (t, J = 15.6 Hz, 1H), 7.20 (t, J = 14.8 Hz, 1H), 6.84-6.79 (m, 
4H), 6.67 (t, J = 17.6 Hz, 1H), 6.46 (d, J = 8.8 Hz, 2H), 4.77 (broad, 1H), 4.35 (d, J = 6 Hz, 2H), 3.78 
(s, 3H); 13C NMR δ 190.30, 164.65, 162.30, 160.52, 155.91, 153.42, 151.84, 141.21, 132.59, 129.44, 
127.57, 124.61, 123.37, 122.25, 121.04, 113.90, 111.39, 110.91, 109.23, 108.98, 103.00, 55.27, 
46.70; ES-MS m/z: 470 (M + H+); Compound 105: yield: 23.02%; yellow oil; 1H NMR δ 7.82 (d, J = 
9.2 Hz, 2H), 7.72 (d, J = 8.8 Hz, 2H), 7.54 (d, J = 8 Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H), 7.33-7.21 (m, 
3H), 6.88 (d, J = 8.8 Hz, 2H), 6.75-6.66 (m, 5H), 6.60 (d, J = 9.2 Hz, 2H), 4.65(s, 4H), 3.82 (s, 3H); 
13C NMR δ 164.58, 162.10, 160.47, 155.69, 153.43, 151.75, 142.52, 132.61, 129.36, 129.08, 
127.61, 124.59, 123.34, 122.29, 121.02, 115.21, 113.94, 111.79, 110.92, 109.76, 102.83, 55.27, 
53.66; ES-MS m/z: 596 (M + H+), 618 (M + Na) 
 
(2-(4-methoxyphenyl)benzofuran-3-yl)(4-((pyridin-2-ylmethyl)amino)phenyl) methanone (106) 
Compound 106 was obtained following the same procedure described for compound 100 using 115 
and 2-(Bromomethyl)pyridine as starting materials. Yield: 31.56%; M.P.: 56° C; 1H NMR δ 8.59 (d, 
J = 4.6 Hz, 1H), 7.80 (d, J = 8.5 Hz, 2H), 7.72 (d, J = 8.7 Hz, 2H), 7.67 (t, J = 7.7 Hz, 1H), 7.53 (d, J 
= 8.2 Hz, 1H), 7.45 (d, J = 7.8 Hz, 1H), 7.32 – 7.26 (m, 2H), 7.21 (dd, J = 14.3, 7.0 Hz, 2H), 6.85 (d, 
J = 8.7 Hz, 2H), 6.57 (d, J = 8.5 Hz, 2H), 5.60 (broad, 1H), 4.49 (d, J = 5.0 Hz, 2H), 3.80 (s, 3H); 13C 
NMR δ 190.43, 178.07, 160.34, 156.87, 155.42, 153.39, 152.22, 149.03, 136.99, 132.65, 129.29, 
129.16, 126.81, 124.51, 123.27, 122.53, 121.84, 121.02, 115.30, 113.91, 111.73, 110.86, 55.26, 
47.96; ES-MS m/z: 435(M + H+), 457 (M + Na) 
 
(4-((4-methoxybenzyl)amino)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl) methanone (107) 
Compound 107 was obtained following the same procedure described for compound 100 using 115 
and 4-methoxybenzylchloride as starting materials. Yield: 29.46%; yellow oil; 1H NMR δ 7.80 (d, J = 
8.8 Hz, 2H), 7.74 (d, 2H), 7.54 (d, J = 8.2 Hz, 1H), 7.45 (d, J = 7.7 Hz, 1H), 7.31 (t, 1H), 7.21 (t, 1H), 
6.88 (dd, 4H), 6.52 (d, J = 8.8 Hz, 2H), 4.30 (s, 2H), 3.82 (s, 3H), 3.81 (s, 3H); 13C NMR δ 192.79, 
162.80, 161.52, 157.82, 155.83, 154.75, 135.08, 132.36, 131.66, 131.18, 130.10, 129.43, 126.93, 
125.68, 124.82, 123.44, 117.77, 116.58, 116.35, 114.01, 113.30, 57.70, 49.47 
 
4-(((4-(2-(4-methoxyphenyl)benzofuran-3-carbonyl)phenyl)amino)methyl)benzonitrile (108) 
Compound 108 was obtained following the same procedure described for compound 100 using 115 
and 4-(Bromomethyl)benzonitrile as starting materials. Yield: 36.28%; yellow oil; 1H NMR δ 7.76 (d, 
J = 8.7 Hz, 2H), 7.70 (d, J = 8.9 Hz, 2H), 7.61 (d, J = 8.2 Hz, 2H), 7.54 (d, J = 8.2 Hz, 1H), 7.45 (d, 
J = 7.7 Hz, 1H), 7.39 (d, J = 8.1 Hz, 2H), 7.34 – 7.16 (m, 2H), 6.85 (d, J = 8.9 Hz, 2H), 6.46 (d, J = 
8.8 Hz, 2H), 4.87 (broad, 1H), 4.45 (d, J = 5.9 Hz, 2H), 3.82 (s, 3H); 13C NMR δ 190.45, 160.44, 
155.73, 153.42, 151.70 , 143.87, 132.61, 132.52 , 129.39 , 129.01, 128.20, 127.52, 125.27, 124.64, 
123.36, 122.27, 120.97, 118.64, 113.91, 111.78, 111.27, 110.95, 55.31, 46.94; ES-MS m/z: 459 (M 
+ H+) 
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(4-((cyclopropylmethyl)amino)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone 
(109) 
Compound 109 was obtained following the same procedure described for compound 100 using 115 
and chloromethylcyclopropane as starting materials. Yield: 25.88%; yellow oil; 1H NMR δ 7.77 (d, J 
= 8.6 Hz, 2H), 7.72 (d, J = 8.8 Hz, 2H), 7.51 (d, J = 8.5 Hz, 1H), 7.42 (d, J = 7.8 Hz, 1H), 7.28 (t, 
1H), 7.18 (t, J = 7.6 Hz, 1H), 6.84 (d, J = 8.7 Hz, 2H), 6.46 (d, J = 8.6 Hz, 2H), 4.37 (s, 1H), 3.82 (s, 
3H), 2.99 (d, J = 7.1 Hz, 2H), 1.12 – 0.96 (m, 1H), 0.56 (d, J = 7.5 Hz, 2H), 0.24 (d, J = 5.0 Hz, 2H); 
13C NMR δ 190.24, 160.35, 155.24, 152.61, 132.71, 132.60, 129.45, 129.25, 126.59, 124.49, 
123.24, 122.40, 121.02, 115.33, 113.93, 111.32, 110.87, 55.27, 48.18, 10.56, 3.50; ES-MS m/z: 398 
(M + H+), 420 (M + Na) 
 
(2-(4-methoxyphenyl)benzofuran-3-yl)(4-(pentylamino)phenyl)methanone (110) 
A mixture of 0.10g (0.29 mmol, 1eq) of 115 and 0.09g (0.58 mmol, 2eq) of 1-Bromopentane were 
dissolved in a biphasic mixture of DCM/NaOH 50%, 1,5:1 (10 mL/6,5 mL); then 0.20g (0.58 mmol, 
2eq) of tetrabutylammonium hydrogensulfate were added and the reaction was stirred at r.t. for 4h. 
The organic layer was collected and it was washed with water. Compound 110 was purified via flash 
chromatography: petroleum ether/ethyl acetate 7:3. 0.01 g of neat compound 110 were obtained. 
Yield: 41.66%; oil; 1H NMR δ 7.77 (d, J = 8.7 Hz, 2H), 7.72 (d, J = 8.9 Hz, 2H), 7.51 (d, J = 8.2 Hz, 
1H), 7.42 (d, J = 7.7 Hz, 1H), 7.28 (t, J = 11.3, 4.1 Hz, 1H), 7.18 (t, J = 7.5 Hz, 1H), 6.84 (d, J = 8.9 
Hz, 2H), 6.45 (d, J = 8.8 Hz, 2H), 4.20 (s, 1H), 3.79 (s, 3H), 3.13 (t, J = 7.1 Hz, 2H), 1.59 (m, 2H), 
1.36 (m, 4H), 0.90 (t, J = 6.9 Hz, 3H); 13C NMR δ 190.30, 160.35, 155.22, 153.41, 152.75, 132.71, 
129.24, 128.24, 126.49, 124.48, 123.24, 122.44, 121.02, 115.49, 113.93, 111.28, 110.86, 55.27, 
43.22, 29.14, 28.94, 22.38, 13.95 
 
(4-(heptylamino)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone (111) 
Compound 111 was obtained following the same procedure described for compound 110 using 115 
and 1-Bromoheptane as starting materials. Yield: 31.06%; oil; 1H NMR δ 7.75 (dd, J = 17.3, 8.8 Hz, 
4H), 7.51 (d, J = 8.2 Hz, 1H), 7.42 (d, J = 7.8 Hz, 1H), 7.27 (t, J = 14.5, 6.3 Hz, 1H), 7.18 (t, J = 7.5 
Hz, 1H), 6.84 (d, J = 8.8 Hz, 2H), 6.45 (d, J = 8.7 Hz, 2H), 4.23 (t, 1H), 3.79 (s, 3H), 3.12 (dd, J = 
12.1, 6.7 Hz, 2H), 1.65 – 1.52 (m, 2H), 1.42 – 1.13 (m, 8H), 0.87 (t, J = 6.1 Hz, 3H); 13C NMR δ 
190.29, 160.35, 155.23, 153.41, 152.76, 132.71, 131.51, 129.24, 126.48, 124.48, 123.23, 122.44, 
121.02, 115.42, 113.84, 111.28, 110.86, 55.27, 43.25, 31.71, 29.26, 28.98, 26.97, 22.55, 14.03  
 
(4-((4-fluorobenzyl)(methyl)amino)phenyl)(2-(4-methoxyphenyl)benzofuran-3-yl)methanone 
(112) 
Compound 112 was obtained following the same procedure described for compound 110 using 102 
and CH3I as starting materials. Yield: 13.87%; yellow oil; 1H NMR δ 7.82 (d, J = 9.0 Hz, 2H), 7.74 
(d, J = 8.9 Hz, 2H), 7.54 (d, J = 8.2 Hz, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.31 (t, J = 7.2 Hz, 1H), 7.22 
(t, J = 7.4 Hz, 1H), 7.12 (dd, J = 8.4, 5.4 Hz, 2H), 7.01 (t, J = 8.6 Hz, 2H), 6.87 (d, J = 8.9 Hz, 2H), 
6.62 (d, J = 9.0 Hz, 2H), 4.58 (s, 2H), 3.82 (s, 3H), 3.09 (s, 3H); 13C NMR δ 160.35, 155.37, 153.47, 
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153.06, 133.03, 132.95, 132.50, 129.29, 129.14, 128.00, 127.92, 125.98, 124.51, 123.25, 122.43, 
121.01, 115.72, 115.51, 115.39, 113.90, 110.87, 55.27, 55.21, 38.55; 19F NMR δ -115.36 – -115.51 
(m); ES-MS m/z: 466 (M + H+), 488 (M + Na), 504 (M + K) 
 
1-fluoro-3-(prop-2-yn-1-yloxy)benzene (116)  
To a solution of 1.00g (8.92 mmol, 1eq) of 3-fluorophenol in 100 mL of acetone, 1.30g (10.70 mmol, 
1.2eq) of propargyl bromide and 1.00g of K2CO3 were added. The reaction was stirred and refluxed 
for 8h then it was filtered hot and it was concentrated under vacuum. Compound 116 was purified 
via flash chromatography: petroleum ether/ethyl acetate 9:1; 1.03g of neat compound 116 were 
obtained. Yield: 76.98%; oil; 1H NMR (200 MHz) δ 7.35-7.28 (m, 1H), 6.98-6.64 (m, 3H), 4.63 (d, J 
= 7.2 Hz, 2H), 2.58-2.48 (m, 1H) 
 
(4-(4-((3-fluorophenoxy) methyl)-1H-1,2,3-triazol-1-yl) phenyl)-(2-(4-methoxyphenyl) 
benzofuran-3-yl) methanone (113)  
To a mixture cooled to 0° C, in a double-neck flask, of 0.38g (1.11 mmol, 1eq) of 115 in 14 mL of 
CH3CN, 0.17g (1.66 mmol, 1.5eq) of tert-Butyl nitrite and 0.15g (1.33 mmol, 1.2eq) of TMSN3 were 
added and the reaction was stirred at r.t. for 2h. 0.25g (1.66 mmol, 1.5eq) of 116 and a solution of 
0.02g (0.11 mmol, 1/10eq) of CuSO4 and 0.11g (0.55 mmol, ½eq) of sodium ascorbate in 2.05 mL 
of water were added dropwise to the reaction flask, that then was stirred for 10h. The reaction was 
quenched with water and the organic compound was extracted with ethyl acetate. Compound 113 
was purified via flash chromatography: petroleum ether/ethyl acetate 3:1; 0.10g of neat compound 
113 were achieved. Yield: 17.39%; oil; 1H NMR δ 8.07 (s, 1H), 7.97 (d, J = 8.6 Hz, 2H), 7.72 (d, J = 
8.6 Hz, 2H), 7.59 (m, 4H), 7.35 (t, 1H), 7.24 (m, 2H), 6.79 (m, 3H), 6.71 (m, 2H), 5.26 (s, 2H), 3.76 
(s, 3H); 13C NMR δ 190.59, 161.05, 158.89, 153.69, 144.91, 139.60, 138.05, 131.52, 130.45, 130.29, 
128.24, 125.22, 123.95, 121.66, 121.23, 120.70, 119.86, 114.45, 113.99, 111.17, 110.31, 108.43, 
108.22, 102.79, 102.55, 62.07, 55.32; 19F NMR δ -111.11 – -111.23 (m); ES-MS m/z: 520 (M + H+), 
542 (M + Na) 
 
3-hexyl-N-(4-(2-(4-methoxyphenyl)benzofuran-3-carbonyl)phenyl)benzamide (117)  
A mixture of 0.15g (0.44 mmol, 1eq) of 115, 0.15g of K2CO3 and 0.10g (0.437 mmol, 1eq) of 4-
hexylbenzoyl chloride in toluene was stirred and refluxed for 24h. The solvent was removed under 
reduced pressure and compound 117 was purified via flash chromatography: petroleum ether/ethyl 
acetate 4:1; 0.09g of neat compound were obtained. Yield: 38.71%; yellow oil; 1H NMR δ 7.95 (s, 
1H), 7.91 (d, J = 8.8 Hz, 2H), 7.78 (d, J = 8.4 Hz, 2H), 7.69 (t, J = 8.4 Hz, 4H), 7.56 (d, J = 8.4 Hz, 
1H), 7.50 (d, J = 7.6 Hz, 1H), 7.31 (m, 4H), 6.85 (d, J = 8.8 Hz, 2H), 3.79 (s, 3H), 2.66 (t, J = 15.6 
Hz, 2H), 1.63 (t, J = 14 Hz, 2H), 1.34-1.25 (m, 6H), 0.88 (t, J = 13.6 Hz, 3H); 13C NMR δ 191.14 , 
165.79, 160.73, 157.41, 153.53, 147.80, 142.71, 133.39, 131.70, 131.38, 129.83, 128.81, 128.66, 
127.10, 124.86, 123.62, 121.95, 121.13, 119.05, 114.80, 113.96, 111.03, 55.28, 35.82, 31.62, 31.07, 
28.86, 22.55, 14.05 
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N-(4-(2-(4-methoxyphenyl)benzofuran-3-carbonyl)phenyl)-6-phenylhexanamide (118)  
Compound 118 was obtained following the same procedure described for compound 117 using 115 
and 6-phenylhexanoyl chloride as starting materials. Yield: 39.83%; yellow oil; 1H NMR δ 7.84 (d, J 
= 8.6 Hz, 2H), 7.67 (d, J = 8.8 Hz, 2H), 7.51 (td, J = 15.6, 8.0 Hz, 4H), 7.35 – 7.13 (m,7), 6.83 (d, J 
= 8.8 Hz, 2H), 3.79 (s, 3H), 2.61 (t, 2H), 2.34 (t, J = 7.5 Hz, 2H), 1.74 (dt, J = 15.3, 7.6 Hz, 2H), 1.65 
(dt, J = 15.4, 7.7 Hz, 2H), 1.46 – 1.34 (m, J = 15.3, 7.7 Hz, 2H); 13C NMR δ 191.05, 171.36, 160.72, 
157.35, 153.54, 142.38, 133.27, 131.36, 129.82, 128.66, 128.34, 128.25, 125.69, 124.86, 123.61, 
121.99, 121.12, 118.60, 114.84, 113.95, 111.03, 106.17, 55.29, 37.71, 35.64, 31.07, 28.74, 25.16 
 
4-fluoro-N-(4-(2-(4-methoxyphenyl)benzofuran-3-carbonyl)phenyl)benzamide (119)  
Compound 119 was obtained following the same procedure described for compound 117 using 115 
and 4-fluorobenzoyl chloride as starting materials. Yield: 52.45%; yellow oil; 1H NMR (200 MHz, 
CDCl3) δ 7.92-7.84 (m, 4H), 7.69-7.63 (m, 4H), 7.58-7.48 (m, 2H), 7.34 (t, J = 9.2 Hz, 1H), 7.26-7.11 
(m, 3H), 6.86 (d, J = 9.2 Hz, 2H), 3.79 (s, 3H); 13C NMR 191.04, 164.58, 163.83, 160.78, 157.55, 
153.58, 142.24, 133.78, 131.41, 130.61, 129.90, 129.44, 128.63, 124.92, 123.66, 121.98, 121.14, 
119.11, 116.10, 115.88, 113.98, 111.06, 55.29; ES-MS m/z: 466 (M + H+), 488 (M + Na) 
 
 (E)-3-(3,5-difluorophenyl)- N-(4-(2- (4-methoxyphenyl) benzofuran-3-carbonyl)phenyl) 
acrylamide (120)  
Compound 120 was obtained following the same procedure described for compound 117 using 115 
and 3,5-difluoricinnamic acid, previously refluxed with 3 mL of SOCl2 for 5h, as starting materials. 
Yield: 17.98%; yellow oil; 1H NMR δ 7.88 (d, J = 8.6 Hz, 2H), 7.73 – 7.59 (m, J = 17.9, 7.3 Hz, 5H), 
7.55 (d, J = 8.2 Hz, 1H), 7.49 (d, J = 7.7 Hz, 1H), 7.33 (t, J = 7.2 Hz, 1H), 7.22 (t, J = 7.4 Hz, 1H), 
7.02 (d, J = 5.9 Hz, 2H), 6.83 (d, J = 8.8 Hz, 3H), 6.53 (d, J = 15.4 Hz, 1H), 3.78 (s, 3H); 13C NMR δ 
191.07, 164.61, 163.00, 162.04, 161.85, 160.78, 157.57, 153.58, 142.22, 133.73, 131.41, 129.90, 
128.63, 124.93, 123.67, 122.90, 121.97, 121.14, 118.98, 114.78, 113.97, 111.07, 110.76, 110.50, 
55.31 
 
N-(4-(2-(4-methoxyphenyl)benzofuran-3-carbonyl)phenyl)octanamide (121)  
Compound 121 was obtained following the same procedure described for compound 117 using 115 
and heptanoyl chloride as starting materials. Yield: 30.11%; oil; 1H NMR δ 7.86 (d, J = 8.8 Hz, 2H), 
7.68 (d, J = 8.4 Hz, 2H), 7.53 (m, 4H), 7.32-7.22 (m, 2H), 6.85(d, J = 8.8 Hz, 2H), 3.80 (s, 3H), 2.36 
(t, J = 15.2 Hz, 2H), 1.34-1.29 (m, 6H), 0.88 (t, J = 13.6 Hz, 3H); 13C NMR δ 191.01, 171.48, 160.72, 
157.33, 153.54, 142.38, 133.35, 131.36, 129.83, 128.66, 124.84, 123.59, 122.01, 121.13, 118.58, 
114.82, 113.95, 111.01, 55.29, 37.89, 31.48, 28.85, 25.31, 22.43, 13.98 
 
2-(3,5-difluorophenyl)-N-(4-(2-(4-methoxyphenyl)benzofuran-3-carbonyl)phenyl)acetamide 
(122)  
0.17g (0.82 mmol, 1.4eq) of DCC were added to a solution of 0.13g (0.76 mmol, 1.3 eq) of 2-(3,5-
difluorophenyl)acetic acid in 10 mL of anhydrous DCM, under nitrogen atmosphere. The reaction 
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was cooled to 0° C, then 0.20g (0.58 mmol, 1eq) of 115 were added to the flask and the reaction 
was stirred at r.t. for 4h. The DCU was then filtrated and the resulting solution was concentrated 
under reduced pressure. The organic compound was purified via flash chromatography: petroleum 
ether/ethyl acetate 7:3. 0.10g of neat compound 122 were obtained. Yield: 34.64; yellow oil; 1H NMR 
(200 MHz, CDCl3) δ 7.84 (d, J = 8.4 Hz, 2H), 7.66 (d, J = 8.8 Hz, 2H), 7.55 (d, J = 8 Hz, 1H), 7.48 
(d, J = 8 Hz, 3H), 7.34-7.20 (m, 3H), 6.78-6.76 (m, 4H), 3.79 (s, 3H), 3.69 (s, 2H); 13C NMR  190.98, 
170.69, 160.78, 157.59, 153.57, 141.69 ,131.32, 129.91, 128.59, 124.92, 123.66, 121.95, 121.12, 
118.81, 114.72, 113.96, 112.55, 112.36, 112.29, 111.06, 103.60, 103.35, 55.29, 44.22; ES-MS m/z: 
498(M + H+), 520 (M + Na) 
 
3-(3,4-difluorophenyl)-N-(4- (2-(4-methoxyphenyl) benzofuran-3-carbonyl)phenyl) 
propanamide (123)  
Compound 123 was obtained following the same procedure described for compound 122 using 115 
and 3-(3,4-difluorophenyl)propanoic acid as starting materials. Yield: 20.24%; oil; 1H NMR δ 7.84 
(d, J = 8.4 Hz, 2H), 7.66 (d, J = 9.2 Hz, 2H), 7.56 (d, J = 8 Hz, 1H), 7.48 (d, J = 8.4 Hz, 2H), 7.34-
7.31 (m, 2H), 7.26-7.22 (m, 2H), 7.06-7.01 (m, 2H), 6.84 (d, J = 9.2 Hz, 2H), 3.79 (s, 3H), 2.99 (t, J 
= 14.8 Hz, 2H), 2.63 (d, J = 14.8 Hz, 2H); 13C NMR 191.03, 160.75, 157.46, 155.24, 155.10, 153.48, 
141.60, 131.34, 129.86, 128.62, 124.88, 124.24, 124.19, 123.62, 121.99, 121.11, 118.68, 117.34, 
117.23, 117.18, 117.06, 114.74, 113.94, 111.03, 55.28, 30.19, 29.66; ES-MS m/z: 534 (M + Na) 
 
(2-(4-methoxyphenyl)benzofuran-3-yl)(phenyl)methanone (131)  
Under nitrogen atmosphere, a solution of 0.50g (2.23 mmol, 1eq) of 2-(4-methoxyphenyl)benzofuran 
in 10 mL of anhydrous DCM and 0.38g (2.68 mmol, 1.2eq) of benzoylchloride was cooled to 0° C; 
0.70g (2.68 mmol, 1.2eq) of SnCl4 were added dropwise to the flask and the reaction was stirred for 
12h. The reaction was quenched with ice; the organic layer was collected and it was washed with 
water. Compound 131 was purified with flash chromatography: petroleum ether/ethyl acetate 4:1. 
0.65g of neat compound were obtained. Yield: 88.79%; oil; 1H NMR δ 7.84 (d, J = 6.8 Hz, 2H), 7.65 
(d, J = 9.2 Hz, 2H), 7.56-7.46 (m, 3H), 7.33 (t, J = 15.6 Hz, 3H), 7.23 (t, J = 12.8 Hz, 1H), 6.81 (t, J 
= 8.4 Hz, 2H), 3.77 (s, 3H) 
 
(2-(4-hydroxyphenyl)benzofuran-3-yl)-(phenyl)methanone (132)  
In a two-neck flask, under nitrogen atmosphere, 0.61g (1.86 mmol, 1eq) of 131 were dissolved in 
20 mL of anhydrous DCM and the tempereature was allowed to 0° C. 3.75g (2.56 mL, solution 1M 
in DCM) of BBr3 were added dropwise and the reaction was stirred at r.t. overnight; then it was 
quenched with ice and the organic layer was washed with water. 0.58g of neat compound 132 were 
obtained and it was used without any further purification for next reactions. Yield: 99.32%; oil; 1H 
NMR δ 7.84 (d, J = 7.1 Hz, 2H), 7.61 (d, J = 8.8 Hz, 2H), 7.57 (d, J = 8.2 Hz, 1H), 7.51 (t, J = 7.6 
Hz, 2H), 7.35 (t, J = 7.7 Hz, 3H), 7.26 – 7-24 (m, 1H), 6.76 (d, J = 8.8 Hz, 2H) 
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Phenyl(2-(4-(prop-2-yn-1-yloxy)phenyl)benzofuran-3-yl)methanone (133)  
To a solution of 0.57g (1.81 mmol, 1eq) of 132 in 30 mL of acetone, 0.26g (2.18 mmol, 1.2eq) of 
propargyl bromide and 0.57g of anhydrous K2CO3 were added and the reaction was refluxed for 8h. 
The solvent was removed and the organic compound was cristallized with petroleum ether. 0.62g of 
133 were obtained. The crude was used for the next reactions without any further purification. Yield: 
97.04%; yellow oil; 1H NMR δ 7.85 (dd, J = 8.2, 1.1 Hz, 2H), 7.68 (d, J = 8.9 Hz, 2H), 7.57 (d, J = 
8.2 Hz, 1H), 7.51 (t, J = 7.3 Hz, 2H), 7.35 (t, J = 7.8 Hz, 3H), 7.26 – 7.22 (m, J = 7.3 Hz, 1H), 6.91 
(d, J = 8.9 Hz, 2H), 4.69 (d, J = 2.4 Hz, 2H), 2.53 (t, J = 2.4 Hz, 1H) 
 
(2-(4-((1-(4-fluorobenzyl)- 1H-1,2,3-triazol-4-yl)methoxy) phenyl)benzofuran-3-yl)(phenyl) 
methanone (124)  
A solution of 0.01g (0.04 mmol, 1/10eq) of CuSO4 and 0.04g (0.21 mmol, ½ eq) of sodium ascorbate 
in 1 mL of water was stirred for 5min, then it was added dropwise to a mixture of 0.15g (0.43 mmol, 
1eq) of 133, 0.08g (0.55 mmol, 1.3eq) of 134 and 0.01g (0.04 mmol, 1/10eq) of TEA in 5 mL of 
DMSO. The reaction was stirred at r.t for 12 h, then it was queched with 10 mL of a saturated solution 
of NH4Cl and the organic compound was extracted with ethyl acetate. Compound 124 was purified 
via flash chromatography: petroleum ether/ethyl acetate 7:3. 0.12g of neat compound were 
obtained. Yield: 56.00%; M.P.: 183.6° C; 1H NMR δ 7.81 (d, J = 7.5 Hz, 2H), 7.63 (d, J = 8.7 Hz, 
2H), 7.54 (d, J = 10.4 Hz, 2H), 7.51 – 7.44 (m, 2H), 7.32 (t, J = 7.7 Hz, 3H), 7.24 (m, 3H), 7.05 (t, J 
= 8.5 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 5.49 (s, 2H), 5.15 (s, 2H); 13C NMR δ 192.23, 163.93, 162.25, 
161.47, 159.14, 157.70, 153.41, 137.74, 132.94, 129.88, 129.80, 129.60, 128.34, 128.25, 124.86, 
123.57, 122.40, 121.16, 116.10, 115.88, 114.93, 114.48, 110.91, 61.80, 53.34; 19F NMR δ -112.45 
– -112.65 (m). 
 
(2-(4-((1-(3,5-difluorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)benzofuran-3-
yl)(phenyl)methanone (125)  
Compound 125 was obtained following the same procedure described for compound 124 using 133 
and 135 as starting materials. Yield: 35.69%; yellow oil; 1H NMR δ 7.84 (d, J = 7.2 Hz, 2H), 7.67 (d, 
J = 8.8 Hz, 2H), 7.56 (m, 2H), 7.49 (m, 2H), 7.34 (t, J = 15.6 Hz, 3H), 7.24 (t, 1H), 6.90 (d, J = 9.2 
Hz, 2H), 6.78 (m, 3H), 5.50 (s, 2H), 5.19 (s, 2H); 13C NMR δ 192.36, 164,60, 162,11, 159.26, 157.81, 
153.59, 144.49, 138.08, 137.94, 133.09, 130.06, 129.78, 129.72, 128.41, 125.02, 123.73, 122.81, 
121.34, 115.13, 114.63, 111.07, 11.91, 104.36, 61.96, 53.13; ES-MS m/z: 544 (M + Na) 
 
(2-(4-((1-(2,4-difluorobenzyl)-1H-1,2,3-triazol-4-yl) methoxy)phenyl)benzofuran-3-yl)(phenyl) 
methanone (126)  
Compound 126 was obtained following the same procedure described for compound 124 using 133 
and 136 as starting materials. Yield: 58.57%; M.P.: 152-153° C; 1H NMR δ 7.81 (d, J = 7.3 Hz, 2H), 
7.65 – 7.57 (m, 3H), 7.53 (d, J = 8.2 Hz, 1H), 7.47 (t, J = 8.2 Hz, 2H), 7.31 (t, J = 7.7 Hz, 3H), 7.28 
– 7.18 (m, 2H), 6.91 – 6.78 (m, 4H), 5.51 (s, 2H), 5.13 (s, 2H); 13C NMR δ 192.29, 159.25, 157.81, 
153.52, 144.05, 137.86, 133.02, 131.57, 130.00, 129.71, 128.47, 128.34, 124.96, 123.66, 122.74, 
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122.51, 121.28, 115.04, 114.57, 112.26, 112.01, 111.00, 104.61, 104.36, 104.11, 61.87, 47.16; 19F 
NMR δ -107.46 – -107.68 (m), -113.57 (q, J = 8.7 Hz) 
 
(2-(4-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)benzofuran-3-yl)(phenyl) 
methanone (127)  
Compound 127 was obtained following the same procedure described for compound 124 using 133 
and 137 as starting materials. Yield: 22.79%; oil; 1H NMR δ 7.82 (d, J = 7.3 Hz, 2H), 7.63 (d, J = 8.9 
Hz, 2H), 7.55 (d, J = 8.2 Hz, 1H), 7.50 (d, J = 7.6 Hz, 1H), 7.47 (t, J = 3.6 Hz, 2H), 7.32 (t, J = 7.6 
Hz, 3H), 7.27 – 7.19 (m, J = 12.2, 5.8 Hz, 3H), 6.88 (t, J = 8.2 Hz, 4H), 5.45 (s, 2H), 5.14 (s, 2H), 
3.79 (s, 3H); 13C NMR δ 192.34, 181.40, 159.34, 157.91, 156.55, 153.56, 143.87, 137.90, 133.02, 
130.03, 129.74, 129.69, 128.51, 128.36, 126.27, 124.96, 123.69, 122.49, 122.37, 121.32, 115.05, 
114.61, 114.48, 111.02, 62.01, 55.29, 53.79; ES-MS m/z: 516 (M + H+) 
 
(2-(4-((1-(3-fluoro-4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)benzofuran-3-yl) 
(phenyl) methanone (128)  
Compound 128 was obtained following the same procedure described for compound 124 using 133 
and 138 as starting materials. Yield: 49.75%; M.P.: 150-151° C; 1H NMR δ 7.96 (s, 1H), 7.84 (d, 
2H), 7.68 (d, J = 8.9 Hz, 2H), 7.59 – 7.42 (m, 5H), 7.35 (t, J = 7.7 Hz, 3H), 7.26 (t, 1H), 7.08 (t, J = 
8.8 Hz, 1H), 6.94 (d, J = 8.9 Hz, 2H), 5.27 (s, 2H), 3.95 (s, 3H); 13C NMR δ 192.35, 159.22, 157.72, 
153.58, 153.50, 137.92, 133.06, 130.10, 129.77, 128.51, 128.39, 125.02, 123.72, 122.68, 121.34, 
120.99, 116.41, 116.37, 115.14, 114.64, 113.72, 113.68, 111.06, 109.80, 109.57, 61.89, 56.50; 19F 
NMR δ -131.24 (dd, J = 15.0, 5.7 Hz) 
 
(2-(4-((1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)benzofuran-3-
yl)(phenyl)methanone (129)  
Compound 129 was obtained following the same procedure described for compound 124 using 133 
and 139 as starting materials. Yield: 57.55%; M.P.: 151-152° C; 1H NMR δ 8.03 (s, 1H), 7.81 (d, J = 
7.6 Hz, 2H), 7.65 (d, J = 8.6 Hz, 2H), 7.56 – 7.41 (m, 6H), 7.31 (t, J = 7.6 Hz, 3H), 7.22 (dd, J = 13.6, 
6.1 Hz, 1H), 7.12 (t, J = 7.6 Hz, 1H), 6.90 (d, J = 8.6 Hz, 2H), 5.23 (s, 2H); 13C NMR δ 192.35, 
164.26, 161.79, 159.19, 157.80, 153.57, 144.63, 137.90, 133.08, 131.27, 131.18, 130.10, 129.77, 
128.49, 128.41, 125.04, 123.73, 122.68, 121.33, 120.93, 115.82, 114.63, 111.07, 108.43, 108.17, 
61.81; 19F NMR δ -109.52 (td, J = 8.5, 5.6 Hz); ES-MS m/z: 512 (M + Na) 
 
(2-(4-((1-(3,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)benzofuran-3-
yl)(phenyl)methanone (130)  
Compound 130 was obtained following the same procedure described for compound 124 using 133 
and 140 as starting materials. Yield: 63.97%; M.P.: 183.6° C; 1H NMR δ 7.98 (s, 1H), 7.83 (d, J = 
7.2 Hz, 2H), 7.71 – 7.61 (m, 3H), 7.54 (d, J = 8.2 Hz, 1H), 7.51 – 7.43 (m, J = 8.1 Hz, 3H), 7.32 (dd, 
J = 16.6, 8.7 Hz, 4H), 7.23 – 7.18 (m, J = 7.6 Hz, 1H), 6.92 (d, J = 8.9 Hz, 2H), 5.27 (s, 2H); 13C 
NMR δ 192.34, 159.13, 157.71, 153.57, 137.92, 133.09, 130.10, 129.78, 128.48, 128.39, 125.03, 
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123.72, 122.79, 121.34, 118.51, 118.34, 116.54, 116.50, 116.47, 116.43, 115.19, 114.63, 111.06, 
110.84, 110.63, 61.81; 19F NMR δ -133.08 – -133.26 (m), -135.80 – -136.02 (m) 
 
1-(azidomethyl)-4-fluorobenzene (134)  
To a solution of 0.14g (0.72 mmol, 1eq) of 4-fluorobenzyl bromide in 3.8 mL of anhydrous DMF, 
0.09g (1.44 mmol, 2eq) of NaN3 were added and the reaction was stirred at 80° C for 4h. The 
reaction was quenched with water and the orgnaic compound was extracted with ether. 0.10g of 
neat compound 134 were obtained and it was used crude for the next reaction. Yield: 91.98%; oil. 
 
1-(azidomethyl)-3,5-difluorobenzene (135)  
A solution of 0.36g (1.74 mmol) of 3,5-difluorobenzyl bromide and 0.13g (1.91 mmol, 1.1eq) of NaN3 
in 5 mL of DMSO was stirred at r.t. for 72h. The reaction was quenched with water and the organic 
compound was extrated with ethyl acetate. 0.24g of neat compound 135 were obtained and it was 
used crude for the next reaction. Yield: 81.71%; oil; 1H NMR δ 6.86 (d, J = 12 Hz, 2H), 6.78(t, J = 
11.2 Hz, 1H), 4.35 (s, 2H) 
 
1-(azidomethyl)-2,4-difluorobenzene (136 
Compound 136 was obtained following the same procedure described for compound 134 using 2,4-
difluorobenzyl bromide as starting material. Yield: 90.40%; oil; 1H NMR δ 6.95 (t, J = 8.8 Hz, 1H), 
6.83 – 6.75 (m, 2H), 3.89 (s, 2H); 19F NMR δ -131.72 – -131.89 (m) 
 
1-(azidomethyl)-4-methoxybenzene (137 
Compound 137 was obtained following the same procedure described for compound 134 using 4-
methoxybenzyl bromide as starting material. Yield: 59.64%; oil; 
 
4-azido-2-fluoro-1-methoxybenzene (138) 
A mixture of 0.11g (0.77 mmol) of 3-fluoro-4-methoxy aniline in 2 mL of water and 0.6 mL of HCl 
37% was cooled to 0° C, then a solution of 0.05g (0.77 mmol) of NaNO2 in 0.33 mL of water was 
added dropwise to the reaction. The suspension was stirred for 10 min, then 0.05g (0.93 mmol) of 
NaN3 were added in portions to the reaction flask that was finally stirred for 90min. The organic 
compound was extracted with ethyl acetate and washed with brine. 0.08g of neat compound 136 
were obtained and it was used crude for the next reaction. Yield: 63.03%; oil; 1H NMR δ 7.28 – 7.18 
(m, 1H), 6.84 – 6.72 (m, 2H), 4.27 (s, 3H); 19F NMR δ 109.26 (dt, J = 15.9, 8.1 Hz), -113.64 (q, J = 
8.8 Hz) 
 
1-azido-3-fluorobenzene (139) 
Compound 139 was obtained following the same procedure described for compound 138 using 3-
fluoroaniline as starting material. Yield: 76.13%; oil; 1H NMR δ 7.33-7.26 (m, 1H), 6.88-6.72 (m, 3H) 
 
4-azido-1,2-difluorobenzene (140) 
134 
 
Compound 140 was obtained following the same procedure described for compound 138 using 3,4-
difluoroaniline as starting material. Yield: 67.29%; oil;  
 
PROJECT 3 
 
Ethyl-3-methyl-2,4-dioxo-4-(thiophen-2-yl)butanoate (134)  
Under a nitrogen atmosphere, 0.86g (37.50 mmol) of sodium were added in small portions to 25mL 
of dry ethanol and stirred at room temperature until all the sodium was dissolved. 7.6 mL (56.30 
mmol) of diethyl oxalate were then added, followed by dropwise addition of a solution of 2.63 g 
(18.65 mmol) in dry ethanol (26 mL) commercially available of 1-(thiophen-2-yl) propan-1-one 2. 
The mixture was stirred at room temperature for 18 h, than slowly poured into a mixture of ice and 
aqueous 1 N HCl. The resulting mixture was extracted with Et2O, the organic layers were dried over 
MgSO4, filtered and the solvent was evaporated under reduced pressure. The crude product was 
purified by flash chromatography: hexane/EtOAc 8:2, to give compound 3.8g 134 as a white solid. 
Yield: 85% Rf 0.57 (Hexane/EtOAc 8:2); 1H NMR δ: 7.51 (d, 1H, J = 8.4 Hz), 7.37 (d, 1H, J = 8.4 
Hz), 7.37 (t, 1H, J = 8.4 Hz), 4.70 (q, 1H, J = 7.0 Hz), 4.25 (q, 2H, J = 7.1 Hz), 1.45 (d, 3H, J = 7.0 
Hz), 1.24 (t, 3H, J = 7.1 Hz); 13C NMR δ: 190.1, 187.5, 160.4, 142.4, 135.3, 133.5, 128.6, 63.1, 52.6, 
14.0, 13.4; MS (ESI): 241.0 (M + H+), 263.0 (M+Na)  
 
ethyl 1-(2,4-dichlorophenyl)-4-methyl-5-(thiophen-2-yl)-1H-pyrazole-3-carboxylate(135)  
4.63g (20.51 mmol) of the α,-diketoester 134 were dissolved in 36mL of absolute EtOH; 4.38g 
(20.51 mmol) of 2,4-dichlorophenylhydrazine hydro-chloride were added in one portion, then the 
mixture was refluxed overnight. The solvent was removed under reduced pressured and the crude 
product was purified by flash chromatography: hexane/EtOAc 8:2. A final recrystallization 
(Hexane/EtOAc 7:3) gave 2.01g of compound 135 as a white solid. Yield: 32%. Rf 0.30 
(Hexane/EtOAc 8:2); 1H NMR δ: 7.46 (d, 1H, J = 2.2 Hz), 7.40 (d, 1H, J = 8.5 Hz), 7.38 (dd, 1H, J = 
1.2, 5.1 Hz), 7.33 (dd, 1H, J = 2.2, 8.5 Hz), 7.02 (dd, 1H, J = 3.6, 5.1 Hz), 6.92 (dd, 1H, J = 1.2, 3.6 
Hz), 4.47 (q, 2H, J = 7.1 Hz), 2.46 (s, 3H), 1.45 (t, 3H, J = 7.1 Hz); 13C NMR δ: 162.7, 142.9, 137.8, 
136.3, 136.0, 133.9, 131.0, 130.0, 128.9, 128.6, 127.8, 127.7, 127.2, 120.0, 61.0, 14.5, 9.9; MS 
(ESI): 381.0 (M + H+) 
 
ethyl 5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylate 
(136)  
2.21g (1.31 mmol) of compound 135 were dissolved in 4.5mL of acetonitrile and the solution was 
cooled to 0° C. 0.39g (2.23 mmol) of NBS were added in small portions, than the mixture was stirred 
overnight at r.t. A saturated solution of Na2S2O3 (5 mL) was added and the solvent was removed 
under reduced pressure. The resulting mixture was extracted with EtOAc, the organic layers were 
washed with water, brine, dried over MgSO4, filtered and the solvent was evaporated under reduced 
pressure. The crude product was purified by flash chromatography: hexane/EtOAc 8:2 to give 0.51g 
of compound 5 as a pale yellow solid. Yield: 83%; Rf 0.38 (Hexane/EtOAc 8:2); 1H NMR δ: 7.45 (dd, 
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1H, J = 0.4, 2.0 Hz), 7.35 (d, 1H, J = 0.4 Hz), 7.33 (d, 1H, J = 2.0 Hz), 6.94 (d, 1H, J = 3.9 Hz), 6.63 
(d, 1H, J = 3.9 Hz), 4.43 (q, 2H, J = 7.1 Hz), 2.41 (s, 3H), 1.40 (t, 3H, J = 7.1 Hz); 13C NMR δ: 162.6, 
142.8, 137.0, 136.7, 135.8, 134.1, 133.9, 131.0, 130.3, 130.3, 129.4, 128.0, 120.5, 115.1, 61.2, 14.6, 
10.1; MS (ESI): 458.9 (M + H+) 
 
5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbaldehyde (137) 
Ester 5 (0.2 g, 0.43 mmol) was dissolved in anhydrous dichloromethane (2 mL), and the mixture 
was cooled to –78°C. DIBAL-H (0.5 mL) was added drop wise over 45 min and the mixture was 
stirred for 4h at –78°C. MeOH (0.5 mL) was added and the solvent was removed under reduced 
pressure. The resulting mixture was extracted with EtOAc, the organic layers were washed with 
brine, dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. The crude 
product was purified by flash chromatography (Hexane/ EtOAc 5:5) to give aldehyde 6 (0.45 g, 55%) 
as a white solid. Rf  0.50 (Hexane/EtOAc 5:5); 1H NMR δ: 10.0 (s, 1H), 7.45 (d, 1H, J = 2.0), 7.31 
(d, 1H, J = 2.0), 7.28-7.30 (m, 1H), 6,90 (d, 1H, J =3.9), , 6.58 (d, 1H, J = 3.5), 2.36 (s, 1H); MS 
(ESI): 414 (M + H+)  
 
5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-3-ethynyl-4-methyl-1H-pyrazole (138) 
To an ice cold solution of 0.45g (1.09 mmol) of aldehyde 137 in 0.5 mL of MeO, 0.11g (0.86 mmol) 
of K2CO3 and 0.09g (0.52 mmol) of dimethyl 1-diazo-2-oxopropylphosphonate were added. After 5 
minutes the ice bath was removed and the reaction was allowed to warm to r.t. and stirred for 
additional 12 hours. Rochelle salt and 2 mL of Et2O were added. The organic layers were washed 
with brine, dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. The 
crude product was purified by flash chromatography: hexane/ EtOAc 7:3 to give 0.15 g of the alkyne 
138 as a withe solid. Yield: 55%; Rf 0.82 (Hexane/EtOAc 7:3); 1H NMR δ 7.45 (d, 1H, J = 2.0Hz), 
7.35 (d, 1H, J = 8.4 Hz), 7.32 (dd, 1H, J = 2.0, 8.4 Hz), 6.94 (d, 1H, J = 3.9 Hz), 6.63 (d, 1H, J = 3.9 
Hz), 3.21 (s, 1H), 2.18(s, 3H); 13C NMR δ: 136.4, 135.3, 135.8, 133.7, 130.9, 130.7, 130.2, 130.1, 
128.4, 127.9, 120.1, 114.5, 81.4, 75.0, 9.4; MS (ESI): 410 (M + H+) 
 
5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-3-(iodoethynyl)-4-methyl-1H-pyrazole (140) 
To a solution of 0.59g (1.432 mmol, 1 eq) of alkyne 138 in 4 mL THF, 0.02g (0.072 mmol, 0.05 eq) 
of CuI and 0.34g (1.575 mmol, 1.1 eq) of 4-iodomorpholine (139)were added. The reaction mixture 
was stirred at room temperature for 1 hour. The mixture was filtered on a neutral alumina pad and 
the solvent was evaporated under reduced pressure. 0.57g of the iodinated derivative 140 was 
obtained as a yellow oil and was used without further purification. Yield: 74%; Rf 0.84 
(Hexane/EtOAc 7:3); 1H NMR δ 7.38 (dd, 1H, J = 1.7, 0.8 Hz), 7.23-7.25 (m, 1H), 6.88 (s, 1H), 6.83 
(d, 1H, J = 3.9 Hz), 6.51 (d, 1H, J = 3.9 Hz), 2.16 (s, 3H); MS (ESI): 536 (M + H+) 
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4-(5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-1-(4- 
fluorobutyl)- 5-iodo- 1H-1,2,3-triazole (131) 
To a solution of 0.20g (0.37 mmol) propargyl iodide 140 in 5 mL THF, 0.40g (0.37 mmol) of 1-azido-
4-fluorobutane (141 a), 0.04g(0.19 mmol) of CuI and 10 mL (0.74 mmol) of TEA were added. The 
reaction was stirred at r.t. for 72 hours, then quenched with 10 mL of a 10% aqueous solution of 
NH4OH and the solvent was removed under reduced pressure. The crude product was diluted with 
Et2O, washed with water, dried over MgSO4, filtered and the solvent was evaporated under reduced 
pressure. The crude product was purified by flash chromatography (Hexane/ EtOAc 4:1) to give 
0.10g of the triazole 131 as a white solid. Yield: 42%; Rf  0.52 (Hexane/EtOAc 4:1); 1H NMR δ 7.50 
(d, 1H, J = 1.9 Hz), 7.30-7.38 (m, 2H), 6.96 (d, 1H, J = 3.9 Hz), 6.66 (d, 1H, J = 3.9 Hz), 4.55 (m, 
3H), 4.44 (t, 1H, J = 5.8 Hz), 2.41 (s, 3H), 2.05-2.19 (m, 2H), 1.79-1.87 (m, 1H), 1.70-1.79 (m, 1H); 
13C NMR δ: 145.1, 143.1, 136.0, 133.9, 131.2, 130.28, 130.31, 128.7, 127.9, 116.9, 114.4, 84.0, 
82.3, 50.3, 27.4, 27.2, 26.0, 10.1;  19F NMR: -219.3 (s, 1F); MS (ESI): 656 (M + H+) 
 
4-(5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-1-(4-
fluorobenzyl)-5-iodo-1H-1,2,3-triazole (132) 
Compound 132 was obtained following the same procedure described for compound 131 using 141 
b as starting material. Yield: 46.86%; 1H NMR δ 7.53 – 7.49 (m, 1H), 7.39 – 7.31 (m, 4H), 7.08 – 
7.02 (m, 2H), 6.98 (d, J = 3.9 Hz, 1H), 6.68 (d, J = 3.9 Hz, 1H), 5.67 (s, 2H), 2.44 (s, 3H); 13C NMR 
δ: 163.94, 161.48, 145.55, 143.02, 136.13, 136.00, 133.85, 131.17, 130.85, 130.26, 130.13, 129.91, 
129.83, 128.68, 127.86, 116.87, 115.98, 115.76, 114.42, 53.63, 10.12; 19F NMR δ: -113.05 (s); MS 
(ESI): 690 (M + H+) 
 
4-(5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-1-(but-3-en-1-
yl)-5-iodo-1H-1,2,3-triazole (133) 
Compound 133 was obtained following the same procedure described for compound 131 using 141 
c as starting material. Yield: 50.70%; 1H NMR δ 7.43 (d, J = 2.1 Hz, 1H), 7.32 – 7.23 (m, 2H), 6.88 
(d, J = 3.9 Hz, 1H), 6.58 (d, J = 3.9 Hz, 1H), 5.75 (dd, J = 17.1, 10.2 Hz, 1H), 5.11 – 4.98 (m, 2H), 
4.50 – 4.38 (m, 2H), 2.65 (dd, J = 14.6, 7.0 Hz, 2H), 2.34 (s, 3H); 13C NMR δ: 144.94, 143.20, 136.19, 
135.96, 135.90, 133.87, 132.91, 131.26, 130.90, 130.27, 130.12, 128.71, 128.64, 127.85, 118.45, 
116.88, 114.37, 50.16, 34.09, 10.10; MS (ESI): 636 (M + H+) 
 
 
4-(5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-1-(but-3-en-1-
yl)-1H-1,2,3-triazole (134) 
Compound 134 was obtained following the same procedure described for compound 131 using 141 
c as starting material. Yield: 52.82%; 1H NMR δ 7.86 (s, 1H), 7.41 (d, J = 2.0 Hz, 1H), 7.32 – 7.24 
(m, 2H), 6.88 (d, J = 3.9 Hz, 1H), 6.59 (d, J = 3.9 Hz, 1H), 5.78 – 5.63 (m, 1H), 5.07 – 4.99 (m, 2H), 
4.41 (t, J = 7.1 Hz, 2H), 2.63 (q, J = 7.0 Hz, 2H), 2.46 (s, 3H); 13C NMR δ: 144.01, 142.08, 136.33, 
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136.12, 133.96, 133.08, 131.11, 131.05, 130.23, 130.10, 128.73, 128.69, 127.93, 121.22, 118.54, 
115.73, 114.35, 49.74, 34.36, 10.11; MS (ESI): 508 (M + H+) 
 
4-iodomorpholine (139) 
To a solution of 4g (31.5 mmol) of iodine in 63 mL of MeOH, 2.75 mL (31.5 mmol) morpholine were 
added dropwise and the mixture was stirred for 1 hour. The precipitate formed was collected by 
filtration, dried under vacuum and used crude, without further purification. Rf 0.32 (DCM/MeOH 
95:5); 1H NMR δ 3.69-3.77 (m, 2H), 2.89-3.00 (m, 2H). 
 
1-azido-4-fluorobutane (141 a) 
To a stirred solution of 0.50g (2.61 mmol) of 1-bromo-4-fluorobutane in 40mL of water/acetone (1:4), 
0.25g (3.96 mmol) of NaN3 were added. The resulting suspension was stirred at r.t. for 24h. The 
mixture was extracted with DCM, dried over MgSO4, filtered and the solvent was evaporated under 
reduced pressure. 0.30g of 141 a were obtained as a yellow oil and was used without further 
purification. Yield: 76% 1H NMR δ 4.22 (s, 2H), 6.95-7.01 (m, 2H), 7.19-7.23 (m, 2H) 
 
1-(azidomethyl)-4-fluorobenzene (141 b) 
Compound 141 b was obtained following the same procedure described for compound 141 a using 
4-fluoro benzylbromide as starting material.141 b was used without further purification. 
 
4-azidobut-1-ene (141 c) 
To a solution of 0.10g (0.741 mmol, 1eq) of 4-bromo-1-butene dissolved in 0.5 mL of DMF, 0.07g 
(1.111 mmol, 1.5eq) of NaN3 were added. The resulting suspension was stirred at r.t. for 24h. The 
reaction was quenched with water, then the organic compound was extracted with Et2O. 141 c was 
used without any further purification and the solvent was not removed; the solution was directly 
added to next reactions. 
 
PROJECT 4 
 
(E)-5-(3-bromophenyl)pent-4-enoic acid (145) 
20.03g (47.19 mmol, 1.1eq) of (4-carboxybutyl) triphenylphosponium bromide were dissolved in 20 
mL of dry DMSO. 10.11g (90.1 mmol, 2.1eq) of tBuOK were added to the solution and it was stirred 
for 30min. Only when all was dissolved, 7.94 mmol (42.9 mmol, 1eq) of 3-bromobenzaldehyde were 
added then the solution was stirred overnight at r.t. The reaction was quenched with water and 
extracted with DMC. The aqueous phase was acidified with conc. HCl and extracted with DCM. The 
organic layer was washed with water, dried and concentrated. 145 was purified via flash 
chromatography hexane/ethyl acetate 9:1. 4.95g of neat compound 145 were obtained. Compound 
was obtained in a mixture of E/Z (72% of E and 28% Z); Yield: 45.43% Compare with spectra 
previously reported in literature. 
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5-(3-bromophenyl)pentanoic acid (146) 
To a solution of 1.20g (4.725 mmol) of 145 dissolved in 20 mL of ethyl acetate, 0.10g (0.945 mmol) 
were added. The suspension was stirred for 24h at r.t. then it was filtered and concentrated. 1.20g 
of neat compound 146 were obtained. Yield: 98%; 1H NMR δ: 7.46 (m, 2H), 7.18 – 7.05 (m, 2H), 
2.57 (dd, J = 22.0, 14.9 Hz, 2H), 2.36 (t, J = 6.9 Hz, 2H), 1.66 (dt, J = 7.3, 3.6 Hz, 4H) 
 
2-bromo-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-one (147) 
A solution of 6.49g (25.46 mmol, 1eq) of 146 dissolved in 36mL of anhydrous DCM was cooled at 
0° C then, 2.18mL (25.46 mmol) of COCl2 in 0.5mL of DMF were added. The reaction was stirred at 
r.t. for 2h, then 15,65g (25.46 mmol) of AlCl3 in 5mL of DCM were added to the solution. The reaction 
was stirred overnight then it was extracted with DCM. The compound was purified via flash 
chromatography: hexane/ ethyl acetate 9:1. 3.65g of neat compound 147 were obtained. Yield: 
60.24%; 1H NMR δ: 7.59 (d, J = 8.3 Hz, 1H), 7.44 (dd, J = 8.3, 1.8 Hz, 1H), 7.38 (d, J = 1.9 Hz, 1H), 
2.94 – 2.83 (m, 2H), 2.72 (dd, J = 6.9, 5.1 Hz, 2H), 1.93 – 1.75 (m, 4H) 
 
ethyl 2-(2-bromo-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-yl)-2-oxoacetate (148) 
0.69g (30.20 mmol, 2eq) of Na were dissolved in 70 mL of EtOH under nitrogen atmosphere then 
2.20g (15.126 mmol, 1 eq) of diethyloxalate were added, subsequently 3.60g (15.126, 1 eq) of 147 
were added dropwise. The reaction was stirred overnight and then was quenched with HCl 1N. The 
organic compound was extracted with DCM and the solvent was removed under reduced pressure. 
4.66g of compound 148 were obtained and it was used crude for next reaction. Yield: 91.19% 
 
ethyl 8-bromo-1-(2,4-dichlorophenyl)-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-
3-carboxylate (149) 
4.66g (13.786 mmol, 1eq) of 148 were dissolved in 86mL of ethanol and 2.94g (13.786 mmol, 1 eq) 
of 2,4-dichloroaniline hydrochloride salt were added then, the solution was stirred at 80° C for 4h 
then the solvent was removed. The organic compound was purified via flash chromatography: 
hexane/ethyl acetate 4:1. 4.92g of neat compound 149 were obtained. Yield: 74.77%; 1H NMR δ: 
7.53 (d, J = 8.1 Hz, 1H), 7.47 (d, J = 1.9 Hz, 1H), 7.40 (dd, J = 10.6, 2.3 Hz, 2H), 7.17 (dd, J = 8.2, 
2.0 Hz, 1H), 6.54 (d, J = 8.2 Hz, 1H), 4.45 (q, J = 7.1 Hz, 2H), 3.22 (s, 2H), 2.66 (t, J = 6.5 Hz, 2H), 
2.26 (s, 2H), 1.43 (t, J = 7.1 Hz, 3H) 
 
(8-bromo-1-(2,4-dichlorophenyl)-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazol-3-
yl)methanol (150) 
To a solution of 0.41g (10.816 mmol, 1.1eq) of LiAlH4 in 20mL of anhydrous THF, 4.90g (9.833 
mmol, 1eq) of 149 in 30mL of THF were added dropwise at 0° C. The reaction was warmed gradually 
to r.t.and it was stirred until 149 disappeared. The solution was allowed to 0° C again and the 
reaction was quenched with H2O and NaOH, then it was stirred for 30 min. The organic compound 
was extracted with ethyl acetate and was purified via flash chromatography: hexane/ethyl acetate 
7:3. 3.44g of neat compound 150 were obtained. Yield: 80.00%; 1H NMR δ: 7.46 – 7.40 (m, 3H), 
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7.39 – 7.34 (m, 1H), 7.15 (dd, J = 8.3, 2.1 Hz, 1H), 6.53 (d, J = 8.3 Hz, 1H), 4.79 (s, 2H), 2.76 – 2.63 
(m, 2H), 2.22 (t, J = 19.9 Hz, 2H), 2.00 (s, 2H). 
 
8-bromo-1-(2,4-dichlorophenyl)-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-
carbaldehyde (151) 
3.44g (7.854 mmol) of 150 were dissolved in 45 mL of DCM and the solution was allow to 0° C; then 
3.99g (9.425 mmol, 1.2eq) of DMP were added. The solution was warmed to r.t and stirred for 4h; 
then 155mL of saturated solution of N2HCO3 and 8.95g (56.54 mmol, 7.2 eq) of Na2S2O3 were 
added. The organic compound was extracted with Et2O. 3.10g of neat compound 151 were obtained 
and it was used crude for the next step of reaction. Yield: 90.52%; 1H NMR δ 10.13 (s, 1H), 7.53 – 
7.40 (m, 4H), 7.18 (dd, J = 8.3, 2.1 Hz, 1H), 6.55 (t, J = 6.0 Hz, 1H), 3.23 (d, J = 32.9 Hz, 2H), 2.68 
(dd, J = 12.8, 6.4 Hz, 2H), 2.29 (d, J = 32.1 Hz, 2H). 
 
8-bromo-1-(2,4-dichlorophenyl)-3-ethynyl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-
c]pyrazole (144) 
To a solution of 3.74g (8.578 mmol, 1eq) of 151 dissolved in 50mL of MeOH, 3.90g (28.307 mmol, 
3.3 eq) of K2CO3 and 4.36g (22.695 mmol, 2.6eq) of Bestmann-Ohira reagent were added and the 
solution was stirred overnight at r.t.; then it was quenched with 30mL of aqueous NaHCO3 5% and 
it was extracted with Et2O. The organic compound was purified via flash chromatography: 
Et2O/Hexane 1:9. 1.2g of neat compound 144 were obtained. Yield: 32.43%. 1H NMR δ; 7.50 – 7.35 
(m, 4H), 7.16 (dd, J = 8.3, 2.1 Hz, 1H), 6.52 (d, J = 8.3 Hz, 1H), 3.27 (s 1H), 2.74 – 2.63 (m, 2H), 
2.58 (s, 2H), 2.24 (s, 2H). 
 
1-azidopentane (156 a) 
To a solution of 0.21g (1.400 mmol, 1eq) of 1-bromopentane in 5.4mL of H2O/acetone 1:4, 0.13g 
(2.100 mmol, 1.5eq) of NaN3 were added and the suspension was stirred at r.t. for 24h. Then, the 
organic compound was extracted with DCM, the solvent was removed and compound 156 a was 
used crude for the next reaction. 
 
(azidomethyl)cyclohexane (156 b) 
To a solution of 0.09g (1.489 mmol, 1.1eq) of NaN3 in 10mL of DMSO, 0.24g (1.354mmol, 1eq) of 
(Bromomethyl)cyclohexane were added and the solution was stirred at 80° C overnight. Then, the 
cool reaction was quenched with water and extracted with ethyl acetate. Compound 156 b was used 
crude for the next step of reaction. 
 
(azidomethyl)benzene (156 c) 
To a solution of 0.07g (0.0463 mmol) of benzylbromide in 2mL of DMF, 0.06g (0.926 mmol) of NaN3 
were added and the solution was stirred for 3h at 65 C. The reaction was quenched with water and 
the organic compound was extracted with ether. Compound 156 c was used crude for the next 
reaction. 
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8-bromo-1- (2,4-dichlorophenyl)- 3- (1-pentyl-1H-1,2,3-triazol-4-yl)- 1, 4, 5, 6- tetrahydrobenzo 
[6,7] cyclohepta [1,2-c]pyrazole (157 a) 
To a solution of 0.40g (0.926mmol, 1eq) of 144 dissolved in 11mL of tBuOH and 5mL of H2O, 0.11g 
(0.926mmol) of 156 a, 0.005g (0.037mmol, 0.04eq) of CuSO4 and 0.04g (0.185mmol, 0.2eq) of 
sodium ascorbate were added. The reaction was stirred at r.t. overnight then it was quenched with 
a saturated solution of NH4Cl and it was extracted with ethyl acetate. The organic compound was 
purified via flash chromatography: hexane/ethyl acetate 7:3. 0.48g of neat compound 157 a were 
obtained. Yield: 96%; 1H NMR δ: 7.96 (s, 1H), 7.52 – 7.36 (m, 4H), 7.17 (dd, J = 8.3, 2.1 Hz, 1H), 
6.57 (d, J = 8.3 Hz, 1H), 4.41 (t, J = 7.2 Hz, 2H), 3.27 (s, 2H), 2.72 (d, J = 6.2 Hz, 2H), 2.31 (s, 2H), 
2.00 – 1.91 (m, 2H), 1.42 – 1.30 (m, 4H), 0.90 (t, J = 7.0 Hz, 3H). 
 
8-bromo-3- (1- (cyclohexylmethyl)- 1H-1,2,3-triazol-4-yl)-1- (2,4-dichlorophenyl)- 1, 4, 5, 6-
tetrahydrobenzo [6,7]cyclohepta[1,2-c]pyrazole (157 b) 
Compound 157 b was obtained following the same procedure described for compound 157 a using 
144 and 156 b as starting materials. Yield: 50.60%;1H NMR δ: 7.94 (s, 1H), 7.54 – 7.34 (m, 4H), 
7.17 (dd, J = 8.2, 2.0 Hz, 1H), 6.57 (d, J = 8.2 Hz, 1H), 4.24 (d, J = 7.1 Hz, 2H), 3.09 (m, 2H), 2.71 
(m, 2H), 2.31 (s, 2H), 1.93 (m, 1H), 1.80 – 1.55 (m, 6H), 1.31 – 1.08 (m, 2H), 1.00 (m, 2H). 
 
3- (1-benzyl-1H-1,2,3-triazol-4-yl)- 8-bromo-1- (2,4-dichlorophenyl)- 1, 4, 5, 6- tetrahydrobenzo 
[6,7]cyclohepta[1,2-c]pyrazole (157 c) 
 
Compound 157 c was obtained following the same procedure described for compound 157 a using 
144 and 156 c as starting materials. Yield: 48.62%; 1H NMR δ 7.80 (s, 1H), 7.43 – 7.22 (m, 9H), 
7.09 (dd, J = 8.2, 2.0 Hz, 1H), 6.48 (d, J = 8.3 Hz, 1H), 5.51 (s, 2H), 3.21 (m, 2H), 2.63 (m, 2H), 2.23 
(s, 2H 
 
8-bromo- 1- (2,4-dichlorophenyl)- 3- (1-methyl-1H-1,2,3-triazol-4-yl)- 1, 4, 5, 6- 
tetrahydrobenzo [6,7]cyclohepta[1,2-c]pyrazole (157 d) 
Compound 157 d was obtained following the same procedure described for compound 157 a using 
144 and CH3I as starting materials. Yield: 30.29%; 1H NMR δ 7.88 (s, 1H), 7.48 – 7.27 (m, 4H), 7.10 
(dd, J = 8.3, 2.1 Hz, 1H), 6.56 – 6.46 (m, 1H), 4.08 (s, 3H), 2.65 (t, J = 6.3 Hz, 2H), 2.23 (m, 2H), 
1.64 (d, J = 4.3 Hz, 2H). 
 
3-(1-(2,4-dichlorophenyl)-3-(1-pentyl-1H-1,2,3-triazol-4-yl)-1,4,5,6-
tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazol-8-yl)prop-2-yn-1-ol (158 a) 
To 0.08g (0.146mmol, 1eq) of 157 a, 0.003g (0.00438mmol, 3%eq) of PdCl2(PPh3)2, 0.12mL (0.438 
mmol, 3eq) of TBAF and 0.01g (0.1606mmol, 1.1eq) of propargyl alcohol were added. The reaction 
was stirred under nitrogen atmosphere at 80° C overnight then, it was quenched with water and 
extracted with ethyl acetate. Compound 158a was purified via flash chromatography: hexane/ethyl 
acetate 7:3. 0.03g of neat compound were obtained. Yield: 39.63%; 1H NMR δ: 8.01 (d, J = 5.8 Hz, 
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1H), 7.52 (d, J = 8.4 Hz, 1H), 7.46 – 7.37 (m, 3H), 7.12 (dd, J = 8.0, 1.7 Hz, 1H), 6.68 (d, J = 8.0 Hz, 
1H), 4.52 (d, J = 7.5 Hz, 2H), 4.43 (t, J = 7.2 Hz, 2H), 2.76 (t, J = 6.3 Hz, 2H), 2.32 (s, 2H), 2.01 – 
1.92 (m, 2H), 1.43 – 1.34 (m, 4H), 1.31 – 1.23 (m, 2H), 0.92 (t, J = 7.0 Hz, 3H) 
 
3-(3-(1-(cyclohexylmethyl)-1H-1,2,3-triazol-4-yl)-1-(2,4-dichlorophenyl)-1,4,5,6-
tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazol-8-yl)prop-2-yn-1-ol (158 b) 
Compound 158 b was obtained following the same procedure described for compound 158 a using 
157 b as starting material. Yield: 29.49%;1H NMR δ: 7.87 (s, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.37 – 
7.27 (m, 3H), 7.02 (dd, J = 8.0, 1.6 Hz, 1H), 6.57 (d, J = 8.0 Hz, 1H), 4.40 (s, 2H), 4.16 (d, J = 6.2 
Hz, 2H), 2.66 (t, J = 6.2 Hz, 2H), 2.23 (s, 2H), 1.93 – 1.78 (m, 2H), 1.72 – 1.53 (m, J = 23.7, 11.7 
Hz, 6H), 1.17 – 1.06 (m, 3H), 1.01 – 0.89 (m, 2H). 
 
3-(3-(1-benzyl-1H-1,2,3-triazol-4-yl)-1-(2,4-dichlorophenyl)-1,4,5,6-
tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazol-8-yl)prop-2-yn-1-ol (158 c) 
Compound 158 c was obtained following the same procedure described for compound 158 a using 
157 c as starting material. Yield: 58.00%; 1H NMR δ 7.81 (s, 1H), 7.33 – 7.23 (m, 9H), 7.02 (dd, J = 
8.0, 1.6 Hz, 1H), 6.56 (d, J = 8.0 Hz, 1H), 5.51 (s, 2H), 4.41 (d, J = 5.9 Hz, 2H), 3.21 (m, 2H), 2.63 
(m, 2H), 2.23 (s, 2H) 
 
3-(1-(2,4-dichlorophenyl)-3-(1-methyl-1H-1,2,3-triazol-4-yl)-1,4,5,6-
tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazol-8-yl)prop-2-yn-1-ol (158 d) 
Compound 158 d was obtained following the same procedure described for compound 158 a using 
157 d as starting material. Yield: 37.65%; 1H NMR δ 7.88 (s, 1H), 7.42 (d, J = 8.4 Hz, 1H), 7.36 – 
7.26 (m, 3H), 7.03 (dd, J = 8.0, 1.6 Hz, 1H), 6.58 (d, J = 8.0 Hz, 1H), 4.41 (d, J = 5.6 Hz, 2H), 4.09 
(s, 3H), 2.66 (t, J = 6.3 Hz, 2H), 2.21 (s, 2H), 1.66 (t, J = 5.9 Hz, 2H). 
 
3-(3-(1-pentyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-
c]pyrazol-8-yl)propan-1-ol (159 a) 
To a solution of 0.03g (0.058 mmol) of 158 a dissolved in 3mL of dry ethanol, a catalytic amount of 
Pd/C (10%) was added then, the solution was stirred under nitrogen atmosphere for 3 days. The 
reaction was filtered through a celite pad. The organic compound was purified via flash 
chromatography: hexane/ethyl acetate 7:3. 0.02g of neat compound 159 a were obtained. Yield: 
75.78%; 1H NMR δ 8.01 (s, 1H), 7.38 (m, 4H), 7.34 (m, 1H), 7.20 (d, J = 1.5 Hz, 1H), 6.90 (dd, J = 
7.9, 1.8 Hz, 1H), 6.74 (d, J = 7.9 Hz, 1H), 4.44 (t, J = 7.2 Hz, 2H), 3.72 (t, J = 6.4 Hz, 2H), 3.03 (t, J 
= 7.3 Hz, 2H), 2.79 (t, J = 6.6 Hz, 2H), 2.75 – 2.62 (m, 2H), 2.40 – 2.27 (m, 2H), 2.02 – 1.87 (m, 4H), 
1.42 – 1.34 (m, J = 8.5, 4.7 Hz, 2H), 1.32 – 1.23 (m, 2H), 0.99 – 0.80 (m, 3H); 13C NMR δ 149.74, 
142.81, 142.10, 141.68, 140.64, 140.05, 129.67, 128.97, 128.69, 127.82, 127.30, 125.89, 124.94, 
120.84, 119.73, 62.36, 50.33, 33.97, 32.74, 31.88, 31.59, 29.99, 28.60, 22.12, 20.58, 13.84; MS 
(ESI): 456 (M + H+), 478 (M + Na) 
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3-(3-(1-(cyclohexylmethyl)-1H-1,2,3-triazol-4-yl)-1-phenyl-1,4,5,6-tetrahydrobenzo[6,7] 
cyclohepta[1,2-c]pyrazol-8-yl)propan-1-ol (159 b) 
Compound 159 b was obtained following the same procedure described for compound 159 a using 
158 b as starting material. Yield: 97.15%;1H NMR δ: 8.00 (s, 1H), 7.40- 7.36 (m, 4H), 7.34 (m, 1H), 
7.19 (d, J = 1.5 Hz, 1H), 6.88 (dd, J = 7.9, 1.8 Hz, 1H), 6.73 (d, J = 7.9 Hz, 1H), 4.26 (dd, J = 7.1, 
3.5 Hz, 2H), 3.77 – 3.62 (m, 2H), 3.01 (dd, J = 14.3, 7.2 Hz, 1H), 2.83 – 2.62 (m, 4H), 2.31 (dd, J = 
8.0, 5.0 Hz, 2H), 1.99 – 1.87 (m, 2H), 1.72 (dd, J = 22.4, 11.3 Hz, 6H), 1.21 (t, J = 14.0 Hz, 4H), 1.11 
– 0.97 (m, 2H); ); 13C NMR δ 149.74, 142.80, 142.08, 141.67, 140.62, 140.01, 129.65, 128.96, 
128.69, 127.83, 127.31, 125.87, 124.91, 120.82, 119.73, 62.27, 56.51, 53.81, 38.77, 33.94, 32.79, 
31.83, 30.51, 29.27, 26.08, 25.53; MS (ESI): 482 (M + H+). 
 
3-(1-phenyl-3-(1H-1,2,3-triazol-4-yl)-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazol-8-
yl)propan-1-ol (159 c) 
Compound 159 c was obtained following the same procedure described for compound 159 a using 
158 c as starting material. Yield: 76.18%;1H NMR δ: 8.05 (s, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.38 – 
7.24 (m, 3H), 7.11 (d, J = 7.0 Hz, 1H), 7.06 (d, J = 11.3 Hz, 1H), 6.80 (dd, J = 7.9, 1.7 Hz, 1H), 6.57 
(dd, J = 7.7, 3.9 Hz, 1H), 3.68 – 3.51 (m, 2H), 2.70 – 2.54 (m, 4H), 2.25 – 2.17 (m, 2H), 1.88 – 1.75 
(m, 2H), 1.62 – 1.48 (m, 2H); 13C NMR δ 142.87, 142.21, 141.79, 136.62, 135.39, 132.77, 130.60, 
130.36, 129.88, 127.88, 127.08, 126.93, 126.14, 122.70, 118.70, 62.27, 33.85, 32.71, 31.68, 31.49, 
21.08; MS (ESI): 386 (M + H+) 
 
3-(3-(1-methyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-
c]pyrazol-8-yl)propan-1-ol (159 d) 
Compound 159 d was obtained following the same procedure described for compound 159 a using 
158 d as starting material. Yield: 69.76%;1H NMR δ: 8.01 (s, 1H), 7.44 – 7.31 (m, 5H), 7.23 – 7.17 
(m, 1H), 6.94 – 6.87 (m, 1H), 6.74 (d, J = 7.9 Hz, 1H), 4.21 – 4.15 (m, 3H), 3.75 – 3.66 (m, 2H), 3.00 
(t, J = 7.4 Hz, 2H), 2.79 (t, J = 6.6 Hz, 2H), 2.76 – 2.67 (m, 2H), 2.36 – 2.27 (m, 2H), 1.94 (dt, J = 
15.7, 6.4 Hz, 2H); 13C NMR δ 142.87, 142.21, 141.79, 136.62, 135.39, 132.77, 130.60, 130.36, 
129.22, 128.95, 127.85, 125.76, 124.90, 122.66, 118.70, 62.37, 36.83, 33.75, 31.86, 30.73, 25.41, 
20.71; MS (ESI): 400 (M + H+), 422 (M + Na) 
 
PROJECT 5 
 
tert-butyl (1-oxo-5- (3- ( ( 2,2,4,6,7- pentamethyl- 2, 3- dihydrobenzofuran- 5-yl) sulfonyl) 
guanidino)-1-((pyridin-3-ylmethyl)amino)pentan-2-yl)carbamate (161)  
To a solution of 0.50g (0.949 mmol, 1eq) of the protected aminoacid Boh-Arg(pbf)-OH dissolved in 
10mL of DCM, 0.505g (1.328 mmol, 1.4eq) of coupling agent HATU were added followed by 0.28g 
(2.752 mmol, 2.9eq) of TEA and, finally, by 0.12 (1.140 mmol, 1.2eq) of pyridin-3-ylmethanamine. 
The resulting lightly yellow mixture was stirred at r.t. for 6h then, the solvent was removed. The 
reaction was worked up by washing with HCl 1N and a saturated solution of sodium bicarbonate 
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and extracted with ethyl acetate. The crude was purified via flash chromatography: DCM/Methanol 
9.5:0.5; 0.38g of neat compound 167 were obtained. Yield: 82.12%; 1H NMR δ 8.46 (s, 1H), 8.41 
(dd, J = 4.8, 1.5 Hz, 1H), 7.95 (s, 1H), 7.58 (d, J = 7.5 Hz, 1H), 7.17 (dd, J = 7.7, 4.9 Hz, 1H), 6.41 
(s, 2H), 5.83 (d, J = 7.8 Hz, 1H), 4.37 (qd, J = 15.3, 6.0 Hz, 2H), 4.21 (s, 1H), 3.22 (d, J = 36.0 Hz, 
2H), 2.94 (s, 2H), 2.54 (s, 3H), 2.46 (s, 3H), 2.17 (s, 2H), 2.09 (m, 3H), 1.79 (d, J = 7.1 Hz, 1H), 1.58 
(dt, J = 19.0, 10.5 Hz, 2H), 1.45 (s, 6H), 1.37 (s, 9H). 
 
tert-butyl (1-oxo-5- (3- ( (2,2,4,6,7- pentamethyl- 2,3- dihydrobenzofuran- 5-yl) sulfonyl) 
guanidino)-1- ((1- (pyridin-3-yl) ethyl) amino) pentan-2-yl) carbamate (163)  
Compound 163 was obtained following the same procedure described for compound 161 using 1-
(pyridin-3-yl)ethan-1-amine as starting material. Yield: 68.58%; 1H NMR δ 8.51 (s, 1H), 8.41 – 8.36 
(m, 1H), 7.97 – 7.77 (m, 1H), 7.62 (s, 1H), 7.16 (ddd, J = 12.5, 7.8, 4.9 Hz, 1H), 6.42-6.39 (m, 3H), 
6.01 – 5.75 (m, 1H), 5.05 – 4.91 (m, 1H), 4.28 – 4.01 (m, 1H), 3.09 (d, J = 55.2 Hz, 2H), 2.95 (d, J 
= 20.1 Hz, 2H), 2.57 (s, 3H), 2.47 (s, 3H), 2.17 (s, 3H), 2.07 (s, 3H), 1.74 (dd, J = 13.2, 5.6 Hz, 1H), 
1.63-1.58 (m, 2H), 1.43 (s, 6H), 1.38 – 1.30 (m, 9H) 
 
tert-butyl (1-(methyl(pyridin-3-ylmethyl)amino)-1-oxo-5-(3-((2,2,4,6,7-pentamethyl-2,3-
dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentan-2-yl)carbamate (165)  
Compound 165 was obtained following the same procedure described for compound 161 using N-
methyl-1-(pyridin-3-yl)methanamineas starting material. Yield: 93.68%; 1H NMR δ 1H NMR δ 8.47 
(dd, J = 4.8, 1.4 Hz, 1H), 8.44 (s, 1H), 7.54 (d, J = 7.7 Hz, 1H), 7.24 (dd, J = 7.6, 4.7 Hz, 1H), 6.39 
– 6.29 (m, J = 19.5 Hz, 2H), 5.72 (d, J = 8.2 Hz, 1H), 4.55 (t, J = 12.3 Hz, 2H), 3.40 (s, 2H), 3.19-
3.17 (m, 2H), 2.96 (s, 2H), 2.84 (dd, J = 15.1, 4.8 Hz, 2H), 2.78 (s, 3H), 2.54 (s, 3H), 2.47 (s, 3H), 
1.73 -1.54 (m, 2H), 1.42 (s, 6H), 1.40 (s, 9H) 
 
methyl 2-(2- ( (tert-butoxycarbonyl) amino)- 5- (3- ((2,2,4,6,7- pentamethyl- 2,3- 
dihydrobenzofuran-5-yl) sulfonyl) guanidino) pentanamido)- 3- (pyridin- 3-yl) propanoate 
(167)  
Compound 167 was obtained following the same procedure described for compound 161 using N-
methyl-1-(pyridin-3-yl)methanamineas starting material. Yield: 93.68%; 1H NMR δ 8.39 (dd, J = 4.7, 
1.6 Hz, 2H), 7.65 (d, J = 6.3 Hz, 1H), 7.54 (d, J = 7.9 Hz, 1H), 7.18 (dd, J = 7.7, 4.9 Hz, 1H), 6.42 
(s, 2H), 6.26 (s, 1H), 5.78 (d, J = 7.6 Hz, 1H), 4.78 (td, J = 8.2, 5.5 Hz, 1H), 3.69 (s, 3H), 3.17 (dd, J 
= 14.1, 5.1 Hz, 3H), 3.01 (dd, J = 14.0, 8.4 Hz, 1H), 2.94 (s, 2H), 2.58 (s, 2H), 2.51 (s, 3H), 2.08 (s, 
3H), 2.03 (s, 3H), 1.77 – 1.54 (m, 3H), 1.50 (s, 6H), 1.38 (s, 9H) 
 
2-amino-5-guanidino-N-(pyridin-3-ylmethyl)pentanamide (160)  
0.55g (0.893 mmol) of 161 were dissolved in 10mL of TFA then the reaction was stirred at room 
temperature for 4.5h. The solvent was removed with N2 and, finally, with rotavapor. The precipitate 
was washed with diethyl ether. Compound 160 was dissolved in 5mL of HCl and 5mL of water and 
it was evaporated with freeze drying. This process was repeated three times in order to obtain 160 
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as hydrochloride salt. 1H NMR (D2O) δ 8.70 (s, 1H), 8.67 (d, J = 5.8 Hz, 1H), 8.49 (d, J = 8.2 Hz, 
1H), 8.00 (dd, J = 8.1, 5.9 Hz, 1H), 4.63 – 4.54 (m, 2H), 4.03 (t, J = 6.6 Hz, 1H), 3.15 (t, J = 6.9 Hz, 
2H), 1.87 (td, J = 8.7, 2.3 Hz, 2H), 1.61 – 1.48 (m, 2H) 
 
2-amino-5-guanidino-N-(1-(pyridin-3-yl)ethyl)pentanamide (162)  
Compound 162 was obtained following the same procedure described for compound 160 using 163 
as starting material. 1H NMR (D2O) δ 8.74 (d, J = 7.8 Hz, 1H), 8.67 (dd, J = 11.1, 5.7 Hz, 1H), 8.53 
(d, J = 6.5 Hz, 1H), 8.01 (dt, J = 8.3, 5.2 Hz, 1H), 5.13 (q, J = 7.3 Hz, 1H), 3.99 (dt, J = 9.9, 5.0 Hz, 
1H), 3.19 (t, J = 6.8 Hz, 1H), 3.09 (t, J = 6.9 Hz, 1H), 1.95 – 1.76 (m, 2H), 1.67 – 1.58 (m, 1H), 1.53 
(dd, J = 7.1, 3.9 Hz, 3H), 1.46 – 1.34 (m, 1H) 
 
2-amino-5-guanidino-N-methyl-N-(pyridin-3-ylmethyl)pentanamide (164)  
Compound 164 was obtained following the same procedure described for compound 160 using 165 
starting material. 1H NMR (D2O) δ 8.69 (s, 2H), 8.50 – 8.43 (m, J = 8.0 Hz, 1H), 8.01 (dd, J = 8.1, 
6.1 Hz, 1H), 4.93 – 4.82 (m, J = 12.6 Hz, 1H), 4.68 – 4.62 (m, J = 8.0 Hz, 1H), 4.55 (dd, J = 7.0, 5.1 
Hz, 1H), 3.18 (dd, J = 14.4, 7.7 Hz, 2H), 3.13 (s, 3H), 1.94-1.89 (m, 2H), 1.68 – 1.55 (m, 2H) 
 
Methyl 2-(2-amino-5-guanidinopentanamido)-3-(pyridin-3-yl)propanoate (166)  
Compound 166 was obtained following the same procedure described for compound 160 using 167 
starting material. 1H NMR (D2O) δ 8.68 (s, 1H), 8.64 (d, J = 5.8 Hz, 1H), 8.49 (d, J = 8.1 Hz, 1H), 
7.97 (dd, J = 8.0, 6.0 Hz, 1H), 4.90 (dd, J = 8.8, 5.9 Hz, 1H), 3.96 (dd, J = 8.0, 4.8 Hz, 1H), 3.70 (s, 
3H), 3.53 – 3.39 (m, 1H), 3.35 – 3.20 (m, 1H), 3.15 (dd, J = 12.8, 6.1 Hz, 2H), 1.86 (dd, J = 15.1, 
8.3 Hz, 2H), 1.59 (td, J = 13.7, 6.6 Hz, 2H) 
 
2-(2-((tert-butoxycarbonyl)amino)-5-(3-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-
yl)sulfonyl)guanidino)pentanamido)-3-(pyridin-3-yl)propanoic acid (169)  
To a solution of 0.43g (0.6278 mmol, 1eq) of 167 dissolved in 26mL of THF and 9mL of water, 0.05g 
(1.2556 mmol, 2eq) of LiOH were added and it was stirred at r.t. for 2h. The reaction was quenched 
with HCl 1N and the THF was evaporated. Then, the organic compound was extracted with ethyl 
acetate. 0.16g of neat compound 169 were obtained. Yield: 37.82%; 1H NMR δ 9.01 (s, 1H), 8.39 
(dd, J = 4.7, 1.6 Hz, 2H), 7.65 (d, J = 6.3 Hz, 1H), 7.54 (d, J = 7.9 Hz, 1H), 7.18 (dd, J = 7.7, 4.9 Hz, 
1H), 6.42 (s, 2H), 6.26 (s, 1H), 5.78 (d, J = 7.6 Hz, 1H), 4.78 (td, J = 8.2, 5.5 Hz, 1H), 3.17 (dd, J = 
14.1, 5.1 Hz, 3H), 3.01 (dd, J = 14.0, 8.4 Hz, 1H), 2.94 (s, 2H), 2.58 (s, 2H), 2.51 (s, 3H), 2.08 (s, 
3H), 2.03 (s, 3H), 1.77 – 1.54 (m, 3H), 1.50 (s, 6H), 1.38 (s, 9H) 
 
2-(2-amino-5-guanidinopentanamido)-3-(pyridin-3-yl)propanoic acid (169)  
Compound 168 was obtained following the same procedure described for compound 160 using 169 
starting material. 1H NMR (D2O) δ 8.66 – 8.61 (m, 2H), 8.47 (d, J = 8.3 Hz, 1H), 7.96 (dd, J = 8.0, 
5.8 Hz, 1H), 4.68 – 4.59 (m, 1H), 3.97 (t, J = 6.3 Hz, 1H), 3.37 (dd, J = 14.4, 6.2 Hz, 1H), 3.28 – 3.19 
(m, 1H), 3.15 (t, J = 6.8 Hz, 2H), 1.87 (dd, J = 14.9, 8.1 Hz, 2H), 1.67 – 1.50 (m, 2H). 
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methyl 2-amino-3-(pyridin-3-yl)propanoate (170) 
To a cooled (0° C) solution of 0.25g (1.506 mmol) of 3-(3-pyridyl)-L-alanine dissolved in 5mL of 
anhydrous methanol, 0.4mL of SOCl2 were added dropwise and the reaction was stirred at r.t. for 
24H. The solvet was removed under reduced pressure and 0.26g of neat compound 170 were 
obtained. Yield: 95.91%; 1H NMR (D2O) δ 8.74 – 8.68 (m, 2H), 8.49 (d, J = 8.2 Hz, 1H), 8.00 (dd, J 
= 8.1, 5.8 Hz, 1H), 4.52 (dd, J = 7.7, 6.6 Hz, 1H), 3.74 (s, 3H), 3.52 (dd, J = 14.9, 7.8 Hz, 1H), 3.44 
(dd, J = 14.8, 6. 
 
PROCEDURE 1 
0.500 mmol of aginine derivative was dissolved in 5mL of HCl and 5mL of water. Then the solvent 
was evaporated with the afford of the freeze drying. The process was repeated three times until the 
total conversion of the salt. 
Compounds 171-175 were converted from trifluoroacetic salt into hydrochloride salt 
following procedure 1. 
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